{
    "title": "Coronavirus Disease 2019 (COVID-19) | FDA",
    "body": "\n\n\nSkip to main content\nSkip to FDA Search\nSkip to in this section menu\nSkip to footer links\n\n \n\n \n\n\n\n\nAn official website of the United States government\nHere\u2019s how you know  \n\n\n\n\n\nThe .gov means it\u2019s official.Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\nThe site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\nU.S. Food and Drug Administration\n\n\n\n\n\n\u00a0\nSearch\n\n\n\u00a0\nMenu\n\n\n\n\n\n\nSearch FDA\n\n\nSubmit search\n\n\n\n\n\n \n\nFeatured\n\nContact FDA\nFDA Guidance Documents\nRecalls, Market Withdrawals and Safety Alerts\nPress Announcements\nWarning Letters\nAdvisory Committees\nEn Espa\u00f1ol\n\n\n\n\n\nProducts\n\nFood\nDrugs\nMedical Devices\nRadiation-Emitting Products\nVaccines, Blood, and Biologics\nAnimal and Veterinary\nCosmetics\nTobacco Products\n\n\n\nTopics\n\nAbout FDA\nCombination Products\nRegulatory Information\nSafety\nEmergency Preparedness\nInternational Programs\nNews and Events\nTraining and Continuing Education\nInspections and Compliance\nScience and Research\n\n\n\nInformation For\n\nConsumers\nPatients\nIndustry\nHealth Professionals\nFederal, State and Local Officials\n\n\n\n\n\n\n\n\n\nIn this section:\n\n        Counterterrorism and Emerging Threats\n\n    \n\n\n\n\nCoronavirus Disease 2019 (COVID-19)\n\n\n\nCOVID-19-Related Guidance Documents for Industry, FDA Staff, and Other Stakeholders\nCOVID-19 Frequently Asked Questions\nCOVID-19 Vaccines\nCOVID-19 Bivalent Vaccines\nMultilingual COVID-19 Resources\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nHome\n\n\nEmergency Preparedness and Response\n\n\nCounterterrorism and Emerging Threats\n\n\nCoronavirus Disease 2019 (COVID-19)\n\n\n\n\n\n     Counterterrorism and Emerging Threats\n    \n\n\n\n\n\n\n\n\nCoronavirus Disease 2019 (COVID-19)\n\n\n\nShare\n\n\nTweet\n\n\nLinkedin\n\n\nEmail\n\n\nPrint\n\n\n\n\n\n\n\n\n\nEspa\u00f1ol\n\u00a0\n\n\nApril 18, 2023: FDA authorizes changes to simplify use of bivalent mRNA COVID-19 vaccines. Read the press release and listen to the\u00a0media call.\n\n\n \n\nOn this page:\nLatest COVID-19 News from FDA\nPersonal Protective Equipment\nEmergency Use Authorizations and Guidances\nFrequently Asked Questions\nPopular Topics\nFDA Response to COVID-19\nCOVID-19 Information About FDA Regulated Products\nContact FDA\nInformation from the Federal Government\n\n\n\n\nCOVID-19 Vaccines\nPfizer-BioNTech COVID-19 Vaccine, Bivalent\nModerna COVID-19 Vaccine, Bivalent\nJanssen COVID-19 Vaccine\nNovavax COVID-19 Vaccine, Adjuvanted\n\n\nResources for Health Professionals \nKey resources for health professionals during the COVID-19 pandemic. (Last updated 4/28/2023)\n\n\nCOVID-19 FAQs \nFrequently asked questions (FAQs) in English and Spanish.\n\n\n\n\n\nLatest COVID-19 Information from the FDA\n\n\n\nType of Information COVID-19 UpdateDaily RoundupPress Release / Public StatementEventFDA Voices: Leadership PerspectivesSafety InformationConsumer InformationPodcast / Video\n\n\nTopic Animal & VeterinaryBiologicsDrugsFood & BeveragesGuidance DocumentsImportsInspectionsMedical DevicesRecallsResearchTobacco ProductsWarning Letters\n\n\nClear Filters\n\n\n\nDate \nUpdate \nType \nTopic \n4/28/2023\n\nFDA Roundup Friday, April 28, 2023:\nToday, the FDA issued a final guidance for industry titled Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products. The FDA intends for this guidance to assist sponsors in the clinical development of nicotine replacement therapy (NRT) drug products intended to help cigarette smokers stop smoking and for other related indications.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n4/21/2023\n\nFDA Roundup Friday, April 21, 2023:\nOn Thursday, the FDA authorized for marketing the Bateman Bottle Breast Implant Removal System (BIRS), a single-patient, single use suction device used to assist in the removal of one intracapsular ruptured silicone breast implant. The FDA also announced it will reopen the comment period for the draft guidance entitled \u201cLabeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements; Draft Guidance for Industry.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n4/18/2023\n\nFDA Roundup Tuesday, April 18, 2023:\nOn Monday, the FDA granted marketing authorization to the NTX100 Tonic Motor Activation (NTX100 ToMAc) System to reduce the symptoms of primary moderate-severe Restless Legs Syndrome (RLS) and improve sleep quality among drug-resistant RLS patients.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n4/18/2023\n\nFDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines\nToday, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals. This action includes authorizing the current bivalent vaccines (original and omicron BA.4/BA.5 strains) to be used for all doses administered to individuals 6 months of age and older, including for an additional dose or doses for certain populations.\n\nPress Release / Public Statement\nBiologics\n4/14/2023\n\nFDA Roundup Friday, April 14, 2023:\nToday, the FDA issued an emergency use authorization (EUA) for the Azure Fastep COVID-19 Antigen Pen Home Test (manufactured by Azure Biotech, Inc.). The test can be used for people aged 14 years or older with a self-collected nasal swab sample and aged 2 years or older when an adult collects the nasal swab sample.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n4/11/2023\n\nFDA Roundup Tuesday, April 11, 2023:\nOn Monday, the FDA authorized for marketing the MISHA Knee System, an implant placed alongside the knee joint to help reduce the amount of load carried by part of the joint. Additionally, the FDA, in partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Reagan-Udall Foundation for the FDA, announced a virtual public meeting on May 10-11 titled, Considerations for Buprenorphine Initiation and Maintenance Care.\u00a0\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n4/7/2023\n\nFDA Roundup Friday, April 7, 2023:\nToday, the FDA issued a recall notice about Philips Respironics Recall Certain Reworked DreamStations CPAP, BiPAP machines for the risk they may deliver inaccurate or insufficient therapy.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n4/3/2023\n\nFDA Roundup Tuesday, April 4, 2023:\nToday, the FDA issued draft Guidance for Industry #278, Human User Safety in New and Abbreviated New Animal Drug Applications.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n3/31/2023\n\nFDA Roundup Friday, March 31, 2023:\nToday, the FDA granted marketing authorization for the Masimo SafetyNet Opioid System, a monitoring device intended to recognize and respond by a series of escalating notifications when an individual may be experiencing Opioid Induced Respiratory Depression (OIRD) due to opioid use or overdose.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n3/28/2023\n\nFDA Roundup Tuesday, March 28, 2023:\nToday, the FDA released an Immediate National Strategy to Increase the Resiliency of the U.S. Infant Formula Market following a months-long infant formula shortage sparked by unsanitary conditions at one of the nation\u2019s largest infant formula facilities.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n3/24/2023\n\nFDA Roundup Friday, March 24, 2023:\nToday, the FDA finalized two guidances outlining the FDA\u2019s general recommendations to transition from certain policies adopted and operations implemented during the COVID-19 pandemic to normal operations.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n3/21/2023\n\nFDA Roundup Tuesday, March 21, 2023:\nToday, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The agency also posted a warning letter issued to www.ivermectin4covid.com for offering drugs for sale in the U.S. that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n3/17/2023\n\nFDA Roundup Friday, March 17 2023:\nToday, the FDA issued an emergency use authorization (EUA) for the Cue Mpox (Monkeypox) Molecular Test for use in a point-of-care (POC) setting. The Cue Mpox (Monkeypox) Molecular Test is molecular-based test intended to detect monkeypox virus DNA in lesion swab specimens from individuals suspected of monkeypox by their healthcare provider.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n3/14/2023\n\nFDA Authorizes Bivalent Pfizer-BioNTech COVID-19 Vaccine as Booster Dose for Certain Children 6 Months through 4 Years of Age\nThe FDA amended the emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to provide for a single booster dose in children 6 months through 4 years of age at least 2 months after completion of primary vaccination with three doses of the monovalent Pfizer-BioNTech COVID-19 Vaccine.\n\nPress Release / Public Statement\nBiologics\n3/14/2023\n\nFDA Roundup Tuesday, March 14, 2023\nYesterday, the Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) was revised to include a Warning conveying that reports of adverse events following use of the vaccine under emergency use authorization suggest increased risks of myocarditis and pericarditis, particularly within the period 0 through 7 days following vaccination.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n3/10/2023\n\nFDA Roundup Friday, March 10, 2023\nToday, the FDA issued a notice addressing the agency\u2019s COVID-19-related guidance documents, including which of those guidance documents will no longer be in effect after the expiration of the COVID-19 public health emergency (PHE) declared under the Public Health Service (PHS) Act, and which of those guidance documents the FDA is revising to temporarily continue in effect.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n3/7/2023\n\nFDA Roundup Tuesday, March 7, 2023\nToday, the FDA issued a Letter to Health Care Providers about our expanded work to evaluate the potential risk of exposure to toxic compounds when using hemodialysis and peritoneal dialysis systems that have parts made of chlorinated peroxide cured silicone.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n3/3/2023\n\nFDA Roundup Friday, March 3, 2023\nThe FDA and the Federal Trade Commission have been working to help advance competition for biologics, including biosimilars and interchangeable biosimilars. Together, they have developed an educational resource for consumers about biosimilars and interchangeable biosimilars to help address common misperceptions.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n2/28/2023\n\nFDA Roundup Tuesday, Feb 28, 2023\nToday, the FDA is withdrawing the 2005 proposed rule, \u201cFood Standards; General Principles and Food Standards Modernization,\u201d in response to comments received in 2005 after publication of the proposed rule and in 2020 after the FDA reopened the comment period for the proposed rule.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n2/24/2023\n\nFDA Authorizes First Over-the-Counter At-Home Test to Detect Both Influenza and COVID-19 Viruses\nToday, the FDA issued an emergency use authorization (EUA) for the first over-the-counter (OTC) at-home diagnostic test that can differentiate and detect influenza A and B, commonly known as the flu, and SARS-CoV-2, the virus that causes COVID-19. The Lucira COVID-19 & Flu Test is a single-use at-home test kit that provides results from self-collected nasal swab samples in roughly 30 minutes.\u00a0\n\nPress Release / Public Statement\nMedical Devices\n2/24/2023\n\nFDA Roundup Friday, Feb 24 2023\nOn Thursday, the FDA issued a letter to health care providers informing health care providers and facilities about the potential for exposure to airborne chemicals that may be released from neonatal incubators.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n2/21/2023\n\nFDA Roundup Tuesday, Feb 21, 2023\nOn Friday, the FDA published the FDA Voices: \u201cHighlighting Major Issues Critical to FDA Across Our Diverse Agency After One Year Back,\u201d by Robert M. Califf, M.D., Commissioner of Food and Drugs. In the first of a two-part series, Dr. Califf reflects on his one-year anniversary back at the agency and shares his vision for the future of the agency and its mission to protect and promote public health amid the enormous workload and societal forces that make the mission more challenging than in other times.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n2/17/2023\n\nFDA Roundup Friday, Feb 17, 2023\nOn Wednesday, the FDA published the Medical Countermeasures Initiative (MCMi) Program Update report which showcases the FDA's critical role each year in protecting the United States from chemical, biological, radiological and nuclear threats, and emerging infectious diseases, like COVID-19 and mpox.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n2/10/2023\n\nFDA Roundup Friday, Feb 10 2023\nToday, the FDA issued an emergency use authorization (EUA) for the Cepheid Xpert Mpox test for use in a point-of-care setting. This EUA is the latest example of the FDA\u2019s ongoing commitment to advance greater consumer access to tests for infectious diseases.\u00a0\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n2/7/2023\n\nFDA Roundup Tuesday, Feb 7 2023\nOn Monday, the FDA updated its step-by-step guide to include information about reporting your over-the-counter (OTC) at-home COVID-19 test result to MakeMyTestCount.org. The FDA encourages you to voluntarily and anonymously report your positive or negative test results every time you use an at-home COVID-19 test.\u00a0\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n2/3/2023\n\nFDA Roundup Friday, Feb 3 2023\nOn Thursday, the FDA alerted consumers and health care practitioners not to purchase and immediately stop using EzriCare Artificial Tears or Delsam Pharma\u2019s Artificial Tears due to potential bacterial contamination. On Wednesday, the FDA revised the Letters of Authorization for two EUAs, Paxlovid and Lagevrio, to remove the requirement for positive test results to prescribe these products.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n1/31/2023\n\nFDA Roundup Tuesday, Jan 31 2023\nToday, Brian King, director of the Food and Drug Administration\u2019s Center for Tobacco Products (CTP), published a perspective sharing information on key priority areas of the Center\u2019s progress of tobacco regulation in 2022. The FDA and the Reagan-Udall Foundation for the FDA announced a virtual public meeting on March 8-9 titled, Understanding Fatal Overdoses to Inform Product Development and Public Health Interventions to Manage Overdose, exploring the evolving context surrounding fatal overdoses and discussing epidemiological trends, drug supply changes, public health interventions to manage overdose, and drug development opportunities.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n1/26/2023\n\nFDA announces Evusheld is not currently authorized for emergency use in the U.S.\nThe U.S. Food and Drug Administration today revised the Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with cilgavimab) to limit its use to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Based on this revision, Evusheld is not currently authorized for use in the U.S. until further notice by the Agency.\n\nPress Release / Public Statement\nDrugs\n\t\t\tBiologics\n1/24/2023\n\nFDA Roundup Friday, Jan 24, 2023\nOn Monday, the FDA issued a final guidance \u201cCannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Guidance for Industry,\u201d that provides the agency\u2019s current thinking on several topics relevant to clinical research related to the development of drugs containing cannabis and cannabis-derived compounds. The FDA also reopened the comment period for the proposed rule entitled Color Additive Certification; Increase in Fees for Certification Services. Lastly, the agency cleared for marketing a mobile application intended for use with compatible devices for automated insulin dosing to help manage type 1 diabetes in persons six years of age and older.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n1/20/2023\n\nFDA Roundup Friday, Jan 20, 2023\nToday, the FDA issued an immediately-in-effect guidance on compounding certain ibuprofen products in an effort to bolster supply of pediatric ibuprofen amid record high demand. On Thursday, the FDA announced the availability of a draft guidance titled, \u201cMpox: Development of Drugs and Biological Products\u201d.\n\nPress Release / Public Statement\n\nResearch\n\t\t\t\t\t\tDrugs\n\t\t\t\t\t\tBiologics\n\t\t\t\t\t\tMedical Devices\n\n1/13/2023\n\nFDA Roundup Friday, Jan 13, 2023\nToday, the FDA released a fact sheet and constituent update to remind produce stakeholders of the upcoming end of the intended enforcement discretion period for the harvest and post-harvest agricultural water requirements in the Produce Safety Rule for covered produce other than sprouts. On Tuesday, the FDA published a Consumer Update and video reminding consumers that as of January 1, 2023, sesame is required to be labeled as an allergen on packaged foods, including dietary supplements.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n1/10/2023\n\nFDA Roundup Tuesday, Jan 10, 2023\nToday, the FDA\u2019s \u201cThe Real Cost\u201d Youth Cigarette Prevention Campaign announced two new ads focusing on the negative mental health effects of cigarette smoking and withdrawal and the frequency with which teens who smoke will continue into adulthood.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n1/06/2023\n\nFDA Roundup Friday, Jan 6, 2023\nThe FDA posted an update that the agency is closely monitoring the emergence of the XBB.1.5 subvariant. Because of its similarity to variants that are not neutralized by Evusheld (e.g., XBB), the FDA does not anticipate that Evusheld will neutralize XBB.1.5, for more information click here. On Dec. 27, the FDA issued a warning letter to globalpharmacyplus.com for selling unapproved and misbranded drugs for use in treating or preventing COVID-19. Lastly, the FDA Grand Rounds lecture series will have a presentation on Jan. 12 from 12 to 1 pm ET, on the topic, \u201cThe Scientific Basis of Proposed Tobacco Product Standards to Prohibit Menthol as a Characterizing Flavor in Cigarettes and Flavors in Cigars.\u201d\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n12/30/2022\n\nFDA Roundup: December 30, 2022\nThe FDA issued the 2022 edition of the FDA Food Code, which provides guidance to state and local authorities and retailers to help mitigate foodborne illness risks at retail and provide a uniform set of national standards for retail food safety.\n\nPress Release / Public Statement\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n12/23/2022\n\nFDA Roundup December 23, 2022\nThis week, the FDA issued emergency use authorizations for two additional OTC at-home COVID-19 Tests and approved a new indication for Actemra (tocilizumab) injection for the treatment of hospitalized adult patients with COVID-19.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n12/20/2022\n\nFDA Roundup December 20, 2022\nToday, the FDA issued an emergency use authorization for the ImmuView COVID-19 Antigen Home Test and approved Zycosan for the control of clinical signs associated with osteoarthritis in horses.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n12/16/2022\n\nFDA Roundup Dec. 16, 2022\nThe FDA is providing an easy step-by-step guide to help consumers decide when and how many times to test for COVID-19, what their test results mean and what they should do next.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n12/16/2022\n\nFDA to Hold Advisory Committee Meeting to Discuss Future Vaccination Regimens Addressing COVID-19\nOn January 26, 2023, the FDA will hold a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to consider whether and how the composition for primary doses of the currently available COVID-19 vaccines should be modified and how and whether the composition and schedule for booster doses should be adjusted moving forward.\u00a0\n\nPress Release / Public Statement\nBiologics\n12/13/2022\n\nFDA Roundup Tuesday, Dec. 13, 2022\nThe FDA updated the device shortage list to remove medical gloves and will continue to monitor the supply chain and update the device shortage list and device discontinuance list as new information becomes available.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n12/09/2022\n\nFDA Roundup Friday, Dec 9, 2022\nThe FDA, in coordination with the U.S. Department of Agriculture and the Centers for Disease Control and Prevention, collaborated with the Conference of Food Protection to release food safety best practices for third-party delivery services.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n12/08/2022\n\nFDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age\nThe FDA amended the emergency use authorizations (EUAs) of the updated (bivalent) Moderna and Pfizer-BioNTech COVID-19 vaccines to include use in children down to 6 months of age.\n\nPress Release / Public Statement\nBiologics\n12/06/2022\n\nFDA Roundup Tuesday, Dec 6, 2022\nThe FDA issued a final guidance, Homeopathic Drug Products, describing the agency\u2019s approach to prioritizing enforcement and regulatory actions for homeopathic products marketed in the U.S. without the required FDA approval.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n11/29/2022\n\nFDA Roundup Tuesday, Nov. 29, 2022\nToday, the FDA issued two guidance documents about food allergen labeling requirements to help the food industry meet the requirements to list any major food allergen on the labels of FDA-regulated foods.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n11/22/2022\n\nFDA Roundup November 22, 2022\u00a0\nToday, the FDA issued an emergency use authorization (EUA) for the Lucira COVID-19 and Flu Test for use in a point-of-care (POC) setting, following collaboration with the National Institutes of Health (NIH) Independent Test Assessment Program (ITAP). The Lucira COVID-19 and Flu Test is a single use molecular test intended for detection of both the SARS-CoV-2 virus and influenza (A or B) if a patient is suspected of respiratory viral infection consistent with COVID-19.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n11/18/2022\n\nFDA Roundup November 18, 2022\nYesterday, the FDA provided an update on the Philips Respironics June 2021 recall. The FDA also published the FDA Voices: \u201cFDA\u2019s Cybersecurity Modernization Action Plan\u201d and issued emergency use authorizations for the Hotgen COVID-19 Antigen Home Test and NIDS COVID-19 Antigen Home Test. The FDA also updated its Automated External Defibrillator web page yesterday. On Wednesday, the FDA published the FDA Voices: \u201cFocusing on Prevention to Safeguard Infant Formula\u201d and tips for buying medications online safely. The FDA also published a new report on Wednesday, titled \u00a0Successes and Opportunities in Modeling & Simulation for FDA. On Wednesday, the FDA completed its first pre-market consultation for a human food made from cultured animal cells and also announced the availability of a draft amended Environmental Assessment (EA) for an approved application concerning Atlantic salmon with an intentionally altered genome (known as AquAdvantage Salmon, or AAS), and a subsequent virtual public meeting to obtain public input on the draft amended EA. Also on Wednesday, the FDA announced approving Rezvoglar (insulin glargine-aglr) as the second interchangeable biosimilar. On Tuesday, in collaboration with FDA, MITRE updated the Medical Device Cybersecurity Regional Incident Preparedness and Response Playbook.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n11/15/2022\n\nFDA Roundup November 15, 2022\u00a0\nToday, the FDA issued an EUA to Roche Molecular Systems, Inc. for a molecular diagnostic test for monkeypox and released an outline of a prevention strategy to prevent Cronobacter sakazakii illnesses associated with consumption of powdered infant formula. On Thursday, the FDA, in conjunction with CDC, released results on youth tobacco use from the 2022 National Youth Tobacco Survey as well as published a consumer update advising individuals to learn about the risks and benefits of enrolling their children in clinical trials. On Nov. 8, the FDA issued an EUA for Kineret (anakinra) injection.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n11/08/2022\n\n\u00a0\nFDA Roundup November 8, 2022\n\u00a0\nToday, the FDA warned health care professionals to be cautious of possible xylazine inclusion in fentanyl, heroin, and other illicit drug overdoses, as naloxone may not be able to reverse its effects.\n\t\t\t\u00a0\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n11/04/2022\n\nFDA Roundup November 4, 2022\u00a0\nOn Thursday, the FDA issued a safety communication warning parents, caregivers, and health care providers not to use infant head shaping pillows intended to change an infant\u2019s head shape and/or symmetry or claim to prevent or treat any medical condition. The FDA is not aware of any demonstrated benefit with the use of infant head shaping pillows. These infant head shaping pillows are unapproved medical devices that may create an unsafe sleep environment. The safety communication provides important information about unapproved infant head shaping pillows, including:\u00a0\nBackground on the potential risk of death or injury in infants.\u00a0\nRecommendations for parents, caregivers, and health care providers.\u00a0\nFDA actions to increase awareness of this safety concern. \u00a0\nInstructions for reporting problems to the FDA and the manufacturer. \u00a0\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n11/01/2022\n\nFDA Roundup November 1, 2022\nToday, the FDA issued a proposed rule to amend the color additive regulations to increase the fees for certification services.\u00a0\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n10/28/2022\n\nFDA Roundup: October 28, 2022\u00a0\nToday, the FDA updated the list of Breakthrough Devices that have been authorized for marketing. The list includes 56 Breakthrough Devices that the FDA has authorized for marketing. Online metrics show the number of granted Breakthrough Device designations by fiscal year and by clinical panel, which totals 728 as of September 30, 2022.\u00a0\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n10/25/2022\n\nFDA Roundup: October 25, 2022\u00a0\nToday, the FDA issued a Safety Communications warning consumers, caregivers and health care providers not to use the recalled Mighty Bliss electric heating pads distributed by Whele LLC (doing business as Perch) due to the risks of injury, including electric shocks, skin burns, rashes or irritation. Yesterday, Whele LLC, announced a recall of over 500,000 Mighty Bliss electric heating pads that were distributed between July 2021 and July 2022.\u00a0\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n10/21/2022\n\nFDA Roundup: October 21, 2022\nThis week the FDA announced two upcoming workshops with NIH to promote medical device innovation relating to development and monitoring devices for patients using opioids and risk prediction devices of opioid use and opioid use disorder; authorized the Novavax COVID-19 Vaccine, Adjuvanted; and issued several guidance's across the agency.\u00a0\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n10/18/2022\n\nFDA Roundup: October 18, 2022\nToday, in addition to providing COVID-19 testing updates, the FDA issued an emergency use authorization (EUA) for the first over-the-counter molecular test authorized for use with saliva specimens and reminded consumers that the annual influenza, or flu, vaccine is the best way to prevent the flu for people ages 6 months and older.\n\nPress Release / Public Statement\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n10/14/2022\n\nFDA Roundup: October 14, 2022\nToday, in addition to providing COVID-19 testing updates, the FDA published two FDA Voices titled \u201cFDA Seeks Feedback on Distributed and Point-of-Care Drug Manufacturing\u201d and \u201cFDA Releases New, Prevention Strategies to Enhance Food Safety\u201d, published a reminder about how getting vaccinated in the fall can lower your chances of getting the flu, and announced an upcoming public meeting about the Animal Generic Drug User Fee Act (AGDUFA).\n\nPress Release / Public Statement\n\nResearch\n\t\t\tDrugs\n\t\t\tBiologics\n\n10/12/2022\n\nFDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups\nThe FDA amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine, Bivalent and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to authorize their use as a single booster dose in younger age groups.\n\nPress Release / Public Statement\nBiologics\n10/11/2022\n\nFDA Roundup: October 11, 2022\nToday, in addition to providing COVID-19 testing updates, the FDA announced the launch of the FDA\u2019s Center for Devices and Radiological Health voluntary Total Product Life Cycle Advisory Program (TAP) Pilot as well as an independent study by the National Academies of Sciences, Engineering, and Medicine on the Role of Seafood Consumption in Child Growth and Development, which supports the goals of the FDA\u2019s Closer to Zero Action Plan for reducing the exposure of babies and young children to mercury, arsenic, lead and cadmium from foods.\u00a0\n\nPress Release / Public Statement\n\nResearch\n\t\t\tFood & Beverages\n\t\t\tBiologics\n\t\t\tMedical Devices\n\n10/07/2022\n\nFDA Roundup: October 7, 2022\nToday, the FDA issued an Emergency Use Authorization (EUA) to Abbott Molecular, Inc., for the Alinity m MPXV, a real-time polymerase chain reaction (PCR) test intended to detect monkeypox DNA using lesion swab specimens from individuals suspected of monkeypox virus infection. The Alinity m MPXV test is the first commercial test kit to be authorized for detection of monkeypox. The Alinity m MPXV test is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of PCR and in vitro diagnostic procedures and testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. \u00a7263a, that meet the requirements to perform moderate or high complexity tests.\n\nPress Release / Public Statement\n\nResearch\n\t\t\tBiologics\n\t\t\tMedical Devices\n\n10/04/2022\n\nFDA Roundup: October 4, 2022\nToday, the FDA posted a Constituent Update, highlighting that in September, the FDA and CDC signed a MOU to strengthen food safety in retail environments. The goal of the renewed partnership between the FDA and the CDC is to help reduce the occurrence of foodborne illness in retail and foodservice establishments.\u00a0\n\nPress Release / Public Statement\nMedical Devices\n\t\t\tBiologics\n09/30/2022\n\nFDA Roundup: September 30, 2022\nOn Tuesday, the FDA announced updates to its COVID-19 test policy to address public health testing needs during this phase of the COVID-19 public health emergency. Over the last two years more than 400 COVID-19 tests have been granted emergency use authorization and there are generally enough at-home tests, tests that can be used at the point-of-care such as health clinics, and laboratory-based tests to meet testing needs.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tFood & Beverages\n\t\t\tBiologics\n\t\t\tDrugs\n09/27/2022\n\nFDA Updates COVID-19 Test Policy, Encourages Developers to Seek Traditional Premarket Review for Most Test Types\nThe updated policy describes the FDA\u2019s intent to review only a small subset of new emergency use authorization (EUA) requests for diagnostic tests and encourages developers of all test types interested in marketing authorization to pursue authorization through the de novo classification or 510(k) clearance pre-market review pathways.\n\nPress Release / Public Statement\nMedical Devices\n09/27/2022\n\nFDA Roundup: September 27, 2022\nToday, the FDA released its Activities to Enhance the Safety of Imported Produce, which provides an overview of the work underway to advance the safety of produce imported into the United States. This overview follows the 2019 release of the Strategy for the Safety of Imported Food (Import Strategy) that describes the agency\u2019s comprehensive approach to enhancing the safety of food imported into the United States.\n\nPress Release / Public Statement\nFood & Beverages\n\t\t\tMedical Devices\n\t\t\tBiologics\n09/23/2022\n\nFDA Roundup: September 23, 2022\nToday, the FDA published the FDA Voices: \u201cFDA Issues New Guidance to Help Facilitate Availability of Naloxone to Prevent Opioid Overdoses and Reduce Death,\u201d by Marta Sokolowska, Ph.D., Deputy Center Director for Substance Use and Behavioral Health, Center for Drug Evaluation and Research. The FDA is building on actions to help expand the availability and access to this life-saving medication, an effort that it is hoped will be embraced by harm reduction programs and manufacturers.\n\nPress Release / Public Statement\nFood & Beverages\n\t\t\tMedical Devices\n\t\t\tBiologics\n\t\t\tDrugs\n09/20/2022\n\nFDA Roundup: September 20, 2022\nToday, the FDA alerted medical device users about a potential cybersecurity risk for the Medtronic MiniMed 600 Series Insulin Pump System due to a potential issue associated with the communication protocol for the pump system that could allow unauthorized access to the pump system. A nearby person other than the user or care partner may be able to gain access to the pump while the pump is being paired with other system components and, if compromised, may cause the pump to deliver too much or too little insulin.\n\nPress Release / Public Statement\nMedical Devices\n\t\t\tBiologics\n\t\t\tDrugs\n09/16/2022\nFDA Roundup: September 16, 2022\n\t\t\tToday, the FDA announced that it is taking steps to help increase the availability of novel treatments for rare diseases and conditions in dogs and cats and launched ORA News and Stories, a new, public-facing platform on FDA.gov from the Office of Regulatory Affairs as well as warned consumers about social media trends encouraging people to misuse nonprescription medications and provided COVID-19 testing updates.\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n\t\t\tBiologics\n\t\t\tDrugs\n09/13/2022\nFDA Roundup: September 13, 2022\n\t\t\t\u00a0\n\t\t\tToday, the FDA reissued the letter of authorization for Novavax COVID-19 Vaccine, Adjuvanted to revise the conditions of authorization related to the Vaccine Adverse Event Reporting System (VAERS) reporting requirements for vaccination providers and Novavax, Inc. to include myocarditis and pericarditis and also issued a draft guidance that provides recommendations on risk-based computer software assurance activities for computers and automated data processing systems that are used as part of medical device production or the quality system as well as provided COVID-19 testing updates.\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n09/09/2022\nFDA Roundup: September 9, 2022\n\t\t\t\u00a0\n\t\t\tToday, the FDA posted FAQs on Testing for Monkeypox with answers to frequently asked questions relating to the development and performance of tests for monkeypox.\nPress Release / Public Statement\nFood & Beverages\n\t\t\tMedical Devices\n\t\t\tBiologics\n\t\t\tDrugs\n09/06/2022\nFDA Roundup: September 6, 2022\n\t\t\tToday, the FDA published the 2022: Advancing Regulatory Science at FDA: Focus Areas of Regulatory Science (FARS) report, which outlines topics the agency has identified as needing continued targeted investment in regulatory science research.\nPress Release / Public Statement\nMedical Devices\n\t\t\tBiologics\n\t\t\tDrugs\n09/02/2022\nFDA Roundup: September 2, 2022\u00a0\n\t\t\tOn Thursday, the FDA published the FDA Voices: \u201cUsing A Whole-Of-Governments Approach to Combating Illicit Health Products,\u201d by Cathy Hermsen, Assistant Commissioner for Criminal Investigations and Ritu Nalubola, Director of the FDA\u2019s Europe Office.\nPress Release / Public Statement\nMedical Devices\n\t\t\tBiologics\n\t\t\tDrugs\n08/31/2022\n\nFDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose\nThe FDA amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as a single booster dose at least two months following primary or booster vaccination.\n\nPress Release / Public Statement\nBiologics\n08/30/2022\n\nFDA Roundup: August 30, 2022\nToday, the FDA published the FDA Voices: \u201cFDA\u2019s Overdose Prevention Framework Aims to Prevent Drug Overdoses and Reduce Death,\u201d by Robert M. Califf, M.D., Commissioner of Food and Drugs.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tMedical Devices\n\t\t\tBiologics\n\t\t\tDrugs\n08/26/2022\n\nFDA Removes N95 Respirators from Medical Device Shortage List, Signaling Sufficient Supply\nThis action is the result of increased domestic manufacturing of N95 respirators, as well as updates to the FDA\u2019s supply chain assessment based on engagement with industry and federal stakeholders, and the Centers for Disease Control and Prevention\u2019s National Institute for Occupational Safety and Health\u2019s (NIOSH) approval of new disposable N95s and reusable respirators.\n\nPress Release / Public Statement\nMedical Devices\n08/26/2022\n\nFDA Roundup: August 26, 2022\nToday, FDA provided additional guidance to help prescribers evaluate potential drug interactions when using Paxlovid therapy for COVID-19. Prescribers should review each patient\u2019s full list of medications and use other resources to evaluate for potential drug interactions in patients who take medications that are not included on the Fact Sheet or checklist at this time.\n\nPress Release / Public Statement\nFood & Beverages\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tTobacco\n08/23/2022\n\nFDA Roundup: August 23, 2022\nToday, the FDA\u2019s Office of Global Policy and Strategy posted an article about the FDA\u2019s fruitful partnership with the Inter-American Institute for Cooperation in Agriculture. Additionally, on October 11, the FDA and the Duke-Margolis Center for Health Policy will hold a virtual public workshop titled, \u201cChallenges and Opportunities for REMS Integration, Innovation, and Modernization.\u201d\u00a0\n\nPress Release / Public Statement\nFood & Beverages\n\t\t\tBiologics\n\t\t\tDrugs\n08/19/2022\n\nFDA Roundup: August 19, 2022\nToday, the FDA authorized the emergency use of Novavax COVID-19 Vaccine, Adjuvanted for the prevention of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 through 17 years of age.\n\nPress Release / Public Statement\nMedical Devices\n\t\t\tBiologics\n08/18/2022\n\nReport: FDA's Work to Combat the COVID-19 Pandemic\nOutlines much of the broad range of work the FDA is undertaking to combat the COVID-19 pandemic and prepare for future emergencies.\n\nConsumer Information\nFood & Beverages\n\t\t\tAnimal & Veterinary\n\t\t\tMedical Devices\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tInspections\n\t\t\tWarning Letters\n\t\t\tGuidance Documents\n\t\t\tResearch\n08/16/2022\n\nFDA Roundup: August 16, 2022\nToday, the FDA issued a final rule to improve access to hearing aids which may in turn lower costs for millions of Americans. The agency also warned the public about certain spray sunscreens that have been recalled because of benzene contamination and launched a new external webpage to highlight the Operation Lascar Initiative.\u00a0\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n08/12/2022\n\nFDA Roundup: August 12, 2022\nToday, the FDA posted a safety communication to provide information to blood establishments regarding monkeypox virus and blood donations.\u00a0\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n08/09/2022\n\nFDA Roundup: August 9, 2022\nToday, the FDA\u2019s Office of Global Policy and Strategy published \u201cHow a European Data Law is Impacting FDA,\u201d which looks at how the European Union\u2019s General Data Protection Regulation may be impacting the FDA\u2019s public health activities.\n\nPress Release / Public Statement\n\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\n08/05/2022\n\nFDA Roundup: August 5, 2022\nOn Wednesday, the FDA published the FDA Voices: \u201cFDA Recognizes National Immunization Awareness Month,\u201d by Robert M. Califf, M.D., FDA Commissioner. The FDA plays a key role in immunization by evaluating vaccines for safety and effectiveness before they are made available to the public.\u00a0\n\nPress Release / Public Statement\n\nBiologics\n\t\t\tDrugs\n\t\t\tAnimal & Veterinary\n\t\t\tMedical Devices\n\t\t\tTobacco\n\n08/02/2022\n\nFDA Roundup: August 2, 2022\nThe FDA announced the approval of the first generic firocoxib tablets for pain and inflammation associated with osteoarthritis in horses.\n\nPress Release / Public Statement\nFood & Beverages\n\t\t\tAnimal & Veterinary\n07/29/2022\n\nFDA Roundup: July 29, 2022\nOn Tuesday, the FDA updated the FAQs on Testing for SARS-CoV-2 to note that no tests remain on the commercial manufacturer serology test notification list described in the FDA\u2019s Policy for Coronavirus Disease-2019 Tests. All tests previously on the commercial manufacturer serology test notification list have either been issued an Emergency Use Authorization or should no longer be distributed, marketed, or offered.\n\nPress Release / Public Statement\nFood & Beverages\n\t\t\tAnimal & Veterinary\n\t\t\tMedical Devices\n07/26/2022\n\nFDA Roundup: July 26, 2022\nThe FDA released new updates detailing the agency\u2019s Cyclospora prevention and research efforts. Cyclospora cayetanensis (C. cayetanensis) is a parasite that causes the foodborne intestinal illness cyclosporiasis. People can become infected with cyclosporiasis by ingesting food or water that\u2019s contaminated with C. cayetanensis. The most common symptoms of cyclosporiasis are diarrhea, weight loss, nausea, and fatigue.\u00a0\n\nPress Release / Public Statement\nDrugs\n\t\t\tMedical Devices\n\t\t\tFood & Beverages\n07/22/2022\n\nFDA Roundup: July 22, 2022\nThe FDA today published the \u201cFailure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe\u201d guidance which provides information and recommendations for industry on potential courses of action for an abbreviated new drug application applicant after the issuance of a complete response letter and the actions the FDA can take if the applicant fails to respond to a CRL.\n\nPress Release / Public Statement\n\nDrugs\n\t\t\tMedical Devices\n\t\t\tFood & Beverages\n\n07/19/2022\n\nFDA Roundup: July 19, 2022\nThe FDA today updated the device shortage list and the device discontinuance list on the web page for Medical Device Shortages During the COVID-19 Public Health Emergency. In addition, the FDA is providing information about devices that have been removed from the device shortage list at this time.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n07/15/2022\n\nFDA Roundup: July 15, 2022\nThe FDA today announced the agency\u2019s Total Diet Study Report: Fiscal Years 2018-2010 Elements Data. The agency also issued a safety communication advising people to use swab samples taken directly from a lesion when testing for the monkeypox virus; announced the availability of educational resources for parents and caregivers with questions about using imported infant formula; provided updates on the FDA\u2019s continued implementation of a new law to regulate non-tobacco nicotine products; and authorized additional over-the-counter at-home COVID-19 antigen tests.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n\t\t\tTobacco\n07/13/2022\n\nFDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted\nThe FDA issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.\n\nPress Release / Public Statement\nBiologics\n07/08/2022\n\nFDA Roundup: July 8, 2022\nThe FDA announced approved COMIRNATY (COVID-19 Vaccine, mRNA) for active immunization to prevent COVID-19 in individuals 12 through 15 years of age. The agency also finalized the Guidance for Industry (GFI) #245: Hazard Analysis and Risk-Based Preventive Controls for Food for Animals. Additionally, the agency will continue hosting virtual town halls for test developers for SARS-CoV-2 on July 27 and August 24 from 12:05 p.m. \u2013 1 p.m. ET.\n\nPress Release / Public Statement\nBiologics\n\t\t\tAnimal & Veterinary\n\t\t\tMedical Devices\n07/06/2022\n\nCoronavirus (COVID-19) Update: FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations\nThe FDA revised the EUA for Paxlovid to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid.\n\nPress Release / Public Statement\nDrugs\n07/05/2022\n\nFDA Roundup: July 5, 2022\nThe FDA announced registration opened for the 2022 Public Meeting of National Antimicrobial Resistance Monitoring System. The agency also issued warning letters, jointly with the Federal Trade Commission to four companies for selling unapproved kratom products and to one company for selling essential oils for the treatment or cure of opioid use disorder and withdrawal symptoms. Additionally the agency announced its July Grand Rounds lecture series topic, \u201cOne Health at FDA: From Concept to Application.\u201d\n\nPress Release / Public Statement\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n07/01/2022\n\nFDA Roundup: July 1, 2022\nToday, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future.\u00a0\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n06/30/2022\n\nCoronavirus (COVID-19) Update: FDA Recommends Inclusion of Omicron BA.4/5 Component for COVID-19 Vaccine Booster Doses\nThe FDA has advised manufacturers seeking to update their COVID-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine, beginning in Fall 2022.\n\nPress Release / Public Statement\n\nBiologics\n\n06/28/2022\n\nFDA Roundup: June 28, 2022\nThe FDA announces the authorization of an extension to the shelf-life of the refrigerated AstraZeneca monoclonal antibody, Evusheld, which is currently authorized for emergency use for pre-exposure prophylaxis of COVID-19 in certain adults and pediatric individuals. Consumers concerned about COVID-19 should consult with their health care provider.\n\nPress Release / Public Statement\n\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n\t\t\tFood & Beverages\n\n06/24/2022\n\nFDA Roundup: June 24, 2022\nToday, the FDA announced its recognition of JANAAC as an Accreditation Body Under FSMA- Accredited Third Party Certification Program for a period of five years.\n\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n\t\t\tFood & Beverages\n06/17/2022\n\nFDA Roundup: June 17, 2022\nThe FDA sends Congress its Report on Drug Shortages for Calendar Year 2021 and announces the publication of three International Test Method Standards in Nanotechnology by the American Society for Testing and Materials (ASTM) International.\n\nPress Release / Public Statement\n\nBiologics\n\n06/17/2022\n\nFDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age\nToday, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include use in children down to 6 months of age.\n\nPress Release / Public Statement\n\nBiologics\n\n06/16/2022\n\nAn Update on the Ongoing Federal Response to COVID-19: Current Status and Future Planning\nHearing before the U.S. Senate Committee on Health, Education, Labor and Pensions; Commissioner Robert Califf, M.D. testifies for the FDA. View written testimony.\n\nEvent\n\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n\t\t\tFood & Beverages\n\n06/14/2022\n\nFDA Roundup: June 14, 2022\nOn Friday, the FDA issued an emergency use authorization (EUA) for the Laboratory Corporation of America (Labcorp) VirSeq SARS-CoV-2 NGS Test on the PacBio Sequel II sequencing system.\n\nPress Release / Public Statement\n\nMedical Devices\n\n06/10/2022\n\nFDA Roundup June 10, 2022\nToday, the FDA authorized the marketing of two new tobacco products through the Premarket Tobacco Product Application (PMTA) pathway. On Thursday, the FDA warned about the potential dangers of products for treating moles, seborrheic keratoses, or skin tags. The agency is advising consumers to avoid these products because of their potentially harmful side effects and serious risks.\n\nPress Release / Public Statement\n\nBiologics\n\t\t\tTobacco\n\n06/07/2022\n\nFDA Roundup June 7, 2022\nOn Friday, the FDA provided additional guidance to help prescribers evaluate potential drug interactions when using Paxlovid therapy for COVID-19.\n\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n06/03/2022\n\nFDA Roundup June 3, 2022\nWednesday, the FDA authorized changes to the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) for the PBS/Sucrose formulation of Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older (supplied in multiple dose vials with purple caps), to include additional updated expiration dates in the Fact Sheet. \u00a0A copy of the granting letter and updated Fact Sheet are posted on the FDA\u2019s website.\n\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n05/31/2022\n\nFDA Roundup May 31, 2022\nThe FDA\u2019s Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH), and Center for Biologics Evaluation and Research (CBER) are pleased to invite you to their free, virtual Regulatory Education for Industry (REdI) Annual Conference 2022 which will be held June 6 through June 10.\n\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n05/27/2022\n\nFDA Roundup May 27, 2022\u00a0\nOn May 20, the FDA and HHS/ASPR announced the authorization of an extension to the shelf-life from 12 months to 18 months for specific lots of the refrigerated Eli Lilly monoclonal antibody, bebtelovimab, which is currently authorized for emergency use.\n\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n05/24/2022\n\nFDA Roundup May 24, 2022\nOn May 23, the FDA announced the availability of one final guidance and two draft guidances for blood establishments, as well as the availability of a report drafted by the Regan-Udall Foundation summarizing key findings from a series of targeted conversations with stakeholders about the feasibility of establishing a voluntary public-private partnership to collect and analyze antimicrobial use data from food-producing animals. On May 17, the FDA authorized marketing of BONESUPPORT AB Cerament G, a bone void filler (bone graft substitute) with the antibiotic gentamicin added, that is the first device-drug combination product of its kind.\n\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n05/20/2022\n\nFDA Roundup May 20, 2022\nOn May 17, the FDA published the refreshed Know Your Treatment Options for COVID-19 Consumer Update with the latest information on COVID therapies.\n\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n05/17/2022\n\nFDA Roundup May 17, 2022\nOn May 15, the FDA issued an Emergency Use Authorization (EUA) for the Laboratory Corporation of America (Labcorp) Pixel by Labcorp COVID-19+Flu+RSV Test Home Collection Kit for use with the Labcorp Seasonal Respiratory Virus RT-PCR DTC Test.\n\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n05/17/2022\n\nCoronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years\nToday, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 Vaccine.\u00a0\n\nPress Release / Public Statement\nBiologics\n05/16/2022\n\nFDA Authorizes First COVID-19 Test Available without a Prescription That Also Detects Flu and RSV\nToday, the FDA authorized the Labcorp Seasonal Respiratory Virus RT-PCR DTC Test for use without a prescription by individuals with symptoms of respiratory viral infection consistent with COVID-19. The test can identify and differentiate multiple respiratory viruses at the same time, detecting influenza A and B, commonly known as the flu, respiratory syncytial virus, commonly known as RSV, along with SARS-CoV-2, the virus that causes COVID-19.\n\nPress Release / Public Statement\nMedical Devices\n05/10/2022\n\nFDA Roundup: May 10, 2022\nToday, the FDA approved a new indication for Olumiant (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).\u00a0\n\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n05/06/2022\n\nFDA Roundup: May 6, 2022\nOn Thursday, through the American Rescue Plan Act of 2021, Congress provided temporary funding for the FDA to develop the capacity to sequence SARS-CoV-2 RNA from wastewater samples and to conduct a sampling and sequencing project through 2022.\n\nPress Release / Public Statement\nBiologics\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n05/05/2022\n\nCoronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals\nToday, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.\n\nPress Release / Public Statement\nBiologics\n05/03/2022\n\nFDA Roundup: May 3, 2022\nOn Friday, the FDA warned there are counterfeit versions of the following at-home over-the-counter (OTC) COVID-19 diagnostic tests being distributed or used in the United States.\n\nPress Release / Public Statement\nBiologics\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n04/29/2022\n\nFDA Roundup: April 29, 2022\nOn Thursday, the FDA updated the page, At-Home OTC COVID-19 Diagnostic Tests, to include expiration date information to help consumers find the current expiration date for any FDA authorized at-home OTC COVID-19 diagnostic test.\n\nPress Release / Public Statement\nBiologics\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n04/29/2022\n\nCoronavirus (COVID-19) Update: FDA Announces Tentative Advisory Committee Meeting Schedule Regarding COVID- 19 Vaccines\nToday, the FDA is announcing its plans to hold virtual meetings of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) in anticipation of complete submissions of emergency use authorization (EUA) requests in the coming months that have been publicly announced by COVID-19 vaccine manufacturers.\n\nPress Release / Public Statement\nBiologics\n04/26/2022\n\nFDA Roundup: April 26, 2022\nThe FDA announced the May and June dates for the Virtual Town Hall Series for Test Developers on Coronavirus (COVID-19). The new time for the events will be from 12:05 p.m. \u2013 1 p.m. ET\n\nPress Release / Public Statement\nTobacco\n\t\t\tMedical Devices\n04/22/2022\n\nFDA Roundup: April 22, 2022\nTuesday, as part of the FDA\u2019s effort to protect consumers, the agency issued a warning letter to Kleenhanz, LLC for selling unapproved products with unproven COVID-19 claims. Consumers concerned about COVID-19 should consult with their health care provider.\n\nPress Release / Public Statement\nDrugs\n\t\t\tMedical Devices\n04/19/2022\n\nFDA Roundup: April 19, 2022\nToday, the FDA issued its final rule titled \"Beverages: Bottled Water\". This final rule amends the allowable level for fluoride in domestically packaged and imported bottled water to which fluoride is added to 0.7 milligrams per liter (mg/L). The proposed rule published in April 2019.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n\t\t\tTobacco\n04/15/2022\n\nFDA Roundup: April 15, 2022\nOn April 14, the FDA issued an emergency use authorization (EUA) to InspectIR Systems for their InspectIR COVID-19 Breathalyzer test. The InspectIR COVID-19 Breathalyzer test is the first COVID-19 diagnostic test that detects chemical compounds in breath samples associated with SARS-CoV-2 infection. The authorization for the InspectIR COVID-19 Breathalyzer test is an example of the FDA\u2019s continued commitment to support the development of innovative, appropriately accurate and reliable diagnostic tests that increase testing options for COVID-19.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n\t\t\tTobacco\n04/14/2022\n\nCoronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples\nToday, the FDA issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test that detects chemical compounds in breath samples associated with a SARS-CoV-2 infection.\n\nPress Release / Public Statement\nMedical Devices\n04/12/2022\n\nFDA Roundup: April 12, 2022\nAs part of the FDA\u2019s effort to protect consumers, on April 5, the agency issued a warning letter to CofixRx, LLC for selling an unapproved product with misleading COVID-19 claims. Consumers concerned about COVID-19 should consult with their health care provider.\n\nPress Release / Public Statement\nDrugs\n\t\t\tMedical Devices\n04/08/2022\n\nFDA Roundup: April 8, 2022\nOn April 7, the FDA authorized an extension for the shelf life of the refrigerated Janssen COVID-19 Vaccine, allowing the product to be stored at 2-8 degrees Celsius for 11 months.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n04/05/2022\n\nFDA Roundup: April 5, 2022\nToday, the FDA announced sotrovimab is no longer authorized to treat COVID-19 in any U.S. region due to increases in the proportion of COVID-19 cases caused by the Omicron BA.2 sub-variant.\n\nPress Release / Public Statement\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n04/01/2022\n\nFDA Roundup: April 1, 2022\nThe FDA published two FDA voices - \u201cGive Your Community a Boost: Combatting Misinformation Through Communication and Research\u201d and \u201cFDA\u2019s Technology and Data Modernization in Action in 2022.\u201d The FDA also published findings from a facility inspection of Abbott Nutrition in Sturgis, Michigan, revised the guidance: Emergency Use Authorization for Vaccines to Prevent COVID-19, denied two the request in two citizen petitions, published the FDA voices announced the extension of a public comment period, approved a new animal drug, updated a list of which regions in which the drug Sotrovimab is not authorized, approved a medical device to treat defects or legions that can occur in cartilage covering bones in the knee joint, authorized marketing of a medical device for measuring the brain temperature of neonates (infants less than four weeks old) and updated a fact sheet and FAQ regarding dosing information of Evusheld.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n03/29/2022\n\nFDA Roundup: March 29, 2022\nToday, the FDA authorized a manufacturing change for the Moderna COVID-19 Vaccine to include an additional presentation of the vaccine for booster vaccination doses only.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n03/29/2022\n\nCoronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals\nThe FDA authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.\n\nPress Release / Public Statement\nBiologics\n03/25/2022\n\nFDA Roundup: March 25, 2022\nToday, the FDA announced the COVID-19 treatment sotrovimab is no longer authorized for use at this time in the U.S. Health and Human Services (HHS) regions 1 and 2 due to the high frequency of the Omicron BA.2 sub-variant and data showing that the authorized dose of sotrovimab is unlikely to be effective against that sub-variant.\n\nPress Release / Public Statement\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n03/22/2022\n\nFDA Roundup: March 22, 2022\nOn March 21, the FDA issued a Letter to Health Care Personnel to provide recommendations, including conservation strategies, for prefilled 0.9% sodium chloride IV lock/ flush syringes. Prefilled 0.9% sodium chloride IV lock/ flush syringes are in shortage because of an increase in demand during the COVID-19 public health emergency.\n\nPress Release / Public Statement\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n03/21/2022\n\nCoronavirus (COVID-19) Update: FDA to Hold Advisory Committee Meeting on COVID-19 Vaccines to Discuss Future Boosters\nOn Wed., April 6, FDA will hold a virtual meeting of its Vaccines and Related Biological Products Advisory Committee to discuss considerations for future COVID-19 vaccine booster doses and the strain selection process to address current and emerging variants during the Fall season 2022.\n\nPress Release / Public Statement\nBiologics\n03/18/2022\n\nFDA Roundup: March 18, 2022\nThe FDA issues warning letters against companies selling misbranded and unapproved drugs, and updates frequently asked questions to the COVID-19 Test FAQs.\n\nPress Release / Public Statement\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n03/15/2022\n\nFDA Roundup: March 15, 2022\nOn March 10, as part of the FDA\u2019s effort to protect consumers, the agency issued a warning letter jointly with the Federal Trade Commission to Soda Pharm for selling unapproved products with fraudulent COVID-19 claims.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n03/11/2022\n\nFDA Roundup: March 11, 2022\nAs part of the FDA\u2019s effort to protect consumers, on March 7, the agency issued a warning letter jointly with the Federal Trade Commission to Viraldine, LLC for selling unapproved products with fraudulent COVID-19 claims. On March 4, the FDA authorized an extension for the shelf life of the refrigerated Janssen COVID-19 Vaccine, from six to nine months, allowing the product to be stored at 2-8 degrees Celsius. Update: The FDA updated this safety communication to clarify that the ACON Flowflex SARS-CoV-2 Antigen Rapid Test (Self-Testing) in dark blue packaging is a product of ACON Biotech (Hangzhou) Co., Ltd.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n03/08/2022\n\nFDA Roundup: March 8, 2022\nToday, the FDA announced the signing of a domestic mutual reliance partnership agreement with the Minnesota Department of Agriculture, a consent decree of permanent injunction was signed by a judge requiring Salud Natural Entrepreneur, Inc. of Illinois not to engage in any distribution operations until it completes corrective actions to ensure the company is in compliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act), and announced a low-risk determination for the marketing of products from two genome-edited beef cattle and their offspring after determining that the intentional genomic alteration (IGA) does not raise any safety concerns.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n03/04/2022\n\nFDA Roundup: March 4, 2022\nFDA posted an FDA Voices piece on speeding therapies for rare diseases and announced, with NASA, NIH and HHS, the award of eight contracts to extend longevity of complex in vitro (human) models.\n\nPress Release / Public Statement\nDrugs\n\t\t\tMedical Devices\n03/01/2022\n\nFDA Roundup: March 1, 2022\nToday, the FDA issued a safety communication warning people not to use the Celltrion DiaTrust COVID-19 Ag Rapid Test that is in green and white packaging. The test has not been authorized, cleared or approved by the FDA for distribution or use in the United States. The FDA is concerned about the risk of false results when using this unauthorized test.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n02/25/2022\n\nFDA Roundup: February 25, 2022\nOn Feb. 24, the FDA issued an update on our continuing efforts to understand and reduce exposure to PFAS from foods. The FDA made available new PFAS test results from our most recent survey of the general food supply that showed three samples\u2014tilapia, cod, and shrimp, had detectable levels of at least one type of PFAS. Based on the best available current science, the FDA has no scientific evidence that the levels of PFAS found in the samples tested indicate a need to avoid any particular food. The FDA also posted on the Authorized Uses of PFAS in Food Contact Applications webpage, the first annual updates provided to the FDA from the three manufacturers that committed to the voluntary market phase-out of certain short-chain PFAS used in food packaging.\n\nPress Release / Public Statement\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n02/22/2022\n\nFDA Roundup: February 22, 2022\nToday, the FDA posted a new resource, At-Home COVID-19 Diagnostic Tests, that provides a list of all FDA-authorized at-home over-the-counter (OTC) COVID-19 diagnostic tests. Testing and other protective steps like mask-wearing and COVID-19 vaccination are essential to stop the spread of COVID-19. At-home OTC COVID-19 diagnostic tests play a key role in the fight against COVID-19.\n\nPress Release / Public Statement\nDrugs\n\t\t\tMedical Devices\n02/18/2022\n\nFDA Roundup: February 18, 2022\nToday, the FDA that it has found an additional four lots of AstraZeneca COVID-19 vaccine drug substance manufactured at the Emergent facility in Baltimore, Maryland, to be acceptable for use for potential export. The agency also warned consumers not to use certain powdered infant formula produced in Abbott Nutrition\u2019s facility in Sturgis, Michigan. Additionally, the FDA published a new batch of product-specific guidances to provide recommendations for developing generic drugs and generating the evidence needed to support abbreviated new drug application (ANDA) approval.\n\nPress Release / Public Statement\nBiologics\n\t\t\tFood & Beverages\n\t\t\tDrugs\n\t\t\tMedical Devices\n02/15/2022\n\nFDA Roundup: February 15, 2022\nToday, the FDA released a request for public comments about antimicrobial use in companion animals and the potential impact of this use on antimicrobial resistance in both animals and people. The agency also published the FDA Voices, \u201cInnovation and Scientific Collaboration Moved the Generic Drug Program Forward In 2021.\u201d Additionally, the FDA provided updates on interim results from two postmarket studies on Essure. Finally, the agency issued a warning letter to the operator of one website, www.pharmacy2home.com, for offering for sale in the U.S. unapproved drugs for multiple diseases, including COVID-19.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tDrugs\n\t\t\tMedical Devices\n02/11/2022\n\nFDA Roundup: February 11, 2022\nOn Feb. 7, the FDA approved an abbreviated new drug application for succinylcholine chloride injection USP 200 mg/10 mL, which is indicated, in addition to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Also, as of today, 421 tests and sample collection devices for the virus that causes COVID-19 are authorized by the FDA under emergency use authorizations (EUAs).\n\nPress Release / Public Statement\nDrugs\n\t\t\tMedical Devices\n02/11/2022\n\nFDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant\nBebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other monoclonal antibodies that have been authorized for the treatment of high-risk patients with mild to moderate COVID-19 and shown a benefit in reducing the risk of hospitalization or death.\n\nPress Release / Public Statement\nDrugs\n\t\t\tBiologics\n02/11/2022\n\nFDA Postpones Advisory Committee Meeting to Discuss Request for Authorization of Pfizer-BioNTech COVID-19 Vaccine for Children 6 Months Through 4 Years of Age\nThe FDA has been notified by Pfizer that new data have recently emerged regarding its emergency use authorization request for the use of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age. Based on the agency\u2019s preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization.\n\nPress Release / Public Statement\nBiologics\n02/08/2022\n\nFDA Roundup: February 8, 2022\nThe FDA issued a guidance for industry and investigators to announce a policy discouraging sponsors from developing or seeking approval or authorization for the use of sanitation tunnels, that spray humans with a mist of disinfectant or aerosolized antiseptic with the aim of preventing or treating COVID-19. The agency also warned health care providers, parents and caregivers of pediatric patients (children) who receive enteral feeding that there is a risk of strangulation from the use of enteral feeding delivery sets.\n\nPress Release / Public Statement\nDrugs\n\t\t\tMedical Devices\n02/04/2022\n\nFDA Roundup: February 4, 2022\nThe FDA determined that beginning on Feb. 7, the agency will resume conducting domestic surveillance inspections across all commodities given the decline in COVID-19 cases across the country. The FDA also issued a draft guidance advising sponsors on the premarketing assessment of a drug\u2019s effect on blood pressure. Additionally, the FDA announced its 2022-2025 strategic priorities for the Center for Devices and Radiological Health, a proposed rule to improve the security of the drug supply chain as well as a new website showcasing the Center for Veterinary Medicine\u2019s innovative research to protect human and animal health.\n\nPress Release / Public Statement\nDrugs\n\t\t\tAnimal & Veterinary\n\t\t\tMedical Devices\n02/01/2022\n\nCoronavirus (COVID-19) Update: FDA Advisory Committee Meeting to Discuss Request for Authorization of Pfizer-BioNTech COVID-19 Vaccine for Children 6 Months Through 4 Years of Age\nFDA announced a virtual meeting of its Vaccines and Related Biological Products Advisory Committee on Feb. 15 to discuss the request for emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine for use in children 6 months through 4 years of age.\n\nPress Release / Public Statement\nBiologics\n02/01/2022\n\nFDA Roundup: February 1, 2022\nThe FDA issued a safety communication warning people to stop using the Empowered Diagnostics CovClear COVID-19 Rapid Antigen Test and ImmunoPass COVID-19 Neutralizing Antibody Rapid Test. The FDA also published the 2021 Center for Devices and Radiological Health (CDRH) annual report, announced an upcoming workshop related to multi-component biomarkers and released a list of guidance topics that are a priority for the FDA Foods Program as well as a video that provides an overview of the Food Allergy Safety, Treatment, Education, and Research (FASTER) Act.\n\nPress Release / Public Statement\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n01/31/2022\n\nFDA Takes Key Action By Approving Second COVID-19 Vaccine\nThe FDA approved a second COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine; the approved vaccine will be marketed as Spikevax for the prevention of COVID-19 in individuals 18 years of age and older.\n\nPress Release / Public Statement\nBiologics\n01/28/2022\n\nFDA Roundup: January 28, 2022\nThe FDA added four bulk drug substances to list of substances that may be used in compounding by outsourcing facilities. FDA also posted an article discussing the agency\u2019s commitment toward advancing two proposed tobacco product standards and published several guidances on generic drug application submissions, labeling and review.\n\nPress Release / Public Statement\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n\t\t\tTobacco\n01/25/2022\n\nFDA Roundup: January 25, 2022\nThe FDA authorized another over-the-counter COVID-19 antigen test and also provided updates to its web pages on In Vitro Diagnostics EUAs for Molecular and Antigen Diagnostic Tests for SARS-CoV-2.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n01/24/2022\n\nCoronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant\nThe FDA revised the authorizations for two monoclonal antibody treatments to limit their use to only when the patient is likely to have been infected with or exposed to a variant that is susceptible of these treatments.\n\nPress Release / Public Statement\nDrugs\n01/21/2022\n\nFDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19\nThe FDA took two actions to expand the use of the antiviral drug Veklury (remdesivir) to certain non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease in places such as skilled nursing facilities, home healthcare settings and outpatient facilities.\n\nPress Release / Public Statement\nDrugs\n01/21/2022\n\nFDA Roundup: January 21, 2022\nThe FDA extended the previously announced temporary changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as the agency further adapts to the evolving COVID-19 pandemic and the spread of the omicron variant.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tDrugs\n\t\t\tMedical Devices\n01/18/2022\n\nFDA Roundup: January 18, 2022\nThe FDA published the CDRH Health of Women Program Strategic Plan, which outlines the program\u2019s priorities to protect and promote the health of women.\n\nPress Release / Public Statement\nFood & Beverages\n\t\t\tMedical Devices\n01/14/2022\n\nFDA Roundup: January 14, 2022\nThe FDA published an FDA Voices entitled, Many Important Drugs Approved in 2021 as COVID-19 Pandemic Continues, which highlights the wide variety of safe and effective new drug therapies approved in 2021 despite challenges brought on by the ongoing COVID-19 pandemic.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tCosmetics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n01/13/2022\n\nFDA 2021 Year in Review - Working for You\nThis year end report highlights key FDA actions in 2021 to protect and improve public health, including a COVID-19 vaccine approval and authorizations of COVID-19 tests and treatments. The report also highlights ways the FDA strengthened maternal and infant health, modernized food safety, and protected young people from the harmful effects of tobacco.\n\nConsumer Information\nAnimal & Veterinary\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n\t\t\tResearch\n\t\t\tTobacco\n01/11/2022\n\nFDA Roundup: January 11, 2022\nThe FDA announced in a letter of enforcement discretion that it does not intend to object to the use of certain qualified health claims regarding the consumption of magnesium and a reduced risk of high blood pressure (hypertension).\n\nPress Release / Public Statement\nDrugs\n\t\t\tMedical Devices\n01/11/2022\n\nAddressing New Variants: A Federal Perspective on the COVID-19 Response\nHearing before the U.S. Senate Committee on Health, Education, Labor and Pensions; Acting Commissioner Janet Woodcock, M.D. testifies for the FDA. View written testimony.\n\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n01/07/2022\n\nFDA Roundup: January 7, 2022\nThe FDA published an interactive public data dashboard for viewing historical data from the Reportable Food Registry, issued an outbreak advisory regarding two salad blends, announced two virtual public meetings on a recently released proposed rule, and added organ preservation solutions to the device shortage list.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n01/07/2022\n\nCoronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months\nToday, the FDA amended the emergency use authorization (EUA) for the Moderna COVID-19 Vaccine to shorten the time between the completion of a primary series of the vaccine and a booster dose to at least five months for individuals 18 years of age and older.\n\nPress Release / Public Statement\nBiologics\n01/04/2022\n\nFDA Roundup: January 4, 2022\nThe FDA published a webpage describing the FDA has developed the capacity to sequence SARS-CoV-2 RNA from wastewater samples, approved a generic drug application for Albuterol Sulfate Inhalation Solution, implemented temporary changes to agency inspection activities, issued warning letters to two companies for selling unapproved products with fraudulent COVID-19 claims, announced three lots of AstraZeneca COVID-19 vaccine drug substance manufactured at the Emergent facility in Baltimore, Maryland, to be acceptable for use for potential export, updated the SARS-CoV-2 viral mutations webpage, and authorized two additional OTC antigen tests.\n\nPress Release / Public Statement\nDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n01/03/2022\n\nFDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine\nThe FDA amended the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine to take several actions that will expand the use of the vaccine in certain populations.\n\nPress Release / Public Statement\nBiologics\n12/28/2021\n\nCoronavirus (COVID-19) Update\nThe FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests\u202fweb page to share\u202fnew\u202finformation regarding the impact of the\u202fSARS-CoV-2 omicron variant on antigen diagnostic tests.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n12/23/2021\n\nCoronavirus (COVID-19) Update\nThis week, the FDA authorized two oral antivirals for the treatment of COVID-19 in certain patients; and released a joint statement with ASPR on the circulating SARS-CoV-2 viral variants, including Omicron.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n12/23/2021\n\nCoronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults\nThe FDA issued an emergency use authorization for Merck\u2019s molnupiravir for the treatment of mild-to-moderate COVID-19 in certain adults.\n\nPress Release / Public Statement\nDrugs\n12/22/2021\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19\nToday, the FDA issued an emergency use authorization for the first oral antiviral for treatment of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds).\n\nPress Release / Public Statement\nDrugs\n12/21/2021\n\nCoronavirus (COVID-19) Update\nThe FDA and its global partners will use machine learning approaches to enhance the understanding of nonclinical model responses to SARS-CoV-2.\n\nCOVID-19 Update\nMedical Devices\n12/17/2021\n\nCoronavirus (COVID-19) Update\nThe FDA approved a manufacturing change for Comirnaty to include a formulation that uses a different buffer; and an abbreviated new drug application for increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines (a class of neurotransmitters).\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n12/14/2021\n\nCoronavirus (COVID-19) Update\nThe Janssen COVID-19 fact sheets have been updated to include contraindications for people with a history of thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine or any other adenovirus-vectored COVID-19 vaccine.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n12/10/2021\n\nCoronavirus (COVID-19) Update\nThe FDA updates information about the Meridian Bioscience, Inc. Revogene SARS-CoV-2 test, including the impact of the SARS-CoV-2 omicron variant on test performance.\n\nCOVID-19 Update\nMedical Devices\n12/09/2021\n\nCoronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Booster Dose to 16- and 17-Year-Olds\nToday, the FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 16 and 17 years of age at least six months after completion of primary vaccination with the Pfizer-BioNTech COVID-19 Vaccine.\n\nPress Release / Public Statement\nBiologics\n12/08/2021\n\nCoronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals\nToday, the FDA issued an emergency use authorization (EUA) for AstraZeneca\u2019s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).\n\nPress Release / Public Statement\nDrugs\n12/07/2021\n\nCoronavirus (COVID-19) Update\nThe FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information, including FDA recommendations for clinical laboratory staff and health care providers. Additionally, the agency also added the Tide Laboratories, LLC, DTPM COVID-19 RT-PCR Test to another list of impacted tests.\n\nCOVID-19 Update\nMedical Devices\n12/03/2021\n\nFDA Expands Authorization of Two Monoclonal Antibodies for Treatment and Post-Exposure Prevention of COVID-19 to Younger Pediatric Patients, Including Newborns\nFDA revised the EUA of bamlanivimab and etesevimab, administered together, to treat mild to moderate COVID-19 in all younger pediatric patients, including newborns. The drug combination is also now authorized for post-exposure prevention of COVID-19 in all pediatric patients, including newborns.\n\nPress Release / Public Statement\nDrugs\n11/30/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issues a statement regarding its work with federal partners, international regulators and medical product companies to quickly address any potential impacts of the new omicron variant and announces a new project to expand the FDA-ARGOS database.\n\nCOVID-19 Update\nMedical Devices\n11/30/2021\n\nCoronavirus (COVID-19) Update: FDA Actively Working to Investigate, Address Potential Impacts of Omicron Variant; Urges Vaccination and Boosters\nFDA is working with federal partners, international regulators and medical product companies to quickly address any potential impacts of the omicron variant.\n\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n11/30/2021\n\nAntimicrobial Drugs Advisory Committee Meeting\nThe committee will discuss Emergency Use Authorization (EUA) 000108, submitted by Merck & Co. Inc., for emergency use of molnupiravir oral capsules for treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization. View webcast.\n\nEvent\nDrugs\n11/23/2021\n\nCoronavirus (COVID-19) Update\nThe FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests; and approved an abbreviated new drug application to treat serious or severe infections caused by susceptible strains of methicillin-resistant (\u03b2-lactam-resistant) staphylococci.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n11/19/2021\n\nFDA Expands Eligibility for COVID-19 Vaccine Boosters\nThe FDA amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals 18 years of age and older after completion of primary vaccination with any FDA-authorized or approved COVID-19 vaccine.\n\nPress Release / Public Statement\nBiologics\n11/16/2021\n\nCoronavirus (COVID-19) Update\nThe FDA takes several actions to increase access to accurate and reliable COVID-19 tests.\n\nCOVID-19 Update\nMedical Devices\n11/15/2021\n\nCoronavirus (COVID-19) Update: FDA Updates Test Policies to Help to Ensure Accuracy and Reliability of Tests and Increase Access to At-Home Tests\nToday, the FDA is taking several important actions to support ongoing nationwide COVID-19 testing efforts.\n\nPress Release / Public Statement\nMedical Devices\n11/12/2021\n\nCoronavirus (COVID-19) Update\nThe FDA posted an updated Molecular and Antigen Home Use Test Template intended to assist test developers and facilitate the Emergency Use Authorization (EUA) request and Pre-EUA submission processes for COVID-19 tests. The template is intended to help test developers provide validation data and other information to the FDA. Developers can use alternative approaches and can discuss them with the FDA.\n\nCOVID-19 Update\nMedical Devices\n11/05/2021\n\nCoronavirus (COVID-19) Update\nThe FDA has issued an emergency use authorization (EUA) for the iHealth COVID-19 Antigen Rapid Test, an OTC COVID-19 antigen diagnostic test that delivers results in 15 minutes.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n11/04/2021\n\nNext Steps: The Road Ahead for the COVID-19 Response\nHearing before the U.S. Senate Committee on Health, Education, Labor and Pensions; Acting Commissioner Janet Woodcock, M.D. testifies for the FDA. View written testimony.\n\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n11/02/2021\n\nCoronavirus (COVID-19) Update\nThe FDA recently revised several extramural research contracts in the Medical Countermeasures Initiative (MCMi) Regulatory Science Program to expand efforts supporting COVID-19 medical countermeasure development.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n10/29/2021\n\nCoronavirus (COVID-19) Update\nThe FDA discussed the agency\u2019s actions to expand the use of a single booster dose for COVID-19 vaccines in eligible populations. In addition, the FDA authorized the 11th over-the-counter (OTC) COVID-19 test and is investigating certain imported medical gloves that appear to have been reprocessed, cleaned or recycled and sold as new.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n10/29/2021\n\nFDA Authorizes COVID-19 Vaccine in Children 5 through 11\nThe authorization was based on the FDA\u2019s thorough and transparent evaluation of the data that included input from independent advisory committee experts who overwhelmingly voted in favor of making the vaccine available to children in this age group.\n\nPress Release / Public Statement\nBiologics\n10/26/2021\n\nCoronavirus (COVID-19) Update\nThe FDA authorized the 10th over-the-counter (OTC) COVID-19 test, reissued the emergency use authorization (EUA) for another OTC COVID-19 test, and updated the EUA templates for test developers seeking an EUA for OTC tests.\n\nCOVID-19 Update\nMedical Devices\n10/26/2021\n\nVaccines and Related Biological Products Advisory Committee Meeting\nThe committee will discuss a request to amend Pfizer-BioNTech\u2019s Emergency Use Authorization (EUA) for administration of their COVID-19 mRNA vaccine to children 5 through 11 years of age. View livestream.\n\nEvent\nBiologics\n10/22/2021\n\nCoronavirus (COVID-19) Update\nToday, the FDA began posting materials for the next Vaccine and Related Biological Products Advisory Committee (VRBPAC) meeting, happening on Tuesday, Oct. 26. The committee will meet in open session to discuss a request to amend Pfizer-BioNTech\u2019s Emergency Use Authorization (EUA) for administration of their COVID-19 mRNA vaccine to children 5 through 11 years of age.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n10/20/2021\n\nFDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines\nThe FDA took additional actions regarding booster doses of COVID-19 vaccines, including authorizing heterologous (or \u201cmix and match\u201d) booster doses in eligible individuals following completion of primary vaccination with a different available COVID-19 vaccine. Listen to the media call.\n\nPress Release / Public Statement\nBiologics\n10/19/2021\n\nCoronavirus (COVID-19) Update\nOn Oct. 12, the FDA approved an abbreviated new drug application for propofol injectable emulsion, single patient-use vials. This drug is an intravenous general anesthetic and sedation drug listed in the FDA Drug Shortage Database. Side effects of propofol emulsion injection include hypotension (low blood pressure), bradycardia (low heart rate), and apnea (temporary stopping of breathing).\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n10/15/2021\n\nCoronavirus (COVID-19) Update\nOn Oct. 12, the FDA posted information about an assessment of the Emergency Use Authorization (EUA) process that the FDA\u2019s Center for Devices and Radiological Health (CDRH) implemented to help authorize COVID-19 tests. The Center for Food Safety and Applied Nutrition published a Constituent Update intended for food and agriculture workers/industry encouraging vaccination against influenza and COVID-19.\n\nCOVID-19 Update\nMedical Devices\n\t\t\tFood & Beverages\n10/14/2021 - 10/15/2021\n\nVaccines and Related Biological Products Advisory Committee Meeting\nThe committee will discuss the Emergency Use Authorization (EUA) of the ModernaTX Inc. COVID-19 vaccine and the Janssen Biotech Inc. COVID-19 vaccine for the administration of an additional dose, or \u201cbooster\u201d dose, following completion of the primary series, to individuals 18 years of age and older. View October 14 livestream. View October 15 livestream.\n\nEvent\nBiologics\n10/14/2021\n\nFDA to Hold Advisory Committee Meeting to Discuss Merck and Ridgeback\u2019s EUA Application for COVID-19 Oral Treatment\nThe U.S. Food and Drug Administration is announcing an upcoming meeting of its Antimicrobial Drugs Advisory Committee (AMDAC) on November 30 to discuss Merck and Ridgeback\u2019s request for an emergency use authorization (EUA) for molnupiravir, an investigational antiviral drug to treat COVID-19.\n\nPress Release / Public Statement\nDrugs\n10/12/2021\n\nCoronavirus (COVID-19) Update\nToday, the FDA announced that it intends to withdraw, effective Dec. 31, 2021, guidance documents originally issued in March 2020 outlining temporary policies for manufacturers that were not drug manufacturers at the time to produce certain alcohol-based hand sanitizer and alcohol for use in hand sanitizers during the public health emergency.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n10/08/2021\n\nCoronavirus (COVID-19) Update\nOn Tuesday October 5, the FDA issued a safety communication to alert test users, caregivers, health care personnel and the public of the potential for false positive results with certain lots of the Ellume COVID-19 Home Test due to a recently identified manufacturing issue.\n\nCOVID-19 Update\nMedical Devices\n10/05/2021\n\nCoronavirus (COVID-19) Update\nOn Sept. 28, the FDA will issue a warning letter to Strategia Project Management, Inc. for selling an unapproved product with unproven COVID-19 claims. The agency recommends that consumers who have concerns about COVID-19 should consult with their health care provider.\n\nCOVID-19 Update\nMedical Devices\n10/04/2021\n\nCoronavirus (COVID-19) Update: FDA Authorizes Additional OTC Home Test to Increase Access to Rapid Testing for Consumers\nFDA issued an emergency use authorization (EUA) for the ACON Laboratories Flowflex COVID-19 Home Test, an over-the-counter (OTC) COVID-19 test, which adds to the growing list of tests that can be used at home without a prescription.\n\nPress Release / Public Statement\nMedical Devices\n10/01/2021\n\nCoronavirus (COVID-19) Update\nThe FDA authorizes an emergency use authorization for one additional batch of the Janssen COVID-19 vaccine and the FDA\u2019s Acting Commissioner, Dr. Janet Woodcock, discusses the authorization of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n10/01/2021\n\nFDA to Hold Advisory Committee Meetings to Discuss Emergency Use Authorization for Booster Doses and COVID-19 Vaccines for Younger Children\nThe FDA is announcing two upcoming meetings of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss newly available data for the currently available COVID-19 vaccines.\n\nPress Release / Public Statement\nBiologics\n09/24/2021\n\nStakeholder Call: Pfizer-BioNTech COVID-19 Vaccine Booster Dose\nActing FDA Commissioner, Janet Woodcock, M.D. and Director, FDA Center for Biologics Evaluation and Research, Peter Marks, M.D., Ph.D., discuss the Pfizer-BioNTech COVID-19 Vaccine booster dose.\n\nPodcast / Video\nBiologics\n09/22/2021\n\nFDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations\nFDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for the use of a single booster dose, to be administered at least six months after completion of the primary series with the Pfizer-BioNTech COVID-19 Vaccine in certain populations.\n\nPress Release / Public Statement\nBiologics\n09/20/2021\n\nPodcast: COVID-19 Vaccine Boosters and COVID-19 Vaccines for Kids\nActing FDA Commissioner Dr. Janet Woodcock discusses additional shots of the COVID-19 vaccine (\"boosters\") and COVID-19 vaccines for kids under 12\n\nPodcast / Video\nBiologics\n09/17/2021\n\nCoronavirus (COVID-19) Update\nThe FDA took the following actions in the agency\u2019s ongoing response to the COVID-19 pandemic: issued a Letter to Health Care Providers about the potential for false positive results with Abbott Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP Kits; revised the Emegency Use Authorization (EUA) for bamlanivimab and etesevimab, administered together, to include an emergency use as post-exposure prophylaxis for COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) who are at high risk for progression to severe COVID-19; issued a revised guidance to help expand the availability of face masks, barrier face coverings and face shields for the general public, including health care personnel, as well as surgical masks and particulate filtering facepiece respirators (FFRs) (including N95 respirators) for health care personnel for the duration of the COVID-19 public health emergency; and authorized the use, under the EUA for the Janssen COVID-19 vaccine, of two additional batches of vaccine drug substance manufactured at the Emergent facility.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n09/17/2021\n\nVaccines and Related Biological Products Advisory Committee\nThe Vaccines and Related Biological Products Advisory Committee will meet in open session to discuss the matter of additional doses of COVID-19 vaccines and specifically to discuss the Pfizer-BioNTech supplemental Biologics License Application for administration of a third (\u201cbooster\u201d) dose of Comirnaty (COVID-19 Vaccine, mRNA) in individuals 16 years of age and older. View livestream.\n\nEvent\nBiologics\n09/16/2021\n\nFDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19\nThe FDA revised the emergency use authorization (EUA) for bamlanivimab and etesevimab, administered together, to include emergency use as post-exposure prophylaxis (prevention) for COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. Post-exposure prophylaxis with bamlanivimab and etesevimab, administered together, is not a substitute for vaccination against COVID-19.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n09/10/2021\n\nCoronavirus (COVID-19) Update\nThe FDA approved an abbreviated new drug application indicated for the sedation of initially intubated and mechanically ventilated patients during treatment in an intensive-care setting, authorized the use--under the emergency use authorization (EUA) for the Janssen COVID-19 vaccine--of one additional batch of vaccine drug substance manufactured at the Emergent facility, and issued a revised guidance which provides general recommendations to prospective generic drug applicants in the form of questions and answers that have been addressed during the COVID-19 public health emergency. The FDA also posted a statement titled \u201cFDA Will Follow The Science On COVID-19 Vaccines For Young Children\u201d.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n09/10/2021\n\nFDA Will Follow The Science On COVID-19 Vaccines For Young Children\nFDA leadership outlines steps the FDA will take to ensure the safety and efficacy of COVID-19 vaccines for young children.\n\nPress Release / Public Statement\nBiologics\n09/08/2021\n\nVirtual Town Hall Series - COVID-19 Test Development and Validation\nFDA will host a virtual Town Hall on 9/8/2021 from 12:15 to 1:15 ET to help answer technical questions about the development and validation of tests for SARS-CoV-2. Participants may ask questions during the call or submit questions by noon on 9/8/2021 to CDRHWebinars@fda.hhs.gov.\n\nEvent\nMedical Devices\n09/07/2021\n\nCoronavirus (COVID-19) Update\nFDA issued a warning letter to a company for not complying with federal laws and regulations during the clinical investigation of an investigational drug to mitigate and treat COVID-19.\n\nCOVID-19 Update\nMedical Devices\n09/01/2021\n\nFDA In Brief: FDA to Hold Advisory Committee Meeting to Discuss Pfizer-BioNTech\u2019s Application for COVID-19 Booster\nToday, the U.S. Food and Drug Administration announced a virtual meeting of its Vaccines and Related Biological Products Advisory Committee to discuss the matter of additional doses of COVID-19 vaccines and specifically to discuss the Pfizer-BioNTech supplemental Biologics License Application for administration of a third (\u201cbooster\u201d) dose of Comirnaty (COVID-19 Vaccine, mRNA) in individuals 16 years of age and older.\n\nPress Release / Public Statement\nBiologics\n08/31/2021\n\nCoronavirus (COVID-19) Update\nThe FDA makes changes to the authorized use of the monoclonal antibodies bamlanivimab and etesevimab, and issues a letter to veterinarians and retailers about the dangerous misuse of animal ivermectin to prevent or treat COVID-19 in people.\n\nCOVID-19 Update\nMedical Devices\n08/30/2021\n\nHelp Stop Misuse of Animal Ivermectin to Prevent or Treat COVID-19 in Humans\nToday the FDA issued a letter to veterinarians and retailers to help stop the misuse of animal ivermectin to prevent or treat COVID-19 in humans. Poison control centers across the United States are seeing a sharp spike in reports of people suffering adverse health effects after taking animal ivermectin.\n\nSafety Information\nAnimal & Veterinary\n08/27/2021\n\nResumption in Use and Distribution of Bamlanivimab/Etesevimab in Certain States\nToday the FDA reissued the Letter of Authorization to allow for the emergency use of bamlanivimab and etesevimab, administered together, only in states, territories, and U.S. jurisdictions in which recent data shows the combined frequency of variants resistant to bamlanivimab and etesevimab administered together is less than or equal to 5%. Health care providers may refer to the fact sheet and frequently asked questions for more information.\n\nPress Release / Public Statement\nDrugs, Biologics\n08/27/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issued a letter to health care providers alerting health care facility risk managers, procurement staff and health care personnel to stop using certain N95 respirators manufactured by Shanghai Dasheng Health Products Manufacture Co., Ltd. and the agency issued a warning letter to Invisi Smart Technologies for offering for sale adulterated and misbranded Invisi Smart Masks.\n\nCOVID-19 Update\nMedical Devices\n08/24/2021\n\nCoronavirus (COVID-19) Update\nThe FDA updated the Pfizer-BioNTech emergency use authorization (EUA) to support the extension of shelf-life of the Pfizer-BioNTech COVID-19 Vaccine stored at -90 degrees to -60 degrees Celsius from 6 months to 9 months.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n08/23/2021\n\nFDA Approves First COVID-19 Vaccine\nToday, the U.S. Food and Drug Administration approved the first COVID-19 vaccine, known as the Pfizer-BioNTech COVID-19 Vaccine, now marketed as Comirnaty (koe-mir'-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older.\n\nPress Release / Public Statement\nBiologics\n08/20/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issued a warning letter regarding sale of unapproved products with unproven COVID-19 claims and held a stakeholder call in recognition of National Immunization Awareness Month to discuss vaccines for younger children and adolescents in preparation for the school year.\n\nCOVID-19 Update\nMedical Devices\n08/18/2021\n\nJoint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots\nPublic health and medical experts from the U.S. Department of Health and Human Services released a statement on the Administration\u2019s plan for COVID-19 booster shots for the American people.\n\nPress Release / Public Statement\nBiologics\n08/13/2021\n\nCoronavirus (COVID-19) Update\nA new FDA Consumer Update highlights 5 Things to Know about COVID-19 Vaccination for Adolescents and FDA\u2019s vaccine expert, Dr. Peter Marks, participated in the HHS Ask An Expert video series to answer some of your most frequently asked questions about COVID-19 vaccination.\n\nCOVID-19 Update\nBiologics\n08/12/2021\n\nFDA Authorizes Additional Vaccine Dose for Immunocompromised People\nToday, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.\n\nPress Release / Public Statement\nBiologics\n08/06/2021\n\nCoronavirus (COVID-19) Update\nToday, FDA announced that it has found certain lots of Astra Zeneca COVID-19 vaccine drug substance manufactured at the Emergent facility in Baltimore, Maryland, to be acceptable for use for potential export. The AstraZeneca vaccine is not authorized for use in the U.S., but FDA understands that these AstraZeneca lots, or vaccine made from the lots, will now be exported for use.\n\nCOVID-19 Update\nMedical Devices\n08/03/2021\n\nCoronavirus (COVID-19) Update\nIn mid-July, the FDA held a stakeholder call to discuss COVID-19 vaccines, including preliminary reports of Guillain-Barr\u00e9 Syndrome following Janssen (Johnson & Johnson) COVID-19 vaccination. Acting FDA Commissioner Janet Woodcock, M.D. and the Director of FDA's Center for Biologics Evaluation and Research, Peter Marks, M.D., Ph.D. were featured speakers. The call can be found on the FDA\u2019s YouTube page.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n07/30/2021\n\nCoronavirus (COVID-19) Update\nThe FDA revised the Emergency Use Authorization for REGEN-COV as post-exposure prophylaxis for COVID-19 in adults and pediatric individuals who are at high risk for progression to severe COVID-19, including hospitalization or death.\n\nCOVID-19 Update\nMedical Devices\n07/23/2021\n\nCoronavirus (COVID-19) Update\nOn Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Becton, Dickinson and Company (BD) for its BD Vacutainer Plus Citrate Plasma Tubes (UK Manufacturing Site), which are sodium citrate blood specimen collection tubes used to collect, transport, and store blood samples for coagulation testing.\n\nCOVID-19 Update\nMedical Devices\n07/20/2021\n\nCoronavirus (COVID-19) Update\nToday, Acting FDA Commissioner Janet Woodcock, M.D. testified before the U.S. Senate Committee on Health, Education, Labor and Pensions in a hearing titled, The Path Forward: A Federal Perspective on the COVID-19 Response.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n07/20/2021\n\nThe Path Forward: A Federal Perspective on the COVID-19 Response\nHearing before the U.S. Senate Committee on Health, Education, Labor and Pensions; Acting Commissioner Janet Woodcock, M.D. testifies for the FDA. Read written testimony.\n\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n07/16/2021\n\nCoronavirus (COVID-19) Update\nThe FDA formally accepts Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n07/13/2021\n\nCoronavirus (COVID-19) Update\nThe FDA announces revisions to the vaccine recipient and vaccination provider fact sheets for the Johnson & Johnson (Janssen) COVID-19 Vaccine.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n07/13/2021\n\nWebinar: Revocation of EUAs for Non-NIOSH-Approved Respirators and Decontamination Systems\nFrom 12:00 to 1:00 p.m. ET on Tuesday, July 13, 2021, the FDA will host a webinar to share information and answer questions about revocation of EUAs for non-NIOSH-approved respirators and decontamination systems.\n\nEvent\nMedical Devices\n07/09/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issued a report on the use of additive manufacturing by non-traditional producers in support of the U.S. COVID-19 response, an EUA to Ortho-Clinical Diagnostics, Inc., for the VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Quantitative Test as well as warning letters to 12 firms for offering for sale in the U.S. adulterated and misbranded tests, face masks, respirators and surgical masks, some of which are intended for use in the mitigation, prevention, treatment, diagnosis or cure of COVID-19 in people.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n07/08/2021\n\nJoint CDC and FDA Statement on Vaccine Boosters\nAmericans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary.\n\nPress Release / Public Statement\nBiologics\n07/06/2021\n\nCoronavirus (COVID-19) Update\nThe FDA holds a stakeholder call with Vaccinate Your Family and pediatric and healthcare groups.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n07/02/2021\n\nCoronavirus (COVID-19) Update\nThe FDA authorized the use, under the emergency use authorization (EUA) for the Janssen COVID-19 vaccine, of an additional batch of vaccine drug substance manufactured at the Emergent facility. Additionally, the FDA issued an updated Letter to Health Care Personnel and Facilities stating that the FDA no longer authorizes use of non-NIOSH-approved or decontaminated disposable respirators.\n\nCOVID-19 Update\n\nBiologics\n\t\t\tMedical Devices\n\n06/30/2021\n\nFDA Revokes Emergency Use Authorizations for Certain Respirators and Decontamination Systems as Access to N95s Increases Nationwide\nFDA announced it is revoking EUAs of all non-NIOSH-approved disposable respirators, which includes imported disposable respirators such as KN95s, along with revoking EUAs for decontamination and bioburden reduction systems.\n\nPress Release / Public Statement\n\nMedical Devices\n\n06/29/2021\n\nCoronavirus (COVID-19) Update\nThe FDA has sent to Congress its Report on Drug Shortages for Calendar Year 2020, which includes a section on the agency\u2019s drug shortage efforts in response to COVID-19. The FDA is also working to implement the drug shortage-related provisions of the Coronavirus Aid, Relief, and Economic Security Act.\n\nCOVID-19 Update\n\nDrugs\n\n06/25/2021\n\nCoronavirus (COVID-19) Update\nThe FDA announced revisions to the patient and provider fact sheets for the Moderna and Pfizer-BioNTech COVID-19 vaccines regarding the suggested increased risks of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) following vaccination; and reached a milestone of approving 1,000 original and supplemental generic drug applications to help in the treatment of patients with COVID-19 since the start of the pandemic.\n\nCOVID-19 Update\n\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n\n06/24/2021\n\nFDA Authorizes Drug for Treatment of COVID-19\nToday, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug Actemra (tocilizumab) for the treatment of hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n06/22/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issued a Drug Safety Communication for hand sanitizers, warning that symptoms such as headache, nausea, and dizziness can occur after applying alcohol-based hand sanitizers to the skin and inhaling the vapors that linger; and issued a warning letter to a company selling an unapproved product with fraudulent COVID-19 claims.\n\nCOVID-19 Update\nDrugs\n\t\t\tWarning Letters\n06/15/2021\n\nCoronavirus (COVID-19) Update\nThe FDA posts updated translations for the Pfizer-BioNTech COVID-19 Vaccine Fact Sheet for Recipients and Caregivers and issues an updated FDA COVID-19 Response At-A-Glance Summary.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n06/11/2021\n\nCoronavirus (COVID-19) Update\nFDA issued a safety communication warning the public to stop using the Innova SARS-CoV-2 Antigen Rapid Qualitative Test for diagnostic use. FDA also added sodium citrate tubes used in blood specimen collection to the device shortage list.\n\nCOVID-19 Update\nMedical Devices\n06/11/2021\n\nFDA Takes Steps to Increase Availability of COVID-19 Vaccine\nFollowing careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson & Johnson) COVID-19 Vaccine to be made available.\n\nPress Release / Public Statement\nBiologics\n06/10/2021\n\nVaccines and Related Biological Products Advisory Committee\nThe Vaccines and Related Biological Products Advisory Committee will meet in open session to discuss, in general, data needed to support authorization and/or licensure of COVID-19 vaccines for use in pediatric populations. View livestream\n\nEvent\nBiologics\n06/08/2021\n\nCoronavirus (COVID-19) Update\nThe White House, HHS and FDA release a series of policy recommendations to address vulnerabilities in U.S. pharmaceutical supply chains, and FDA issues warning letters for sale of unapproved products with unproven COVID-19 claims.\n\nCOVID-19 Update\nMedical Devices\n06/04/2021\n\nCoronavirus (COVID-19) Update\nOn June 1, the FDA approved an abbreviated new drug application for albuterol sulfate inhalation aerosol 90 mcg (base)/actuation. Albuterol sulfate inhalation aerosol is used for the treatment or prevention of bronchospasm (narrowing of the airways) in patients four years of age and older with reversible obstructive airway disease (such as asthma) and for the prevention of exercise-induced bronchospasm in patients four years of age and older.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n06/01/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issued a safety communication to warn the public to stop using the Lepu Medical Technology SARS-CoV-2 Antigen Rapid Test Kit and the Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography) because the FDA has serious concerns about the performance of the tests and believes there is likely a high risk of false results when using these tests.\n\nCOVID-19 Update\nMedical Devices\n05/28/2021\n\nCoronavirus (COVID-19) Update\nFDA releases the Medical Countermeasures Initiative (MCMi) Program Update report which showcases FDA's work each year to prepare for all types of public health emergencies, including COVID-19.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n05/26/2021\n\nFDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19\nToday, the FDA issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death.\n\nPress Release / Public Statement\nDrugs\n05/25/2021\n\nCoronavirus (COVID-19) Update\nThe FDA updated its guidance, Emergency Use Authorization for Vaccines to Prevent COVID-19, to include a new section that clarifies how the agency intends to prioritize review of EUA requests for the remainder of the COVID-19 public health emergency. Additionally, the FDA issued a report that describes some of the approaches used by the South Korean government to address COVID-19, particularly regarding development, authorization and use of diagnostic tests.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n05/21/2021\n\nCoronavirus (COVID-19) Update\nThe FDA updated the definition of high risk for COVID-19 to include additional medical conditions and factors associated with increased risk for progression to severe disease.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n05/19/2021\n\nFDA In Brief: FDA Authorizes Longer Time for Refrigerator Storage of Thawed Pfizer-BioNTech COVID-19 Vaccine Prior to Dilution, Making Vaccine More Widely Available\nFDA authorized undiluted, thawed Pfizer-BioNTech COVID-19 Vaccine vials to be stored in the refrigerator at 2\u00b0C to 8\u00b0C (35\u00b0F to 46\u00b0F) for up to 1 month.\n\nPress Release / Public Statement\nBiologics\n05/19/2021\n\nFDA In Brief: FDA Advises Against Use of SARS-CoV-2 Antibody Test Results to Evaluate Immunity or Protection From COVID-19, Including After Vaccination\nFDA issued a safety communication to advise against using SARS-CoV-2 antibody test results to evaluate immunity after COVID-19 vaccination.\n\nPress Release / Public Statement\nMedical Devices\n05/18/2021\n\nCoronavirus (COVID-19) Update\nThe FDA provided summary information about the status of CytoDyn, Inc.\u2019s development program for the monoclonal antibody investigational drug, leronlimab, for the treatment of COVID-19.\n\nCOVID-19 Update\nMedical Devices\n05/14/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issued a warning letter to Crown Wellness, Inc. for, among other things, selling an unapproved product with COVID-19 claims.\n\nCOVID-19 Update\nMedical Devices\n05/11/2021\n\nCoronavirus (COVID-19) Update\nThe FDA expanded the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine to include 12 \u2013 15 year olds and issued an updated FDA COVID-19 Response At-A-Glance Summary.\n\nCOVID-19 Update\nBiologics\n\t\t\tWarning Letters\n05/11/2021\n\nAn Update from Federal Officials on Efforts to Combat COVID-19\nHearing before the U.S. Senate Committee on Health, Education, Labor and Pensions; Director of the FDA Center for Biologics Evaluation and Research, Peter Marks, M.D., Ph.D. testifies for the FDA. View written testimony.\n\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n05/10/2021\n\nFDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents\nToday, the U.S. Food and Drug Administration expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age. View press briefing.\n\nPress Release / Public Statement\nBiologics\n05/10/2021\n\nFDA to Hold Meeting of its Vaccines and Related Biological Products Advisory Committee to Discuss Pediatric Use of COVID-19 Vaccines\nThe U.S. Food and Drug Administration\u2019s Center for Biologics Evaluation and Research (CBER) will convene a virtual meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on June 10, 2021, via webcast. During the meeting the agency will provide a status update on our approach to emergency use authorization (EUA) for COVID-19 vaccines intended for use in individuals 12 through 17 years of age.\n\nPress Release / Public Statement\nBiologics\n05/07/2021\n\nCoronavirus (COVID-19) Update\nThe agency issued a warning letter to Disinfect & Shield for selling an unapproved product with fraudulent COVID-19 claims.\n\nCOVID-19 Update\nMedical Devices\n05/05/2021\n\nCoronavirus (COVID-19) Update: FDA Outlines Inspection and Assessment Activities During Pandemic, Roadmap for Future State of Operations\nFDA issued a new report outlining the agency\u2019s inspectional activities during the COVID-19 pandemic and its detailed plan to move toward a more consistent state of operations.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n05/04/2021\n\nCoronavirus (COVID-19) Update\nThe FDA updated the CDER\u2019s work to meet user fee goals webpage to include data from Fiscal Year 2021 Quarter 2.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n04/30/2021\n\nCoronavirus (COVID-19) Update\nThe FDA revoked the emergency use authorization (EUA) of the Battelle CCDS Critical Care Decontamination System and updated the EUA Authorized Serology Test Performance page on the FDA\u2019s website.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n04/27/2021\n\nCoronavirus (COVID-19) Update\nThe FDA lifted the recommended pause on the use of Janssen (Johnson & Johnson) COVID-19 Vaccine following a thorough safety review; and issued warning letters to companies selling unapproved products with fraudulent COVID-19 claims.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n04/23/2021\n\nFDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review\nFollowing a thorough safety review, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted.\n\nPress Release / Public Statement\nBiologics\n04/23/2021\n\nCoronavirus (COVID-19) Update\nThe FDA completed an inspection of Emergent BioSolutions, a proposed manufacturing facility for the Johnson & Johnson COVID-19 Vaccine and cited a number of observations concerning whether the facility\u2019s processes met the agency\u2019s requirements and standards. Additionally, the FDA\u2019s Center for Food Safety and Applied Nutrition updated its COVID-19 Vaccination & Food and Agriculture Sector webpage to include the HHS COVID-19 Vaccination Toolkit for agriculture workers.\n\nCOVID-19 Update\nMedical Devices\n04/21/2021\n\nFDA Continues Important Steps to Ensure Quality, Safety and Effectiveness of Authorized COVID-19 Vaccines\nThe FDA takes its responsibility to ensure medical product quality, safety and effectiveness very seriously. The American public puts its trust in the agency to ensure that all medical products, including COVID-19 vaccines, meet the agency\u2019s standards for quality, safety and effectiveness.\n\nPress Release / Public Statement\nBiologics\n04/20/2021\n\nCoronavirus (COVID-19) Update\nThe FDA took steps to further facilitate the authorization of tests for pooling specimens from asymptomatic individuals in serial testing programs, and issued a pooling and serial testing amendment for many molecular diagnostic COVID-19 tests that had received an emergency use authorization (EUA) for testing individual samples.\n\nCOVID-19 Update\nMedical Devices\n04/20/2021\n\nFDA Announces New Streamlined Approach to Add Pooled Serial Screening Claims to Certain Authorized Tests for Use in Serial Testing Programs\nToday, the FDA took steps to further facilitate the authorization of molecular tests for screening asymptomatic individuals using pooled anterior nasal respiratory specimens in serial testing programs.\n\nPress Release / Public Statement\nMedical Devices\n04/16/2021\n\nCoronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab\nToday, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.\n\nPress Release / Public Statement\nDrugs\n04/16/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issues a statement regarding the Janssen COVID-19 vaccine, issues a warning letter and updates a frequently asked question about the Moderna COVID-19 vaccine.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n04/13/2021\n\nCoronavirus (COVID-19) Update\nThe FDA publishes a new FDA Voices on addressing COVID-19 health disparities among racial and ethnic minority communities.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n04/13/2021\n\nJoint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine\nAs of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine.\n\nPress Release / Public Statement\nBiologics\n04/12/2021\n\nVaccine Ready: Addressing COVID-19 Health Disparities among Racial and Ethnic Minority Communities\nAs FDA celebrates National Minority Health Month, we\u2019re working to address concerns about vaccines among diverse communities, and to protect and promote the health of diverse populations by focusing our efforts on strategies that address health disparities.\n\nFDA Voices: Leadership Perspectives\nBiologics\n04/09/2021\n\nCoronavirus (COVID-19) Update\nThe FDA recommends health care personnel and facilities transition from the use of decontaminated disposable respirators, and issues warning letters to two companies for selling unapproved products with fraudulent COVID-19 claims.\n\nCOVID-19 Update\nMedical Devices\n\t\t\tWarning Letters\n04/06/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issues COVID-19 related Emergency Use Authorization and implements a new guidance.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n04/06/2021\n\nCoronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for the Symbiotica COVID-19 Self-Collected Antibody Test System\nThe FDA today announced it has issued an emergency use authorization (EUA) for the Symbiotica COVID-19 Self-Collected Antibody Test System, the first antibody test authorized for use with home collected dried blood spot samples.\n\nPress Release / Public Statement\nMedical Devices\n04/02/2021\n\nCoronavirus (COVID-19) Update\nThe FDA has taken swift action to get more tests for screening asymptomatic individuals on the market by authorizing several COVID-19 tests for over-the-counter (OTC) use without a prescription when used for serial screening; posted a new web page SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests for clinical laboratory staff and health care providers; posted five additional translations to a COVID-19 consumer update; and issued a warning letter jointly with the Federal Trade Commission to Natural Adventure, LLC for selling unapproved products with fraudulent COVID-19 claims.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n04/02/2021\n\nFDA In Brief: FDA Provides Update on COVID-19 Pandemic Recovery and Preparedness Plan Initiative\nThis FDA In Brief provides an update on the PREPP initiative\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n04/01/2021\n\nCoronavirus (COVID-19) Update: FDA Makes Two Revisions to Moderna COVID-19 Vaccine Emergency Use Authorization to Help Increase the Number of Vaccine Doses Available\nToday, the U.S. Food and Drug Administration announced two revisions regarding the number of doses per vial available for the Moderna COVID-19 Vaccine.\n\nPress Release / Public Statement\nBiologics\n03/31/2021\n\nCoronavirus (COVID-19) Update: FDA Continues to Advance Over-the Counter and Other Screening Test Development\nFollowing recent FDA actions to support test development, the FDA took swift action this week to get more tests for screening asymptomatic individuals on the market. Today, the agency authorized several tests for over-the-counter (OTC) use without a prescription when used for serial screening.\n\nPress Release / Public Statement\nMedical Devices\n03/30/2021\n\nCoronavirus (COVID-19) Update\nThe FDA has updated its FDA COVID-19 Response At-A-Glance Summary and has approved an abbreviated new drug application for succinylcholine chloride injection USP 200 mg/10 mL. The FDA recognizes the increased demand for certain products during the COVID-19 public health emergency, and we remain deeply committed to facilitating access to safe and effective medical products to help address critical needs of the American public.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n03/26/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issues an emergency use authorization (EUA) to a company for the SARS-CoV-2 NGS Assay and provides a consumer update on common questions about COVID-19 vaccines.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n3/24/2021\n\nLearn More About COVID-19 Vaccines From the FDA\nAnswers from the FDA to common questions about COVID-19 vaccines.\n\nConsumer Information\nBiologics\n03/23/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issues a warning letter to a company selling unapproved products with fraudulent COVID-19 claims and provides a consumer update on steps to help slow the spread of the coronavirus disease.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n03/19/2021\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Machine Learning-Based Screening Device to Identify Certain Biomarkers That May Indicate COVID-19 Infection\nToday, the FDA issued an emergency use authorization (EUA) for the first machine learning-based Coronavirus Disease 2019 (COVID-19) non-diagnostic screening device that identifies certain biomarkers that are indicative of some types of conditions, such as hypercoagulation (a condition causing blood to clot more easily than normal).\n\nPress Release / Public Statement\nMedical Devices\n03/19/2021\n\nCoronavirus (COVID-19) Update\nFDA authorizes the first SARS-CoV-2 diagnostic test for marketing beyond the public health emergency and posts a web page with screening information for newly established testing programs.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n03/18/2021\n\nFDA authorizes revisions to fact sheets to address SARS-CoV-2 variants for monoclonal antibody products under emergency use authorization\nFDA is providing this information to equip health care providers with the most current data so they can make informed decisions and provide appropriate care to patients with COVID-19.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n03/18/2021\n\nFDA\u2019s Ongoing Use of Inspectional Tools for Ensuring Access to Safe, Quality Food and Medical Products During the COVID-19 Pandemic\nThe agency\u2019s approach to foreign and domestic inspections for food and medical products has been both risk-based and deliberate.\n\nFDA Voices: Leadership Perspectives\nInspections\n03/18/2021\n\nSenate Health, Education, Labor, and Pensions Committee Hearing\nFDA leadership will participate in the hearing titled \u201cExamining Our COVID-19 Response: An Update from Federal Officials.\u201d\nView livestream and written testimony\n\nEvent\nImports\n\t\t\tInspection\n\t\t\tRecalls\n\t\t\tAnimal & Veterinary\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n03/17/2021\n\nWebinar: Therapeutics for Use in COVID-19\nActing FDA commissioner, Janet Woodcock, M.D. participated in a webinar for physicians to discuss the state of therapeutic clinical trials worldwide.\n\nPodcast / Video\nDrugs\n\t\t\tResearch\n03/17/2021\n\nFDA Permits Marketing of First SARS-CoV-2 Diagnostic Test Using Traditional Premarket Review Process\nToday, the U.S. Food and Drug Administration granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic test for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of COVID-19 and other respiratory tract infections.\n\nPress Release / Public Statement\nMedical Devices\n03/17/2021\n\nHouse Subcommittee Hearing on COVID-19 Vaccinations\nFDA leadership will participate in the House Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce hearing entitled, \"Leading the Way Forward: Biden Administration Actions to Increase COVID-19 Vaccinations.\"\nView livestream and written testimony\n\nEvent\nBiologics\n03/16/2021\n\nCoronavirus (COVID-19) Update\nFDA launches the COVID-19 EUA FDA Adverse Events Reporting System Public Dashboard and issues a warning letter for sale of unapproved products with fraudulent COVID-19 claims.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n03/16/2021\n\nCoronavirus (COVID-19) Update: FDA takes steps to streamline path for COVID-19 screening tools, provides information to help groups establishing testing programs\nToday, we are providing information for test developers about a streamlined path to emergency use authorization for these important screening tools as well as information to help these groups as they set up testing programs.\n\nPress Release / Public Statement\nMedical Devices\n03/12/2021\n\nCoronavirus (COVID-19) Update\nFDA issues a warning letter, a Letter to Clinical Laboratory Staff, Point-of-Care Facility Staff and Health Care Providers and an\u202fEmergency Use Authorization (EUA).\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n03/11/2021\n\nKnow Your Treatment Options for COVID-19\nPatients today have more treatment options in the battle against coronavirus disease. The U.S. Food and Drug Administration (FDA) has approved one drug treatment for COVID-19 and authorized others for emergency use.\n\nConsumer Information\nBiologics\n\t\t\tDrugs\n03/09/2021\n\nCoronavirus (COVID-19) Update\nFDA authorizes first molecular non-prescription, at-home test.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n03/05/2021\n\nWhy You Should Not Use Ivermectin to Treat or Prevent COVID-19\nFDA has not approved ivermectin for use in treating or preventing COVID-19 in humans. Never use medications intended for animals. Ivermectin for animals are very different from those approved for humans.\n\nConsumer Information\nAnimal and Veterinary\n\t\t\tDrugs\n03/05/2021\n\nHealth Fraud & COVID-19: What You Need to Know\nFDA\u2019s Office of Minority Health and Health Equity discusses the agency\u2019s efforts to stop fraudulent products from reaching our markets, especially those claiming to prevent, treat, or cure COVID-19.\n\nPodcast / Video\nInspections\n03/05/2021\n\nCoronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test\nToday, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.\n\nPress Release / Public Statement\nMedical Devices\n03/05/2021\n\nCoronavirus (COVID-19) Update\nThe FDA provides update that improper use of thermal imaging systems may provide inaccurate temperature readings and issues several warning letters.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n03/05/2021\n\nCoronavirus (COVID-19) Update: FDA Issues Authorization for First Molecular Non-Prescription, At-Home Test\nToday, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the Cue COVID-19 Test for Home and Over The Counter (OTC) Use. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in the nostrils.\n\nPress Release / Public Statement\nMedical Devices\n03/04/2021\n\nFDA Alerts Public about Improper Use of Thermal Imaging Devices; Warns Firms for Illegally Offering Thermal Imaging Systems for Sale\nThe U.S. Food and Drug Administration today alerted consumers, health care providers and other users of thermal imaging systems intended to measure human body temperature\u2014also known as telethermographic systems, infrared thermographs, thermal cameras, and \u201cfever cameras\u201d\u2014that improper use of the systems may provide inaccurate temperature readings due to a variety of factors.\n\nPress Release / Public Statement\nMedical Devices\n03/03/2021\n\nCOVID-19 Alert: Beware of Misleading Registration Certificates\nIn response to an increase in the use of misleading FDA registration certificates during the COVID-19 pandemic, the FDA has developed a new web resource for consumers: Are there \u201cFDA Registered\u201d or \u201cFDA Certified\u201d Medical Devices?\n\nConsumer Information\nMedical Devices\n\t\t\tWarning Letters\n03/02/2021\n\nNational Consumer Protection Week: FDA Is Vigilant in Protecting Consumers Against COVID-19 Vaccine Scams\nThe FDA is well-equipped to identify and thwart medical product scams while vaccine distribution is underway throughout the country.\n\nFDA Voices: Leadership Perspectives\nBiologics\n\t\t\tWarning Letters\n03/02/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issues Voices on protecting consumers against COVID-19 vaccine scams and issues a warning letter to a company selling unapproved products with fraudulent COVID-19 claims.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n03/01/2021\n\nStakeholder Call: COVID-19 Testing Update\nActing FDA Commissioner, Janet Woodcock, M.D., and Jeff Shuren, M.D., J.D., Director, Center for Devices and Radiological Health, provide updates on recent work and host a question and answer session on #COVID-19 testing.\n\nPodcast / Video\nMedical Devices\n03/01/2021\n\nCoronavirus (COVID-19) Update: FDA Issues Authorization for Quidel QuickVue At-Home COVID-19 Test\nToday, the FDA issued an emergency use authorization (EUA) for the Quidel QuickVue At-Home COVID-19 Test, another antigen test where certain individuals can rapidly collect and test their sample at home, without needing to send a sample to a laboratory for analysis.\n\nPress Release / Public Statement\nMedical Devices\n02/27/2021\n\nFDA Issues Emergency Use Authorization for Third COVID-19 Vaccine\nToday, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\n\nPress Release / Public Statement\nBiologics\n02/26/2021\n\nFDA Statement on Vaccines and Related Biological Products Advisory Committee Meeting\nFollowing today\u2019s positive advisory committee meeting outcome regarding the Janssen Biotech Inc. COVID-19 Vaccine, the FDA has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization.\n\nPress Release / Public Statement\nBiologics\n02/26/2021\n\nCoronavirus (COVID-19) Update\nToday, the FDA added new devices to the device discontinuance list, including sterilization products and oxygen conservers.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n02/26/2021\n\nVaccines and Related Biological Products Advisory Committee\nThe Vaccines and Related Biological Products Advisory Committee will meet in open session to discuss Emergency Use Authorization (EUA) of the Janssen Biotech Inc. COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years and older. View livestream\n\nEvent\nBiologics\n02/25/2021\n\nCoronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine\nToday, the FDA announced that it is allowing undiluted frozen vials of the Pfizer-BioNTech COVID-19 Vaccine to be transported and stored at conventional temperatures commonly found in pharmaceutical freezers for a period of up to two weeks.\n\nPress Release / Public Statement\nBiologics\n02/25/2021\n\nHealth Equity and Covid-19: What Minority Communities Need To Know\nJoin the FDA\u2019s Office of Minority Health and Health Equity for a conversation about health equity and COVID-19 with Dr. Peter Marks and RADM Richardae Araojo. Learn about the latest COVID-19 updates, including information about vaccines and the FDA\u2019s approval process.\n\nEvent\nBiologics\n02/23/2021\n\nCoronavirus (COVID-19) Update\nFDA issued guidances for medical product developers to address the emergence and potential future emergence of variants of SARS-CoV-2.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n02/22/2021\n\nCoronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants\nToday, the FDA issued guidances for medical product developers, specifically covering vaccines, diagnostics and therapeutics products, to address the emergence and potential future emergence of variants of SARS-CoV-2, the virus that causes COVID-19.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n02/19/2021\n\nCoronavirus (COVID-19) Update\nFDA issued a warning letter to Dr. Paul\u2019s Lab for selling an unapproved product with fraudulent COVID-19 claims.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n02/18/2021\n\nCOVID-19 Update: USDA, FDA Underscore Current Epidemiologic and Scientific Information Indicating No Transmission of COVID-19 Through Food or Food Packaging\nThe USDA and FDA underscore epidemiologic and scientific information indicating no transmission of COVID-19 Through Food or Food Packaging\n\nPress Release / Public Statement\nFood & Beverages\n02/16/2021\n\nCoronavirus (COVID-19) Update\nFDA issued a warning letter to Evolved Ayurvedic Discoveries, Inc./BioCBDPlus for selling unapproved products, including unapproved products with fraudulent COVID-19 claims.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n02/12/2021\n\nCoronavirus (COVID-19) Update\nFDA issued an emergency use authorization (EUA) for the treatment of mild to moderate COVID-19 in adults and pediatric patients and also revised its guidance, Investigational COVID-19 Convalescent Plasma.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n02/09/2021\n\nCoronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19\nToday, the FDA issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.\n\nPress Release / Public Statement\nDrugs\n02/09/2021\n\nCoronavirus (COVID-19) Update\nFDA issued a Letter to Health Care Providers on using ventilator splitters during the COVID-19 pandemic to provide up-to-date information concerning multiplexing ventilator tubing connectors, also known as ventilator splitters.\n\nCOVID-19 Update\nMedical Devices\n02/05/2021\n\nCoronavirus (COVID-19) Update\nThe FDA has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee; alerted health care professionals and compounders of potential risks associated with compounding remdesivir drug products; revised the Letter of Authorization for COVID-19 convalescent plasma; and issued a statement that FDA continues important work to support medical product development to address new virus variants.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n02/04/2021\n\nCoronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Janssen Biotech Inc.\u2019s COVID-19 Vaccine Candidate\nThe FDA has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Feb. 26, 2021, to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Janssen Biotech Inc.\n\nPress Release / Public Statement\nBiologics\n02/04/2021\n\nFDA In Brief: FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma to Reflect New Data\nThe FDA is issuing a revision of the Emergency Use Authorization (EUA) for COVID-19 convalescent plasma as a result of our evaluation of the most recent information available.\n\nPress Release / Public Statement\nBiologics\n02/04/2021\n\nCoronavirus (COVID-19) Update: FDA Continues Important Work to Support Medical Product Development to Address New Virus Variants\nAs the public health agency responsible for regulating medical products, we must ensure that health care providers have the most up-to-date diagnostics, treatments and vaccines in their toolbox to fight this pandemic.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n01/29/2021\n\nCoronavirus (COVID-19) Update\nThe FDA placed all alcohol-based hand sanitizers from Mexico on a country-wide import alert; issued warning letters jointly with the Federal Trade Commission to two companies selling unapproved products with fraudulent COVID-19 claims; and updated the COVID-19 frequently asked questions (FAQ).\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n01/26/2021\n\nCoronavirus (COVID-19) Update\nThe FDA has updated its COVID-19 Response At-A-Glance Summary; and posted a CDER Conversation with Katie Gray, Pharm.D., acting director of CDER\u2019s Office of Prescription Drug Promotion (OPDP) discussing OPDP\u2019s COVID-19 response.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n01/26/2021\n\nCoronavirus (COVID-19) Update: FDA Takes Action to Place All Alcohol-Based Hand Sanitizers from Mexico on Import Alert to Help Prevent Entry of Violative and Potentially Dangerous Products into U.S., Protect U.S. Consumers\nUnder the import alert, alcohol-based hand sanitizers from Mexico offered for import are subject to heightened FDA scrutiny, and FDA staff may detain the shipment.\n\nPress Release / Public Statement\nDrugs\n01/22/2021\n\nCoronavirus (COVID-19) Update\nThe FDA has investigated a case of fraud that led to an arrest and the filing of a criminal complaint by the U.S. Department of Justice; reissued the Emergency Use Authorization for decontamination systems for compatible N95 respirators; and added two new devices to the device discontinuance list.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n01/19/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issued a new guidance to help protect consumers from methanol poisoning, created a new collaboration with the National Institute of Standards and Technology to help strengthen the nation\u2019s public health infrastructure, updated its guidance on convalescent plasma donation, and provided updates for blood donation centers on blood donation during the COVID-19 pandemic.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n01/19/2021\n\nFDA Insight: Pandemic Recovery and Preparedness Plan\nListen to this FDA podcast featuring the FDA Commissioner and Deputy Commissioner for Medical and Scientific Affairs, for a discussion on FDA\u2019s Pandemic Recovery and Preparedness Plan.\n\nPodcast / Video\nBiologics\n\t\t\tFood & Beverages\n\t\t\tDrugs\n\t\t\tMedical Devices\n01/15/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issued three new guidances in its ongoing response to the COVID-19 pandemic.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n01/13/2021\n\nPandemic Response, Pandemic Preparation\nThis report reflects highlights of the agency\u2019s response, accomplishments and activities and describes a broad set of potential prospective actions that the agency could consider going forward.\n\nFDA Voices: Leadership Perspectives\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n01/08/2021\n\nCoronavirus (COVID-19) Update\nThe FDA posts a new webpage regarding Moderna COVID-19 vaccine frequently asked questions and issues letter to clinical laboratory staff and health care providers.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n01/08/2021\n\nFDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health Care Providers and Clinical Laboratory Staff\nFDA is alerting labs and health care providers that it is monitoring the impact of viral mutations, including the B.1.1.7 variant, on SARS-CoV-2 molecular tests.\n\nPress Release / Public Statement\nMedical Devices\n01/05/2021\n\nCoronavirus (COVID-19) Update\nThe FDA issues a warning letter and posts a new webpage on the Coronavirus Aid, Relief, and Economic Security Act (CARES Act).\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n01/05/2021\n\nFDA Insight: Compounded Drugs\nGail Bormel from the Office of Compliance in FDA\u2019s Center for Drug Evaluation and Research joins Dr. Shah for a discussion on drug compounding and its contribution to fighting COVID-19.\n\nPodcast / Video\nDrugs\n01/04/2021\n\nFDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines\nFollowing the Authorized Dosing Schedules for COVID-19 Vaccines\n\nPress Release / Public Statement\nBiologics\n01/04/2021\n\nRisk of False Results with the Curative SARS-Cov-2 Test for COVID-19: FDA Safety Communication\nThe FDA is alerting patients and health care providers of the risk of false results, particularly false negative results, with the Curative SARS-Cov-2 test.\n\nSafety Information\nMedical Devices\n12/30/2020\n\nCoronavirus (COVID-19) Update\nThe FDA publishes a new communications toolkit web hub and a hand sanitizer toolkit, posts a year-end FDA Voices blog and an infographic on tests and collection kits, issues two health frauds WLs, and approves two ANDAs.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n12/28/2020\n\nCoronavirus (COVID-19) Update\nThe FDA posts an updated letter of authorization, health care provider fact sheet and frequently asked questions regarding the number of Pfizer-BioNTech doses in a vial, updated the Device Shortage List, and provides a testing update.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n12/28/2020\n\nVideo Discussion: COVID-19 Vaccines\nIn this 30-minute video discussion, FDA Commissioner Dr. Stephen Hahn and Center for Biologics Evaluation and Research (CBER) Director Dr. Peter Marks talk with WebMD about what we know, what we don't know, and what we might learn in the future about COVID-19 vaccines.\n\nPodcast / Video\nBiologics\n12/22/2020\n\nCoronavirus (COVID-19) Update\nThe FDA posts translations of the Moderna COVID-19 Vaccine fact sheet in multiple languages, issues new ANDAs, and provides a testing update.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n12/21/2020\n\nCoronavirus (COVID-19) Update\nThe FDA posts translations of the Pfizer-BioNTech COVID-19 Vaccine fact sheet in multiple languages, issues a new guidance, and provides a testing update.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n12/18/2020\n\nFDA Media Briefing\nFDA Commissioner Stephen Hahn and CBER Director Peter Marks discuss the EUA issued for the Moderna COVID-19 Vaccine, December 18, 2020.\n\nEvent\nBiologics\n12/18/2020\n\nFDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine\nToday, the FDA issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\n\nPress Release / Public Statement\nBiologics\n12/18/2020\n\nTell Me More About Vaccine Safety\nLearn more about COVID-19 vaccine safety monitoring from FDA Commissioner Dr. Stephen Hahn\n\nPodcast / Video\nBiologics\n12/17/2020\n\nFDA Statement on Vaccines and Related Biological Products Advisory Committee Meeting\nFollowing today\u2019s positive advisory committee meeting outcome regarding the Moderna COVID-19 vaccine, the FDA has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization.\n\nPress Release / Public Statement\nBiologics\n12/17/2020\n\nCoronavirus (COVID-19) Update\nThe FDA holds a VRBPAC meeting, posts a new vaccine Q&A webpage, issues a WL, and provides a testing update.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n12/17/2020\n\nVaccines and Related Biological Products Advisory Committee\nThe Vaccines and Related Biological Products Advisory Committee will meet in open session to discuss Emergency Use Authorization (EUA) of the Moderna Inc. COVID-19 Vaccine for the prevention of COVID-19 in individuals 18 years and older. View livestream recording\n\nEvent\nBiologics\n12/16/2020\n\nCoronavirus (COVID-19) Update\nThe FDA posts materials for the 12/17 VRBPAC, issues two EUAs for at-home diagnostic tests, and provides a testing update.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n12/16/2020\n\nCoronavirus (COVID-19) Update: FDA Issues New Authorization for the BinaxNOW COVID-19 Ag Card Home Test\nToday, the FDA issued a new emergency use authorization (EUA) for the BinaxNOW COVID-19 Ag Card Home Test to allow individuals to perform the test at home with a prescription.\n\nPress Release / Public Statement\nMedical Devices\n12/15/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes Antigen Test as First Over-the-Counter Fully At-Home Diagnostic Test for COVID-19\nToday, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first over-the-counter (OTC) fully at-home diagnostic test for COVID-19.\n\nPress Release / Public Statement\nMedical Devices\n12/14/2020\n\nCoronavirus Vaccine FDA Update\nPeter W. Marks, M.D., Ph.D. and Stephen M. Hahn, M.D. return to JAMA's Q&A series to discuss the Pfizer/BioNTech and Moderna vaccines: the data, the weekend's EUA designation (Pfizer/BioNTech), and the process for future full licensure and postmarketing safety surveillance.\n\nPodcast / Video\nBiologics\n12/14/2020\n\nCoronavirus (COVID-19) Update\nThe FDA releases its Pfizer vaccine review memorandum, issues health fraud warning letters, posts a new video on hand sanitizer use, and more.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n12/12/2020\n\nVirtual Press Conference: First COVID-19 Vaccine\nAs part of the FDA\u2019s commitment to transparency, we invite you to watch our virtual press conference, to be live streamed over the FDA\u2019s YouTube, Facebook and Twitter accounts on December 12, 2020, at 9:00 AM ET.\n\nEvent\nBiologics\n12/11/2020\n\nFDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine\nToday, the FDA issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older.\n\nPress Release / Public Statement\nBiologics\n12/11/2020\n\nFDA Statement on Vaccines and Related Biological Products Advisory Committee Meeting\nFollowing yesterday\u2019s positive advisory committee meeting outcome regarding the Pfizer-BioNTech COVID-19 vaccine, the FDA has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization.\n\nPress Release / Public Statement\nBiologics\n12/10/2020\n\nCoronavirus (COVID-19) Update\nThe FDA holds a VRBPAC meeting, grants an EUA for the first direct-to-home COVID test, issues a health fraud warning letter, and updates testing numbers.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n12/10/2020\n\nVaccines and Related Biological Products Advisory Committee\nThe FDA's Center for Biologics Evaluation and Research\u2019s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet in open session to discuss Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 in individuals 16 years of age and older. View livestream\n\nEvent\nBiologics\n12/10/2020\n\nCoronavirus (COVID-19) Update: FDA Holds Advisory Committee Meeting to Discuss Authorization of COVID-19 Vaccine Candidate as Part of Agency\u2019s Review of Safety and Effectiveness Data\nToday, the FDA\u2019s Vaccines and Related Biological Products Advisory Committee (VRBPAC), made up of independent scientific and public health experts from around the country, is meeting to discuss the first request for emergency use authorization (EUA) for a vaccine for COVID-19 prevention, submitted by Pfizer Inc. in partnership with BioNTech Manufacturing GmbH.\n\nPress Release / Public Statement\nBiologics\n12/09/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Direct-to-Consumer COVID-19 Test System\nToday, the FDA authorized LabCorp\u2019s Pixel COVID-19 Test Home Collection Kit for use by any individual 18 years and older without a prescription.\n\nPress Release / Public Statement\nMedical Devices\n12/08/2020\n\nCoronavirus (COVID-19) Update\nThe FDA adds background material to web for upcoming VRBPAC meeting, approves new ANDA, issues safety message warning consumers not to wear face masks with metal parts during an MRI, authorizes first at-home diagnostic test to detect both COVID-19 and influenza A and B (flu), and provides a testing update.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n12/08/2020\n\nRespirators and Other Personal Protective Equipment (PPE) for Health Care Personnel Use During the COVID-19 Pandemic\nThe FDA continues this series of webinars on topics including respirators, surgical masks, protective barrier enclosures, gowns, and other apparel used by health care personnel during the COVID-19 pandemic.\n\nEvent\nMedical Devices\n12/07/2020\nRemarks by Dr. Hahn to the FDA-CMS Summit\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n12/04/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First COVID-19 and Flu Combination Test for use with home-collected samples\nThe FDA authorized the first diagnostic test for at home collection of patient samples to detect both COVID-19 and influenza A and B (flu).\n\nPress Release / Public Statement\nMedical Devices\n12/04/2020\n\nCoronavirus (COVID-19) Update\nThe FDA issues new guidance and an EUA, updates another guidance, and launches an immunology app-a-thon.\n\nCOVID-19 Update\nMedical Devices\n12/04/2020\nRemarks by Dr. Hahn to the National Academy of Medicine Town Hall on the COVID-19 Vaccine\nEvent\nBiologics\n12/03/2020\n\nCoronavirus (COVID-19) Update\nThe FDA issues a health fraud warning letters and updates the reference panel comparative date online.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n12/02/2020\n\nVirtual Town Hall Series - Coronavirus (COVID-19) Test Development and Validation\nThe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n12/01/2020\n\nCoronavirus (COVID-19) Update\nThe FDA amends the convalescent plasma EUA, issues health fraud warning letters, revises guidance, and updates testing numbers.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n11/30/2020\n\nCoronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate\nThe FDA has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna Inc.\n\nPress Release / Public Statement\nBiologics\n11/25/2020\n\nCoronavirus (COVID-19) Update: FDA Issues New Policy on Dry Heat for Reuse of Certain Respirators\nToday, the FDA issued guidance on the use of dry heat to help support the single-user reuse of certain particulate filtering facepiece respirators (FFRs), such as N95 respirators, by health care personnel when there is a limited supply of respirators during the COVID-19 public health emergency.\n\nPress Release / Public Statement\nMedical Devices\n11/24/2020\n\nThank You, Food and Agriculture Workers! | Espa\u00f1ol\nTo the millions of food and agriculture workers across America at Thanksgiving, the FDA is Giving Thanks for you!\n\nPodcast / Video\nFood & Beverages\n11/24/2020\n\nCoronavirus (COVID-19) Update\nThe FDA publishes new web resources, provides a testing update, approves an ANDA, and posts a \u201cThank You\u201d video to our food and agriculture workers.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n11/23/2020\n\nCoronavirus (COVID-19) Update\nThe FDA issues an ANDA, an EUA, and posts a new infographic on the potential EUA pathway for vaccines.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n11/21/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19\nToday, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19.\n\nPress Release / Public Statement\nDrugs\n11/20/2020\n\nCoronavirus (COVID-19) Update\nThe FDA issues an EUA, two warning letters, and more.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n11/20/2020\n\nCoronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate\nThe FDA has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 10 to discuss the request for emergency use authorization (EUA) of a COVID-19 vaccine from Pfizer, Inc. in partnership with BioNTech Manufacturing GmbH.\n\nPress Release / Public Statement\nBiologics\n11/20/2020\n\nThe FDA published new information about the vaccine development and review process: \nVaccine Development 101\nEmergency Use Authorization for Vaccines Explained\nThe Path for a COVID-19 Vaccine from Research to Emergency Use Authorization (PDF-723KB)\n\nConsumer Information\nBiologics\n11/19/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19\nToday, the FDA issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).\n\nPress Release / Public Statement\nDrugs\n11/19/2020\n\nFDA and Vaccinate Your Family Talk COVID With Minority Community Leaders\nFDA leaders participate in a virtual meeting with racial and ethnic minority community members about FDA\u2019s COVID-19 vaccine work.\n\nEvent\nBiologics\n11/17/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Test for Self-Testing at Home\nToday, the FDA issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test for self-testing at home and that provides rapid results.\n\nPress Release / Public Statement\nMedical Devices\n11/17/2020\n\nCoronavirus (COVID-19) Update\nThe FDA published information on EUA transparency, an update to SARS-CoV-2 FAQs, and a podcast on PPE.\n\nCOVID-19 Update\nMedical Devices\n11/17/2020\n\nFDA Insight: Personal Protective Equipment and COVID-19\nDr. Suzanne Schwartz, director of FDA\u2019s Office of Strategic Partnerships and Technology Innovation at the Center for Devices and Radiological Health, discusses personal protective equipment and its critical role in helping to reduce the spread of COVID-19.\n\nPodcast / Video\nMedical Devices\n11/17/2020\n\nCOVID-19 Update: FDA\u2019s Ongoing Commitment to Transparency for COVID-19 EUAs\nStatement reaffirming FDA\u2019s commitment to transparency around the EUA process and updates on FDA's plan to provide more information about decisions to issue, revise or revoke EUAs for drugs and biological products, including vaccines.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n11/17/2020\nDr. Hahn\u2019s Remarks to the Meeting of the Regulatory Affairs Professionals Society (RAPS)\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n11/16/2020\n\nCoronavirus (COVID-19) Update\nThe FDA updates guidance on investigational COVID-19 convalescent plasma, extending the period of enforcement discretion through the end of February 2021, and publishes a new COVID-19 diagnostic testing webpage for health care providers and others.\n\nCOVID-19 Update\nBiologics\n\t\t\tMedical Devices\n11/16/2020\n\nA Closer Look at COVID-19 Diagnostic Testing\nThis overview may be of interest to health care providers, test purchasers, and public health staff who want to know more about different types of tests. A printable PDF is also available.\n\nConsumer Information\nMedical Devices\n11/13/2020\n\nCoronavirus (COVID-19) Update\nThe FDA takes further action against company distributing a fraudulent product claiming to prevent or treat COVID-19.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n11/12/2020\n\nCoronavirus (COVID-19) Update\nThe FDA issues new Consumer Update offering tips on how to spot fraudulent flu products and updates treatment numbers on its CTAP dashboard.\n\nCOVID-19 Update\nMedical Devices\n11/10/2020\n\nCoronavirus (COVID-19) Update\nThe FDA to host a virtual \u201cGrand Rounds\u201d presentation on the agency\u2019s research to evaluate the ability of facial coverings to reduce the spread of infection and more.\n\nCOVID-19 Update\nMedical Devices\n11/10/2020\n\nFDA Insight Podcast: Hand Hygiene During COVID-19\nDr. Shah welcomes Elizabeth Jungman, director of CDER\u2019s Office of Regulatory Policy, to talk about hand sanitizers and the COVID-19 pandemic.\n\nPodcast / Video\nDrugs\n\t\t\tRecalls\n11/09/2020\n\nCoronavirus (COVID-19) Update\nThe FDA issues an EUA for an investigational monoclonal antibody therapy for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients, a final guidance on designing and executing clinical trials that include people with diverse characteristics, a testing update, and more.\n\nCOVID-19 Update\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n11/09/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19\nThe FDA issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.\n\nPress Release / Public Statement\nDrugs\n11/09/2020\n\nRemarks by FDA Commissioner Dr. Stephen Hahn to the GRx+Biosims 2020 Virtual Conference\n\nEvent\nBiologics\n\t\t\tDrugs\n11/09/2020\n\nFDA Offers Guidance to Enhance Diversity in Clinical Trials, Encourage Inclusivity in Medical Product Development\nStatement by FDA Commissioner Dr. Stephen Hahn about a final guidance Issued today that provides the agency\u2019s current thinking on steps to enhance diversity in clinical trials of any medical product such as treatments or vaccines for COVID-19 \u2013 as well as medical products more broadly.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n11/06/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection\nToday, the FDA authorized the first serology test that detects neutralizing antibodies from recent or prior SARS-CoV-2 infection.\n\nPress Release / Public Statement\nMedical Devices\n11/04/2020\n\nVirtual Town Hall Series - Coronavirus (COVID-19) Test Development and Validation\nThe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n11/03/2020\n\nCoronavirus (COVID-19) Update\nThe FDA issues two health fraud warning letters, an alert that false positive results can occur with antigen tests for the rapid detection of SARS-CoV-2, and more.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n11/01/2020\n\nLessons Learned From COVID\nRemarks by Dr. Stephen Hahn for the Global Pharmaceutical Manufacturing Leadership Forum\n\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n10/30/2020\n\nCoronavirus (COVID-19) Update\nThe FDA issues a new Consumer Update.\n\nCOVID-19 Update\nMedical Devices\n10/28/2020\n\nCoronavirus (COVID-19) Update\nThe FDA updates an immediately in effect guidance, approves two generic muscle relaxation drugs, and issues warning letters.\n\nCOVID-19 Update\nDrugs\n\t\t\tMedical Devices\n10/28/2020\n\nVirtual Town Hall Series - Coronavirus (COVID-19) Test Development and Validation\nThe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n10/27/2020\n\nI'm the FDA point person on COVID-19 vaccines. We'll make sure they're safe and effective.\nUSA Today Opinion: FDA Center for Biologics Evaluation and Research Director Dr. Peter Marks\n\nPress Release / Public Statement\nBiologics\n10/27/2020\n\nGet Your Flu Vaccine\nDr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, discusses this year's flu season and the importance of getting vaccinated as we continue the fight against the COVID-19 pandemic.\n\nPodcast / Video\nBiologics\n10/27/2020\n\nWebinar Series - Respirators and Other Personal Protective Equipment (PPE) for Health Care Personnel Use During the COVID-19 Pandemic\nDuring this webinar, the FDA will share information about surgical mask 510(k)s and representatives from the FDA and from the Centers for Disease Control and Prevention's (CDC) National Institute for Occupational Safety and Health (NIOSH) will be available to answer your questions.\n\nEvent\nMedical Devices\n10/26/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA updates the Antigen Template for Test Developers.\n\nDaily Roundup\n\nMedical Devices\n\n10/26/2020\n\nFDA Presentation: American Public Health Association's 2020 Virtual Annual Meeting\nBruce Ross, director of the FDA's Office of Global Operations, on the topic \"Department of Health and Human Services\u2019 Global Health Workforce \u2013 On the Front Lines of Health Diplomacy During the Time of COVID-19.\"\n\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n10/23/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA approves first drug to treat COVID-19 and issues an updated FDA COVID-19 Response At-A-Glance Summary.\n\nDaily Roundup\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n10/22/2020\n\nFDA Commissioner Talks to AARP About COVID-19 Vaccines\nDr. Stephen Hahn explains the FDA\u2019s role in ensuring safety, effectiveness of COVID-19 vaccines.\n\nConsumer Information\nDrugs\n10/22/2020\n\nFDA Approves First Treatment for COVID-19\nToday, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization.\n\nPress Release / Public Statement\nDrugs\n10/22/2020\n\nVaccines and Related Biological Products Advisory Committee \nThe Committee will meet in open session, to discuss, in general, the development, authorization and/or licensure of vaccines to prevent COVID-19. No specific application will be discussed at this meeting. View webcast\n\nEvent\nBiologics\n10/21/2020\n\nVirtual Town Hall Series - Coronavirus (COVID-19) Test Development and Validation\nThe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n10/20/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA publishes new content on the \"FDA Insight\u201d podcast, in \"FDA Voices\", and issues a Consumer Update.\n\nDaily Roundup\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n10/20/2020\n\nThe FDA\u2019s Vaccines and Related Biological Products Advisory Committee and its Role in Advising the Agency on COVID-19 Vaccines\nThis week, the FDA\u2019s Vaccines and Related Biological Products Advisory Committee is meeting to discuss, in general, the development, authorization and/or licensure of vaccines to prevent COVID-19.\n\nFDA Voices: Leadership Perspectives\nBiologics\n10/20/2020\n\nAdvisory Committee on COVID-19 Vaccines\nDr. Peter Marks provides an update on COVID-19 vaccines and discusses the upcoming Vaccines and Related Biological Products Advisory Committee meeting.\n\nPodcast / Video\nBiologics\n10/19/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA issues a joint warning letter with the Federal Trade Commission to prevent the sale of unapproved products with fraudulent COVID-19 claims.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n10/15/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA re-issues Emergency Use Authorization for certain filtering facepiece respirators.\n\nDaily Roundup\nMedical Devices\n10/15/2020\n\nFDA Reissues Emergency Use Authorization for Certain Non-NIOSH-Approved Filtering Face-Piece Respirators Manufactured in China\nThe FDA reissued the EUA for certain filtering face-piece respirators (FFRs) that are manufactured in China and are not approved by the Centers for Disease Control and Prevention\u2019s (CDC) National Institute for Occupational Safety and Health (NIOSH).\n\nPress Release / Public Statement\nMedical Devices\n10/14/2020\n\nVirtual Town Hall Series - Coronavirus (COVID-19) Test Development and Validation\nThe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n10/13/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA issues and implements new guidance regarding molecular influenza and RSV tests.\n\nDaily Roundup\nGuidance Documents\n\t\t\tMedical Devices\n10/13/2020\n\nWebinar Series - Respirators and Other Personal Protective Equipment (PPE) for Health Care Personnel Use During the COVID-19 Pandemic\nFDA and representatives from the Occupational Safety and Health Administration (OSHA) answered questions about protective barrier enclosures.\n\nEvent\nMedical Devices\n10/09/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA and the Federal Trade Commission issue warning letters for selling fraudulent COVID-19-related products.\n\nDaily Roundup\nDrugs\n\t\t\tWarning Letters\n10/08/2020\n\nThe Review Process for Vaccines to Prevent COVID-19: A Discussion\nFDA Commissioner Dr. Steven Hahn discussed the COVID-19 vaccine review process with the Center for Infectious Disease Research and Policy and others.\n\nPodcast / Video\nBiologics\n10/08/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA updates dashboard on the Coronavirus Treatment Acceleration Program (CTAP) webpage.\n\nDaily Roundup\nDrugs\n10/08/2020\n\nInterview: FDA Commissioner on COVID-19 Vaccines and Other Medical Countermeasures\nFDA Commissioner Dr. Steven Hahn spoke about the COVID-19 vaccine development process and other medical countermeasures for COVID-19.\n\nPodcast / Video\nBiologics\n10/07/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA issues letter to healthcare providers regarding SARS-CoV-2 testing, and a warning letter for failure to comply with regulatory reporting requirements.\n\nDaily Roundup\nMedical Devices\n\t\t\tWarning Letters\n10/07/2020\n\nFDA Issues Warning Letter to Battelle Memorial Institute, a Manufacturer of an Authorized Decontamination System Used on Respirators\nThe FDA issued a warning letter to Battelle Memorial Institute for failure to comply with regulatory requirements for medical device reporting as specified in the Emergency Use Authorization (EUA) for the Battelle Critical Care Decontamination System.\n\nPress Release / Public Statement\nMedical Devices\n\t\t\tWarning Letters\n10/06/2020\n\nTell Me More About Vaccines\nLearn more about how vaccines are developed from U.S. Department of Health and Human Services leaders.\n\nPodcast / Video\nBiologics\n10/06/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA launches new COVID-19 vaccine webpage and issues guidance with recommendations for vaccine sponsors.\n\nDaily Roundup\nBiologics\n\t\t\tGuidance Documents\n10/06/2020\n\nFDA In Brief: FDA Issues Guidance on Emergency Use Authorization for COVID-19 Vaccines\nRecommendations for vaccine sponsors regarding the scientific data and information that would support the issuance of an emergency use authorization (EUA) for an investigational vaccine intended to prevent COVID-19.\n\nPress Release / Public Statement\nBiologics\n\t\t\tGuidance Documents\n10/05/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA awards Stanford University with a research contract to study SARS-CoV-2.\n\nDaily Roundup\nMedical Devices\n\t\t\tResearch\n10/02/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA posts transcript of Dr. Stephen M. Hahn, M.D.\u2019s remarks to the National Consumers League, issues warning letter against unapproved and misbranded product related to COVID-19.\n\nDaily Roundup\nMedical Devices\n\t\t\tDrugs\n10/01/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA revises an emergency use authorization, plus a warning letter to caution consumers against unapproved and misbranded products related to COVID-19.\n\nDaily Roundup\nMedical Devices\n\t\t\tDrugs\n09/30/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues a new warning letter, a new FDA Voices and updates the SARS-CoV-2 reference panel comparative data in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n\t\t\tDrugs\n09/30/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n09/29/2020\n\nDr. Hahn's remarks to the National Consumers League on the vaccine review process\nConsumer Perspectives on the Covid-19 Pandemic: A Conversation with the FDA\n\nEvent\nBiologics\n09/29/2020\n\nA Closer Look at the FDA\u2019s Center for Devices and Radiological Health\u2019s Unprecedented Efforts in the COVID-19 Response\nCDRH\u2019s response to the pandemic has been unprecedented in terms of volume, speed, and agility, including regulatory flexibility and EUAs.\n\nFDA Voices: Leadership Perspectives\nMedical Devices\n09/29/2020\n\nWebinar Series - Respirators and Other Personal Protective Equipment (PPE) for Health Care Personnel Use During the COVID-19 Pandemic\nThe FDA, CDC, NIOSH, and OSHA will host a webinar on Respirators and Other PPE for Health Care Personnel Use during the COVID-19 Pandemic.\n\nEvent\nMedical Devices\n09/25/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues an updated summary of the agency\u2019s COVID-19 response efforts.\n\nDaily Roundup\nDrugs\n\t\t\tBiologics\n\t\t\tFood & Beverages\n\t\t\tImports\n\t\t\tMedical Devices\n09/24/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA\u2019s actions on a re-issued EUA, an update to the Device Discontinuance List and new health education materials in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n09/23/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Point-of-Care Antibody Test for COVID-19\nToday, the FDA issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care (POC) test for COVID-19.\n\nPress Release / Public Statement\nMedical Devices\n09/23/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA\u2019s actions on a new summary of evidence to support an EUA and FDA Commissioner Stephen M. Hahn\u2019s testimony before a Senate committee in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n\t\t\tMedical Devices\n09/23/2020\n\nCOVID-19: An Update on the Federal Response\nHearing before the Senate Committee on Health, Education, Labor and Pensions; FDA Commissioner Stephen M. Hahn, M.D., testifies for the FDA.Written Testimony | Commissioner Hahn's Opening Remarks\n\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n09/23/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n\t\t\tGuidance Documents\n09/21/2020\n\nBeware of Fraudulent Coronavirus Tests, Vaccines and Treatments\nLearn more about how to identify fraudulent claims and false information on products that claim to diagnose, treat, or prevent coronavirus.\n\nConsumer Information\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n09/21/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA\u2019s actions on a new video for consumers and an updated guidance in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n\t\t\tDrugs\n\t\t\tGuidance Documents\n\t\t\tMedical Devices\n09/18/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA\u2019s action on a reissued Emergency Use Authorization in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n09/17/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA\u2019s actions on a new abbreviated drug application approval and a warning to consumers and health care professionals in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n09/16/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA\u2019s actions on a new abbreviated drug application approval and published comparative performance data for COVID-19 molecular diagnostic tests in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n09/16/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n\t\t\tGuidance Documents\n09/15/2020\n\nFDA Publishes Comparative Performance Data for COVID-19 Molecular Diagnostic Tests\nThe FDA published comparative performance data for some authorized COVID-19 molecular diagnostic tests.\n\nPress Release / Public Statement\nMedical Devices\n09/15/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues two warning letters in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tWarning Letters\n09/15/2020\n\nWebinar Series - Gowns and Other Apparel for Use by Health Care Personnel in COVID-19 Pandemic\nThe FDA will present information on both the enforcement policy and the EUA for gowns and other apparel, and representatives from the FDA, CDC, and OSHA will be available to answer your questions.\n\nEvent\nMedical Devices\n09/14/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA awards a new research contract in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nResearch\n\t\t\tMedical Devices\n09/14/2020\n\nFDA and global partners to analyze coronavirus samples\nEffort to help inform development of SARS-COV-2 diagnostics, vaccines, and therapeutics\n\nPress Release / Public Statement\nResearch\n09/11/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues a temporary guidance and an FDA Voices in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nAnimal & Veterinary\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tGuidance Documents\n09/11/2020\n\nThe FDA\u2019s Scientific and Regulatory Oversight of Vaccines is Vital to Public Health\nFDA is committed to making decisions regarding the authorization or approval of COVID-19 vaccines that are guided by science and data.\n\nFDA Voices: Leadership Perspectives\nBiologics\n09/10/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA\u2019s action on a warning letter in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nWarning Letters\n09/10/2020\n\nAdvancing the Science of Real-World Data to Address the COVID-19 Pandemic\nFDA Principal Deputy Commissioner Amy P. Abernethy, M.D., Ph.D., discusses the potential for diverse, real-world data sources such as electronic health records, insurance claims, patient registries and lab results to further inform our pandemic response.\n\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n09/09/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues a consumer update on the Food and Cosmetics Information Center in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nFood & Beverages\n\t\t\tMedical Devices\n09/09/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nhe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n\t\t\tImports\n09/08/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA deactivated the FDA registration for more than 300 foreign establishments in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n09/04/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues an updated COVID-19 Response At-A-Glance Summary in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n09/03/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA expands language availability for consumer updates in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n09/02/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA\u2019s actions on a warning letter, an approved abbreviated new drug application, and an updated guidance in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n\t\t\tDrugs\n09/02/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n\t\t\tGuidance Documents\n09/01/2020\n\nThe Opioid Epidemic and COVID-19 Pandemic\nMegan Moncur, the FDA\u2019s Associate Director of Opioid Policy, discusses the opioid epidemic and how it\u2019s been impacted by the COVID-19 pandemic.\n\nPodcast / Video\nDrugs\n09/01/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA\u2019s action on a warning letter in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n09/01/2020\n\nWebinar Series - CDC/NIOSH's Surgical N95 Respirator Guidance\nCDC/NIOSH will present information on the guidance, and representatives from the CDC/NIOSH, FDA, and Occupational Safety and Health Administration (OSHA) will be available to answer questions about this guidance\n\nEvent\n\nMedical Devices\n\t\t\tGuidance Documents\n\n08/31/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on an emergency use authorization and a letter to health care providers in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n08/28/2020\n\nCoronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss COVID-19 Vaccines\nFDA announced that a public meeting of the Vaccines and Related Biological Products Advisory Committee will be held on Oct. 22, 2020.\n\nPress Release / Public Statement\nBiologics\n08/28/2020\n\nCOVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19\nThe scope of the existing EUA was broadened to include treatment of all hospitalized adult and pediatric patients with suspected or laboratory-confirmed COVID-19, irrespective of their severity of disease.\n\nPress Release / Public Statement\nDrugs\n08/28/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA approves an abbreviated new drug application for sedated and ventilated patients during the COVID-19 public health emergency.\n\nDaily Roundup\nDrugs\n08/27/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA issues a new warning as alcohol-based hand sanitizers are being packaged to appear as food or drink, putting consumers at risk.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n08/27/2020\n\nCOVID-19 Update: FDA Warns Consumers About Hand Sanitizer Packaged in Food and Drink Containers\nFDA is warning consumers about hand sanitizers that are being packaged in containers that may appear as food or drinks and may put consumers at risk of serious injury or death if ingested.\n\nPress Release / Public Statement\nDrugs\n08/26/2020\n\nCOVID-19 Update: FDA Authorizes First Diagnostic Test Where Results Can Be Read Directly From Testing Card\nThe FDA issued an EUA for the first COVID-19 diagnostic that can be run without an analyzer.\n\nPress Release / Public Statement\nMedical Devices\n08/26/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nThe FDA posted a new \u201cFDA Insight\u201d podcast featuring Deputy Commissioner Anand Shah, M.D., discussing drug shortages during the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n08/25/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues new Consumer Update and approves an Abbreviated New Drug Application during COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n08/25/2020\n\nFDA Insight: Drug Shortages and COVID-19\nValerie Jensen, the Associate Director of the Drug Shortages staff in FDA's Center for Drug Evaluation and Research, joins Deputy Commissioner Dr. Anand Shah for a discussion on drug shortages and how the COVID-19 pandemic can impact the drug supply chain.\n\nPodcast / Video\nDrugs\n08/24/2020\n\nIs Your Hand Sanitizer on FDA\u2019s List of Products You Should Not Use?\nFDA testing uncovered toxic ingredients in some hand sanitizers \u2013 find out if your product on the list\n\nConsumer Information\n\t\t\tSafety Information\nDrugs\n08/24/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA provides new webpage with available COVID-19 testing resources.\n\nDaily Roundup\nMedical Devices\n08/23/2020\n\nFDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID\u201319 Treatment, Another Achievement in Administration\u2019s Fight Against Pandemic\nToday\u2019s action follows the FDA\u2019s extensive review of the science and data generated over the past several months stemming from efforts to facilitate emergency access to convalescent plasma for patients as clinical trials to definitively demonstrate safety and efficacy remain ongoing.\n\nPress Release / Public Statement\nBiologics\n08/21/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues new emergency use authorization, plus letter to healthcare providers (HCP) as the COVID-19 public health emergency continues.\n\nDaily Roundup\nMedical Devices\n08/20/2020\n\nFDA Leadership to Accelerate the Recovery from COVID-19\nRemarks by Deputy Commissioner for Medical and Scientific Affairs Anand Shah, M.D. to the Alliance for Health Policy\n\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n08/20/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA releases new checklist and guidance as COVID-19 continues to impact drug development programs and the food industry.\n\nDaily Roundup\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n08/19/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA provides FAQs on UV lights and lamps for disinfection during the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n08/18/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA provides supporting information on respirators for healthcare providers and manufacturers amid COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n08/18/2020\n\nHealth Fraud and COVID-19\nDr. Judy McMeekin, the Associate Commissioner for Regulatory Affairs, joins Dr. Shah on the show to discuss FDA's fight against health fraud during the COVID-19 pandemic.\n\nPodcast / Video\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n08/17/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues an emergency use authorization (EUA) for saliva sample COVID-19 diagnostic test.\n\nDaily Roundup\nMedical Devices\n08/15/2020\n\nCoronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing\nThe FDA issued an emergency use authorization to Yale School of Public Health for its SalivaDirect COVID-19 diagnostic test, which uses a new method of processing saliva samples.\n\nPress Release / Public Statement\nMedical Devices\n08/14/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA provides device shortage list and issues an updated FDA COVID-19 Response-At-A-Glance-Summary as pandemic evolves.\n\nDaily Roundup\nMedical Devices\n08/13/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues warning about certain hand sanitizer products amid COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n08/12/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on consumer tips, warning letters, emergency use authorizations, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n08/11/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on issuing warning statements and warning letters; issuing Emergency Use Authorizations for tests; posting new FAQ webpages on the registration and listing, and importing of medical devices; and more, in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n08/10/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, Emergency Use Authorizations, contaminated hand sanitizers, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n08/10/2020\n\nThe Critical Role of Health Care Practitioners during COVID-19\nRemarks by FDA Commissioner Stephen M. Hahn, M.D., as prepared for a video conversation with health professionals.\n\nEvent\n\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n\n08/07/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on revocation of EUAs, updates on the Coronavirus Treatment Acceleration Program, warning letters and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n08/06/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on the issuance of ventilator- and face-mask-related emergency use authorizations and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n08/05/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n08/05/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n08/04/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, issuances of emergency use authorizations and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n08/04/2020\n\nWebinar Series - FDA\u2019s Regulation of Face Masks and Surgical Masks During the COVID-19 Pandemic\nDuring this webinar, representatives from the FDA will share information and answer questions related to face masks and surgical masks.\n\nEvent\nMedical Devices\n08/03/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on issuing emergency use authorizations for serology tests and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n08/03/2020\n\nInvesting in Advanced Manufacturing to Support Public Health Preparedness\nAdvanced manufacturing provides an approach for protecting our supply chain and improving our response capacity during crisis situations.\n\nFDA Voices: Leadership Perspectives\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n07/31/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Tests that Estimate a Patient\u2019s Antibodies from Past SARS-CoV-2 Infection\nThe FDA authorized the first two COVID-19 serology tests that display an estimated quantity of antibodies present in the individual\u2019s blood. Both tests are known as \u201csemi-quantitative\u201d tests.\n\nPress Release/ Public Statement\nMedical Devices\n07/31/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n07/30/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on FAQs on food safety, serology and remdesivir and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nFood & Beverages\n\t\t\tDrugs\n\t\t\tMedical Devices\n07/29/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on updated molecular diagnostic templates for labs and industry preparing EUA requests, templates for commercial developers submitting EUA requests for at-home diagnostic tests, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n07/29/2020\n\nCoronavirus (COVID-19) Update: FDA Posts New Template for At-Home and Over-the-Counter Diagnostic Tests for Use in Non-Lab Settings, Such as Homes, Offices or Schools\nThe new template will help commercial developers prepare and submit emergency use authorization (EUA) requests for COVID-19 diagnostic tests that can be performed entirely at home or in other settings besides a lab.\n\nPress Release / Public Statement\nMedical Devices\n07/28/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on vaccines, molecular-based diagnostic tests and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n\t\t\tMedical Devices\n07/28/2020\n\nFDA Insight: Vaccines for COVID-19, Part 2\nDr. Peter Marks returns for a more comprehensive discussion on vaccines as they relate to COVID-19. Find out more about \u201cherd immunity,\u201d Operation Warp Speed, and vaccine distribution in this episode.\n\nPodcast / Video\nBiologics\n07/27/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on issuance of emergency use authorizations for tests including for asymptomatic people, pooling data, and qualitative detection of antibodies; contaminated hand sanitizer; and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n07/27/2020\n\nCoronavirus (COVID-19) Update: FDA Reiterates Warning About Dangerous Alcohol-Based Hand Sanitizers Containing Methanol, Takes Additional Action to Address Concerning Products\nThe FDA continues to warn consumers and health care professionals not to use certain alcohol-based hand sanitizers due to the dangerous presence of methanol.\n\nPress Release / Public Statement\nDrugs\n07/24/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test for Screening of People Without Known or Suspected COVID-19 Infection\nThe FDA reissued the LabCorp COVID-19 RT-PCR Test emergency use authorization (EUA) to include two new indications for use: testing for people who do not have COVID-19 symptoms or who have no reason to suspect COVID-19 infection, and to allow pooled sample testing.\n\nPress Release / Public Statement\nMedical Devices\n07/24/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on issuances of emergency use authorizations, tests, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n07/23/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, testing supply substitution strategies and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n07/22/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on updated FAQs on test EUAs, cancer, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n07/22/2020\n\nFDA In Brief: Findings from Real-World Data Study Reveal Higher Risk of Hospitalization and Death Among Cancer Patients with COVID-19, Underscore Health Disparities\nFDA and Syapse presented Real-World Data at the American Association of Clinical Research (AACR) COVID-19 and Cancer meeting. Findings from study reveal higher risk of hospitalization and death among cancer patients with COVID-19.\n\nPress Release / Public Statement\nDrugs\n07/22/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n07/21/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on health fraud, issuances of emergency use authorizations (EUAs) for test development, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n\t\t\tMedical Devices\n07/21/2020\n\nFDA's Ongoing Work to Support and Advance COVID-19 Diagnostic Test Accuracy and Availability\nThe FDA's actions are providing stakeholders with accurate information about COVID-19 diagnostic test performance and allowing for the rapid availability of tests.\n\nFDA Voices: Leadership Perspectives\nMedical Devices\n07/21/2020\n\nFDA Insight: Vaccines for COVID-19, Part 1\nIn Part 1 of FDA Insight\u2019s vaccine series, Dr. Shah welcomes Dr. Peter Marks, director of FDA\u2019s Center for Biologics Evaluation and Research, to discuss the basics of COVID-19 vaccine development.\n\nPodcast / Video\nBiologics\n07/21/2020\n\nWebinar Series - Respirators for Health Care Personnel Use During the COVID-19 Pandemic\nRepresentatives from FDA, NIOSH, and OSHA will answer questions.\n\nEvent\nMedical Devices\n07/21/2020\n\nProtecting Americans from COVID-19 Scams\nWritten testimony presented by Catherine Hermsen, Assistant Commissioner, FDA Office of Criminal Investigations, before the Senate Subcommittee on Manufacturing, Trade, and Consumer Protection, Committee on Commerce, Science, and Transportation\n\nEvent\nDrugs\n\t\t\tMedical Devices\n07/20/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on consumer fraud; reissuance of an EUA for a diagnostic test; guidance for transport media; extension of enforcement discretion for human cell, tissue, and cellular and tissue-based products; and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n\t\t\tMedical Devices\n07/20/2020\n\nFDA Protects Patients and Consumers from Fraud During COVID-19\nThe FDA\u2019s consumer protection work is a cornerstone of our mission and a critical component of our pandemic response efforts.\n\nFDA Voices: Leadership Perspectives\nDrugs\n\t\t\tMedical Devices\n07/18/2020\n\nCoronavirus (COVID-19) Update: FDA Issues First Emergency Authorization for Sample Pooling in Diagnostic Testing\nFDA issued first emergency authorization for sample pooling in COVID-19 diagnostic testing to Quest Diagnostics for its Quest SARS-CoV-2 rRT-PCR test.\n\nPress Release / Public Statement\nMedical Devices\n07/17/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on issuing Emergency Use Authorizations for tests, warning letters, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n07/16/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on hand sanitizer recalls, testing-related emergency use authorizations, Industry Hotline closure, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n07/15/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on Frequently Asked Questions on Testing for SARS-CoV-2 and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n07/15/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe FDA will host a virtual Town Hall for clinical laboratories and commercial manufacturers developing diagnostic tests for SAR-CoV-2. The purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n07/14/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on treatment acceleration, drug compounding, warning letters, hand-sanitizer quiz, therapeutics, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n07/14/2020\n\nAn Update and Behind the Scenes: FDA\u2019s Coronavirus Treatment Acceleration Program\nFDA\u2019s Coronavirus Treatment Acceleration Program (CTAP) leverages cross-agency scientific resources and expertise to bear on COVID-19 therapeutic development and review.\n\nFDA Voices: Leadership Perspectives\nBiologics\n\t\t\tDrugs\n07/14/2020\n\nFDA Insight Podcast: Clinical Trials and Treatments for COVID-19\nDr. Patrizia Cavazzoni, the acting director of FDA\u2019s Center for Drug Evaluation and Research, joins Dr. Shah for an in-depth discussion on clinical trials and treatments for COVID-19. A list of clinical trials are available at ClinicalTrials.gov.\n\nPodcast / Video\nBiologics\n\t\t\tDrugs\n07/13/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on vaccine research, issuances of emergency use authorizations, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n07/10/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on resumption of domestic inspections, issuance of Emergency Use Authorizations for molecular diagnostic tests, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n07/10/2020\n\nCoronavirus (COVID-19) Update: FDA prepares for resumption of domestic inspections with new risk assessment system\nThe FDA is preparing for resumption of domestic inspections with a new risk assessment system.\n\nPress Release / Public Statement\nInspections\n07/09/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions against a seller/distributor of unapproved or misbranded products and more in the agency\u2019s ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n07/08/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, criminal charges, methanol-contaminated hand sanitizers, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n07/08/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe FDA will host a virtual Town Hall for clinical laboratories and commercial manufacturers that are developing or have developed diagnostic tests for SARS-CoV-2. The purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n07/07/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, false positive test results, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n07/07/2020\n\nFDA Insight: Food Safety and COVID-19\nFDA Commissioner Stephen M. Hahn, M.D., returns to FDA Insight to discuss food safety issues during the COVID-19 pandemic.\n\nPodcast / Video\nFood & Beverages\n07/06/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on diagnostic tests, including authorizations, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n07/06/2020\n\nCoronavirus (COVID-19) Update: FDA Issued Emergency Use Authorization for Point of Care Antigen Test\nThe FDA issued an EUA for a COVID-19 antigen diagnostic test, the BD (Becton Dickinson) Veritor System for Rapid Detection of SARS-CoV-2.\n\nPress Release / Public Statement\nMedical Devices\n07/02/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes Additional COVID-19 Combination Diagnostic Test Ahead of Flu Season\nThe FDA has issued an EUA for another combination diagnostic that can test for flu and COVID-19 to prepare for this upcoming flu season.\n\nPress Release / Public Statement\nMedical Devices\n07/02/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on methanol-contaminated hand sanitizers, the FDA COVID-19 Response At-A-Glance Summary, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n07/02/2020\n\nCoronavirus (COVID-19) Update: FDA Takes Action to Warn, Protect Consumers from Dangerous Alcohol-Based Hand Sanitizers Containing Methanol\nFDA is warning consumers and health care professionals about hand sanitizer products containing methanol, or wood alcohol that is dangerous and not an acceptable active ingredient for hand sanitizer products.\n\nPress Release / Public Statement\nDrugs\n07/01/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on issuance of testing-related emergency use authorizations, warning letters, diagnostic reference panel materials, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/30/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on vaccine development and licensure guidance, emergency use authorizations, diagnostics, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n\t\t\tMedical Devices\n06/30/2020\n\nCoronavirus (COVID-19) Update: FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines\nThe FDA published a guidance document to facilitate the timely development of safe and effective vaccines to prevent COVID-19, giving recommendations for those developing COVID-19 vaccines for the ultimate purpose of licensure.\n\nPress Release / Public Statement\nBiologics\n\t\t\tGuidance Documents\n06/30/2020\n\nCOVID-19: Update on Progress Toward Safely Getting Back to Work and Back to School \nHearing before the Senate Committee on Health, Education, Labor and Pensions; FDA Commissioner Stephen M. Hahn, M.D., testified for the FDA.Written testimony\n\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n06/30/2020\n\nFDA Insight Podcast: All About COVID-19 Testing\nDr. Anand Shah, FDA\u2019s Deputy Commissioner for Medical and Scientific Affairs, welcomes Toby Lowe, the Associate Director of the Office of In Vitro Diagnostics and Radiological Health, to discuss the basics of diagnostic tests for COVID-19.\n\nPodcast / Video\nMedical Devices\n06/29/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, Emergency Use Authorizations, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/26/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, lab and manufacturer EUA submission templates for serology tests, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/25/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on ventilator emergency use authorizations, partnering with the European Union and Global regulators, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n06/25/2020\n\nPartnering with the European Union and Global Regulators on COVID-19\nThe FDA and the European Union, including the European Commission and its European Medicines Agency, are collaborating on many scientific and regulatory fronts as part of our COVID-19 response.\n\nFDA Voices: Leadership Perspectives\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n06/24/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on food safety, launch of new \u201cFDA Insight\u201d podcast, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nFood & Beverages\n\t\t\tMedical Devices\n06/24/2020\n\nCoronavirus (COVID-19) Update: Joint Statement from USDA and FDA on Food Export Restrictions Pertaining to COVID-19\nU.S. Secretary of Agriculture Sonny Perdue and FDA Commissioner Stephen M. Hahn, M.D., issued the following statement regarding food export restrictions pertaining to COVID-19.\n\nPress Release / Public Statement\nFood & Beverages\n06/24/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe FDA will host a virtual Town Hall for clinical laboratories and commercial manufacturers that are developing or have developed diagnostic tests for SARS-CoV-2. The purpose of this Town Hall is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n06/23/2020\n\nFDA Insight Podcast: Fighting COVID-19 at the FDA\nIn this first episode of a new podcast series, FDA Commissioner Dr. Stephen Hahn, and FDA Deputy Commissioner for Medical and Scientific Affairs Dr. Anand Shah discuss FDA's COVID-19 efforts, including the drug development process for a COVID-19 treatment.\n\nPodcast / Video\n\nDrugs\n\n06/23/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on food safety, the CURE Drug Repurposing Collaboratory, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n06/23/2020\n\nFDA Maintains the Pace of Meeting Its Goals on Applications for Medical Products During the Pandemic\nFDA is currently on target to meet our user fee goals for drugs this year. We have reviewed and taken timely action on at least 90% of brand, generic, and biosimilar drug applications even during the pandemic.\n\nFDA Voices: Leadership Perspectives\nDrugs\n06/23/2020\n\nHouse Committee on Energy & Commerce Hearing: Oversight of the Trump Administration\u2019s Response to the COVID-19 Pandemic\nFDA Commissioner Stephen M. Hahn, M.D., will be testifying for the FDA.Written testimony\n\nEvent\nMedical Devices\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n06/23/2020\n\nWebinar Series - Respirators for Health Care Personnel Use during COVID-19 Pandemic\nThe FDA will host the second webinar in the webinar series on the topic of Importing Respirators for Health Care Personnel Use during COVID-19 Pandemic.\n\nEvent\nImports\n\t\t\tMedical Devices\n06/22/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters as well as guidance on formal meetings, user-fee applications for medical devices, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/19/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions including its At-A-Glance Summary, a public-private partnership fostering innovation in devices and PPE, warning letters, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/18/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on a web resource listing EUAs, the CURE ID app, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n06/18/2020\n\nFDA Takes Additional Action to Harness Real-World Data to Inform COVID-19 Response Efforts\nThe FDA is announcing its participation in the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder collaborative project to advance the development of diagnostics.\n\nPress Release / Public Statement\nMedical Devices\n06/17/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, statistical issues related to clinical trials, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/17/2020\n\nCoronavirus (COVID-19) Update: FDA Issues Warning Letters to Companies Inappropriately Marketing Antibody Tests, Potentially Placing Public Health at Risk\nThe U.S. Food and Drug Administration has issued warning letters to three companies for marketing adulterated and misbranded COVID-19 antibody tests.\n\nPress Release / Public Statement\nMedical Devices\n06/16/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on an online portal for adverse event reporting on EUA devices or COVID-19-related guidance and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n06/16/2020\n\nCoronavirus (COVID-19) Update: Facilitating Diagnostic Test Availability for Asymptomatic Testing and Sample Pooling\nToday, the FDA posted template updates on the validation of molecular diagnostic tests for developers that intend their assay to be used for pooling patient samples or for screening asymptomatic individuals not suspected of having COVID-19.\n\nPress Release / Public Statement\nMedical Devices\n06/16/2020\n\nCoronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chembio Antibody Test\nToday, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) of the Chembio Diagnostic System, Inc. (Chembio) DPP COVID-19 IgM/IgG System, a SARS-CoV-2 antibody test, due to performance concerns with the accuracy of the test.\n\nPress Release / Public Statement\nMedical Devices\n06/15/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on EUAs (hydroxychloroquine, chloroquine), remdesivir drug interaction alert, pet safety, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nDrugs\nMedical Devices\nAnimal & Veterinary\n\n06/15/2020\n\nCoronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use\nToday, the FDA is warning health care providers about a newly discovered potential drug interaction related to the investigational antiviral drug remdesivir, which has received emergency use authorization for the treatment of hospitalized COVID-19 patients with severe disease.\n\nPress Release / Public Statement\nDrugs\n06/15/2020\n\nCoronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine\n\nPress Release / Public Statement\nDrugs\n06/12/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, an EUA for a point-of-care diagnostic test, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n\t\t\tMedical Devices\n06/11/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on continuing priorities regarding rare diseases, health-fraud warning letters, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/11/2020\n\nRare Disease Therapy Development and Access Remain Top FDA Priorities During COVID-19\nFDA\u2019s work to advance treatments for rare diseases and helping ensure continuity of care for people with rare diseases remain top priorities during COVID-19.\n\nFDA Voices: Leadership Perspectives\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n06/10/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on updates to the CURE ID crowd-sourcing app, an EUA for the first COVID-19 diagnostic test utilizing next-generation gene sequencing, and more in FDA\u2019s ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n06/10/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Next Generation Sequence Test for Diagnosing COVID-19\nThe U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Illumina, Inc. for the first COVID-19 diagnostic test utilizing next generation sequence technology.\n\nPress Release / Public Statement\nMedical Devices\n06/09/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters regarding fraudulent products, approval of an abbreviated new drug application for a drug to facilitate tracheal intubation, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/09/2020\n\nWebinar: CURE ID- Capturing Clinician\u2019s Experiences Repurposing Drugs to Inform Future Studies in the Era of COVID-19\nThis webinar will demonstrate CURE ID \u2013 a mobile app and web platform, that gives the global clinical community the opportunity to report novel uses of existing drugs for patients with difficult-to-treat infectious diseases, including COVID-19.\n\nEvent\nDrugs\n06/09/2020\n\nWebinar Series: Respirators for Health Care Personnel Use during COVID-19 Pandemic\nThe FDA will kick off a webinar series to share information and answer questions about emergency use authorizations (EUAs) for respirators, importing respirators, and overall FDA actions to help assure health care personnel have the necessary supplies of respirators.\n\nEvent\nMedical Devices\n06/08/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on PDMA guidance on prescription drug sample distributions, respirator decontamination EUAs, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/07/2020\n\nCoronavirus (COVID-19) Update: FDA Reissues Emergency Use Authorizations Revising Which Types of Respirators Can Be Decontaminated for Reuse\nIn response to public health and safety concerns about the appropriateness of decontaminating certain respirators, the agency is reissuing certain emergency use authorizations (EUAs) to specify which respirators are appropriate for decontamination.\n\nPress Release / Public Statement\nMedical Devices\n06/05/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on guidance for non-invasive patient monitoring to decrease infection risk, summary of FDA COVID-19 response, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n06/04/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on test performance data, warning letters, video explaining test types, respirators for health care personnel webinar, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/04/2020\n\nCoronavirus (COVID-19) Update: FDA Publicly Shares Antibody Test Performance Data From Kits as Part of Validation Study\nToday, the FDA publicly posted test performance data from four more antibody, or serology, test kits on open.fda.gov from its independent performance validation study effort with the National Institutes of Health\u2019s (NIH) National Cancer Institute (NCI).\n\nPress Release / Public Statement\nMedical Devices\n06/03/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on clinical trials guidance, testing supply substitution strategies, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/03/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe FDA will host a virtual Town Hall for clinical laboratories and commercial manufacturers that are developing or have developed diagnostic tests for SARS-CoV-2 to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n06/02/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on food safety (FDA Voices by Commissioner S. Hahn, Deputy Commissioner F. Yiannis), guidance on single-member IRBs, authorized NASA ventilator and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n06/02/2020\n\nCOVID-19 and Beyond: Oversight of the FDA's Foreign Drug Manufacturing Inspection Process\nFDA officials Judith A. McMeekin, Mark Abdoo, and Douglas Throckmorton testimony before the U.S. Senate Committee on Finance\n\nEvent\nDrugs\n\t\t\tInspections\n06/02/2020\n\nPandemic Challenges Highlight the Importance of the New Era of Smarter Food Safety\nThe FDA will release the New Era of Smarter Food Safety Blueprint in the coming weeks, outlining our plans over the next decade to create a more digital, traceable, and safer food system.\n\nFDA Voices: Leadership Perspectives\nFood & Beverages\n06/01/2020\n\nCoronavirus (COVID-19) Update: FDA Takes Action to Protect Public Health; Increase Supply of Alcohol-Based Hand Sanitizer\nToday, the FDA has taken additional action to help ensure widespread access to hand sanitizers during the COVID-19 public health emergency.\n\nPress Release / Public Statement\nDrugs\n06/01/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA Voices (EUAs), consumer update on regulatory terminology and more on FDA\u2019s ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n06/01/2020\n\nRemarks by Commissioner Stephen Hahn, M.D.\u2014The COVID-19 Pandemic\u2014Finding Solutions, Applying Lessons Learned\nCommissioner Hahn speaks to the Alliance for a Stronger FDA\n\nEvent\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n05/29/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on EUAs, warning letters, health fraud, informed consent, clinical trials and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n05/29/2020\n\nBringing a Cancer Doctor\u2019s Perspective to FDA\u2019s Response to the COVID-19 Pandemic\nFDA Commissioner Stephen M. Hahn, M.D., on the FDA's role in facilitating treatment options during the public health response to the COVID-19 pandemic.\n\nFDA Voices: Leadership Perspectives\nDrugs\n\t\t\tBiologics\n05/29/2020\n\nUnderstanding the Regulatory Terminology of Potential Preventions and Treatments for COVID-19\nFind information about the terms used to describe possible COVID-19 preventions or treatments and what they mean.\n\nConsumer Information\nDrugs\n\t\t\tBiologics\n05/29/2020\n\nCoronavirus (COVID-19) Update: FDA Takes Steps to Streamline Development of Tests With At-Home Sample Collection\nToday, the FDA took steps to further support the development of COVID-19 tests for at-home self-collection by including a voluntary EUA template for at-home sample collection kits to its website.\n\nPress Release / Public Statement\nMedical Devices\n05/28/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on EUAs, N95 respirators, COVID-19 diagnosis, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n05/27/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on guidance for industry, warning letters, testing updates, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tGuidance Documents\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n05/27/2020\n\nCoronavirus (COVID-19) Update: FDA Provides New Tool to Aid Development and Evaluation of Diagnostic Tests That Detect SARS-CoV-2 Infection\nFDA provides SARS-CoV-2 reference panel to ensure the quality of the tests, validation of new assays, test calibration, and monitoring of assay performance.\n\nPress Release / Public Statement\nBiologics\n\t\t\tMedical Devices\n05/27/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe FDA will host a virtual town hall for clinical laboratories and commercial manufacturers that are developing or have developed diagnostic tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n\t\t\tGuidance Documents\n05/26/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on antibody testing updates, new abbreviated new drug applications, guidance on medical devices and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n05/22/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on PPE recommendations for the food and agriculture industry, testing updates, warning letters, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nBiologics\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n\n05/21/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on antibody testing updates, new abbreviated new drug applications, guidance on medical devices and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tTobacco Products\n05/21/2020\n\nCoronavirus (COVID-19) Update: FDA Provides Promised Transparency for Antibody Tests\nToday, the U.S. Food and Drug Administration posted a list of antibody tests that are being removed from the \u201cnotification list\u201d of tests being offered under the Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency.\n\nPress Release / Public Statement\nMedical Devices\n05/20/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, MOU with USDA and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDietary Supplements\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n05/20/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe purpose of this Town Hall for clinical laboratories and commercial manufacturers that are developing or have developed diagnostic tests for SARS-CoV-2 is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n05/19/2020\n\nUSDA, FDA Strengthen U.S. Food Supply Chain Protections\nAs the COVID-19 pandemic response continues, the USDA and the FDA have been working around the clock on many fronts to support the U.S. food and agriculture sector so that Americans continue to have access to a safe and robust food supply.\n\nPress Release / Public Statement\nFood & Beverages\n05/19/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on diagnostics, succinylcholine chloride injection approval and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n05/19/2020\n\nCoronavirus (COVID-19) Update: FDA Collaborations Promote Rigorous Analyses of Real-World Data to Inform Pandemic Response\nThe FDA has entered into an agreement with Aetion to collaborate on advanced analytical techniques to answer urgent coronavirus disease (COVID-19) research questions.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n05/18/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, supply chain update, first standalone at-home sample collection kit EUA and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n05/16/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Standalone At-Home Sample Collection Kit That Can Be Used With Certain Authorized Tests\nThe FDA has authorized an at-home sample collection kit that can then be sent to specified laboratories for COVID-19 diagnostic testing.\n\nPress Release / Public Statement\nMedical Devices\n05/15/2020\n\nConsumer Update: Coronavirus Testing Basics\nLearn more about the different types of coronavirus tests and what they mean. Print out a PDF version of this information.\n\nConsumer Information\nMedical Devices\n05/15/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, industry hotline hours, diagnostics and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n05/15/2020\n\nVirtual Town Hall - 3D Printed Swabs\nThe FDA will host a virtual Town Hall for researchers, clinical laboratories, and commercial manufacturers to discuss the production and use of 3D printed swabs during the COVID-19 public health emergency.\n\nEvent\nMedical Devices\n05/14/2020\n\nCOVID-19 Supply Chain Update: Importation of Vital Food and Medical Products\nA critical part of the FDA\u2019s work is ensuring the safety and security of the U.S. supply of food and medical products during COVID-19.\n\nFDA Voices: Leadership Perspectives\nImports\n\t\t\tAnimal & Veterinary\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n05/14/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on infusion pump EUAs, drug compounding guidance and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n05/14/2020\n\nCoronavirus (COVID-19) Update: FDA Informs Public About Possible Accuracy Concerns with Abbott ID NOW Point-of-Care Test\nToday, the FDA is alerting the public to early data that suggest potential inaccurate results from using the Abbott ID NOW point-of-care test to diagnose COVID-19.\n\nPress Release / Public Statement\nMedical Devices\n05/14/2020\n\nCoronavirus (COVID-19) Update: Federal judge enters temporary injunction against Xephyr LLC doing business as N-Ergetics, preventing sale of Colloidal Silver Products for COVID-19\nA federal court has entered a temporary restraining order against Xephyr LLC, doing business as N-Ergetics, and three individuals associated with the entity, requiring them to immediately stop distributing colloidal silver products.\n\nPress Release / Public Statement\nDietary Supplements\n\t\t\tDrugs\n05/13/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on an upcoming town hall on 3D printing, thermal imaging and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n05/13/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nFDA will host a virtual Town Hall for clinical laboratories and commercial manufacturers that are developing or have developed diagnostic tests for SARS-CoV-2 to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n05/12/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on treatment acceleration, inspection updates and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tInspections\n\t\t\tBiologics\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n05/12/2020\n\nHearing - COVID-19: Safely Getting Back to Work and Back to School\nFDA Commissioner Stephen M. Hahn testified before the U.S. Senate Committee on Health, Education, Labor and Pensions\n\nEvent\nDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n05/12/2020\n\nCOVID-19 Social Media Toolkit\nResources in English and Spanish for sharing information about COVID-19 and the FDA response to the pandemic.\n\nSafety Information\n\t\t\tConsumer Information\nAnimal & Veterinary\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n05/11/2020\n\nCoronavirus (COVID-19) Update: FDA Takes New Actions to Accelerate Development of Novel Prevention, Treatment Options for COVID-19\nToday, the FDA took important actions to help accelerate the development of prevention and treatment options for COVID-19 by providing new guidance with recommendations for innovators and researchers conducting work in this area.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n05/11/2020\n\nCoronavirus (COVID-19) Update: FDA updates on surveillance inspections during COVID-19\nDuring COVID-19, the FDA will continue to utilize and implement additional alternative inspection tools and approaches while postponing domestic and foreign routine surveillance inspections.\n\nPress Release / Public Statement\nInspections\n05/11/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on the first antigen test, warning letters and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n05/09/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients\nThe FDA has issued the first emergency use authorization (EUA) for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic.\n\nPress Release / Public Statement\nMedical Devices\n05/08/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on the first at-home saliva test, warning letters and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n05/08/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens\nToday, the U.S. Food and Drug Administration authorized the first diagnostic test with the option of using home-collected saliva samples for COVID-19 testing.\n\nPress Release / Public Statement\nMedical Devices\n05/07/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on new guidances, warning letters, updated EUAs for non-NIOSH approved respirators manufactured in China and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tFood & Beverages\n\t\t\tAnimal & Veterinary\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n05/07/2020\n\nCoronavirus (COVID-19) Update: FDA Continues to Combat Fraudulent COVID-19 Medical Products\nToday, the FDA is providing an update on the agency\u2019s efforts to combat the extremely concerning actions by companies and individuals that are exploiting or taking advantage of widespread fear among consumers during the COVID-19 pandemic.\n\nPress Release / Public Statement\nDrugs\n\t\t\tMedical Devices\n05/06/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on device manufacturing guidance, diagnostics and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n05/05/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, generic drug approvals and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n05/04/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on an updated serology policy, warning letters and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n05/04/2020\n\nInsight into FDA\u2019s Revised Policy on Antibody Tests: Prioritizing Access and Accuracy\nToday, the FDA announced important updates to our March 16, 2020 policy on commercial manufacturers\u2019 serology\u2014or antibody\u2014tests for #COVID19. Under the new policy, FDA expects commercial manufacturers to submit Emergency Use Authorization (EUA) requests, including their validation data, within 10 days of the updated policy publication date, or the date they notify FDA of their test validation, whichever is later.\n\nFDA Voices: Leadership Perspectives\nMedical Devices\n05/01/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on the remdesivir EUA, convalescent plasma guidance, grocery shopping safety tips and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n\t\t\tFood & Beverages\n\n05/01/2020\n\nCoronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment\nFDA has issued emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.\n\nPress Release / Public Statement\nDrugs\n04/30/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on new EUAs including an innovative ventilator developed in partnership with NASA, consumer update on pets, drug supply guidance and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tAnimal & Veterinary\n04/30/2020\n\nHelpful Questions and Answers about Coronavirus (COVID-19) and Your Pets\nQuestions and answers to help keep you, your family, and your pets safe during the pandemic.\n\nConsumer Information\nAnimal & Veterinary\n04/30/2020\n\nCoronavirus (COVID-19) Update: FDA Includes Ventilator Developed by NASA in Ventilator Emergency Use Authorization\nThe U.S. Food and Drug Administration included, under the ventilator emergency use authorization (EUA), a ventilator developed by the National Aeronautics and Space Administration (NASA), which is tailored to treat patients with COVID-19.\n\nPress Release / Public Statement\nMedical Devices\n04/30/2020\n\nWebinar: Conducting Clinical Trials During the COVID-19 Public Health Emergency\nFDA will discuss the challenges of, and guidance for, supporting clinical trials during the COVID-19 public health emergency. Note: This webinar is now full, but the recording of the webinar will be available shortly after the webinar concludes.\n\nEvent\nDrugs\n04/30/2020\n\nRemarks by FDA Commissioner Stephen M. Hahn, M.D., to the 2020 MDMA Annual Meeting\n\nEvent\nMedical Devices\n04/29/2020\n\nTips on Good Nutrition and Using the Updated Nutrition Facts Label During the Coronavirus Pandemic\nThe newly updated Nutrition Facts Label can help you and your family eat healthy when daily routines change.\n\nConsumer Information\nFood & Beverages\n04/29/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on nutrition consumer updates, accelerated approval of new dosing for cancer regimens, EUAs on serology validation and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tFood & Beverages\n04/28/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, video resources on EUAs and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tTobacco Products\n\t\t\tWarning Letters\n04/27/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on hand sanitizer safety information, food production fact sheets and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tFood & Beverages\n04/27/2020\n\nCoronavirus (COVID-19) Update: FDA Continues to Ensure Availability of Alcohol-Based Hand Sanitizer During the COVID-19 Pandemic, Addresses Safety Concerns\nToday, the FDA provided an update on its efforts to ensure the availability of alcohol-based sanitizer to help meet the demand for hand sanitizer during the COVID-19 pandemic.\n\nPress Release / Public Statement\nDrugs\n04/24/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on drug safety confirmation, warning letters and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n\t\t\tDrugs\n\t\t\tWarning Letters\n04/24/2020\n\nCoronavirus (COVID-19) Update: FDA Reiterates Importance of Close Patient Supervision for \u2018Off-Label\u2019 Use of Antimalarial Drugs to Mitigate Known Risks, Including Heart Rhythm Problems\nFDA is reiterating the importance of close patient supervision for \u2018off-label\u2019 use of antimalarial drugs to mitigate known risks, including heart rhythm problems.\n\nPress Release / Public Statement\nDrugs\n04/23/2020\n\nCTTI Webinar: Designing High-Quality COVID-19 Treatment Trials\nFDA participated in a discussion of the current landscape of COVID-19 treatment trial designs and best practices for quickly launching trials that ensure both patient safety and reliable results.\n\nEvent\nDrugs\n04/23/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on new guidances, Spanish resources for grocery shopping and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nMedical Devices\n\t\t\tFood & Beverages\n\t\t\tGuidance Documents\n04/23/2020\n\nCoronavirus (COVID-19) Update: Court Grants FDA\u2019s Request for Extension of Premarket Review Submission Deadline for Certain Tobacco Products Because of Impacts from COVID-19\nAs a result of the COVID-19 pandemic, FDA requested and was granted by the court, a 120-day extension of the May 12 deadline for premarket applications for e-cigarettes, cigars and other new tobacco products. These premarket applications are now required to be filed by Sept. 9, 2020.\n\nPress Release / Public Statement\nTobacco Products\n04/22/2020\n\nVirtual Town Hall Series - Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe purpose of this virtual Town Hall for clinical laboratories and commercial manufacturers that are developing or have developed diagnostic tests for SARS-CoV-2 is to help answer technical questions about the development and validation of tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n\t\t\tGuidance Documents\n04/22/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on remote monitoring EUAs, warning letters on fraudulent products and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n\t\t\tGuidance Documents\n04/21/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on the first diagnostic test with an at-home sample collection options, food supply and safety information and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n04/21/2020\n\nFDA Provides Flexibility to the Food Industry to Support Food Supply Chain and Meet Consumer Demand During COVID-19\nThe FDA is working closely with the food industry and USDA to provide flexibility regarding federal food labeling so consumers have access to the food they want.\n\nFDA Voices: Leadership Perspectives\nFood & Beverages\n04/21/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes First Test for Patient At-Home Sample Collection\nThe FDA authorized the first diagnostic test with a home collection option for COVID-19. Specifically, the FDA re-issued the emergency use authorization (EUA) for the Laboratory Corporation of America (LabCorp) COVID-19 RT-PCR Test to permit testing of samples self-collected by patients at home using LabCorp\u2019s Pixel by LabCorp COVID-19 Test home collection kit.\n\nPress Release / Public Statement\nMedical Devices\n04/20/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on recent agency guidance, the Coronavirus Treatment Acceleration Program, new EUAs for face masks and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n\t\t\tGuidance Documents\n04/20/2020\n\nThe Path Forward: Coronavirus Treatment Acceleration Program\nThe FDA has launched a new program called the Coronavirus Treatment Acceleration Program (CTAP) to move new treatments to patients as soon as possible, while at the same time finding out whether they are helpful or harmful.\n\nFDA Voices: Leadership Perspectives\n\nDrugs\n\t\t\tBiologics\n\n04/18/2020\n\nCoronavirus (COVID-19) Update: Serological Test Validation and Education Efforts\nGiven the active dialogue about serological tests that are currently on the market, and their significance in the nation\u2019s response efforts, we\u2019d like to provide further details about our thinking on these tests and our approach to making accurate and reliable serology tests widely available, while also protecting Americans from tests marketed with false or unsubstantiated claims.\n\nPress Release / Public Statement\n\t\t\tSafety Information\nMedical Devices\n04/17/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on vaccine public-private partnerships, warning letters, EUAs and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n04/17/2020\n\nCoronavirus (COVID-19) Update: Federal judge enters temporary injunction against Genesis II Church of Health and Healing, preventing sale of Chlorine Dioxide Products Equivalent to Industrial Bleach to Treat COVID-19\nA federal court has entered a temporary injunction requiring Genesis to immediately stop distributing its \u201cMiracle Mineral Solution\u201d (MMS), an unproven and potentially harmful treatment offered for sale to treat Coronavirus, which includes Coronavirus Disease 2019 (COVID-19) and many other diseases.\n\nPress Release / Public Statement\nDrugs\n04/17/2020\n\nNIH to launch public-private partnership to speed COVID-19 vaccine and treatment options\nThe FDA will participate in the ACTIV partnership aimed at developing a collaborative framework among all partners to rapidly respond to COVID-19 and future pandemics.\n\nPress Release / Public Statement\n\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n\n04/16/2020\n\nCoronavirus (COVID-19) Update: FDA, Gates Foundation, UnitedHealth Group, Quantigen, and U.S. Cotton Collaborate to Address Testing Supply Needs\nThe FDA announced a further expansion of COVID-19 testing options through the recognition that spun synthetic swabs \u2013 with a design similar to Q-tips \u2013 could be used to test patients by collecting a sample from the front of the nose.\n\nPress Release / Public Statement\nMedical Devices\n04/16/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on guidances, warning letters, food safety resources, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n\t\t\tAnimal & Veterinary\n\t\t\tFood & Beverages\n\t\t\tGuidance Documents\n\t\t\tWarning Letters\n04/16/2020\n\nCoronavirus (COVID-19) Update: FDA Continues User-Fee Related Reviews Through COVID-19\nThe FDA\u2019s User Fee programs help us fulfill our mission to protect public health while also helping to accelerate innovation in industry and bring new treatment options to the American public.\n\nPress Release / Public Statement\nDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n\t\t\tAnimal & Veterinary\n04/16/2020\n\nCoronavirus (COVID-19) Update: FDA Encourages Recovered Patients to Donate Plasma for Development of Blood-Related Therapies\nThe FDA is providing an update on one potential treatment called convalescent plasma and encouraging those who have recovered from COVID-19 to donate plasma to help others fight this disease.\n\nPress Release / Public Statement\nBiologics\n04/15/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on new serology EUAs, warning letters, consumer resources and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tGuidance Documents\n\t\t\tWarning Letters\n04/15/2020\nRemarks by FDA Commissioner Stephen M. Hahn, M.D., to the 2020 Rx Drug Abuse and Heroin Summit\nEvent\n\nDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n\n04/14/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on warning letters, updated consumer information on testing, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n04/13/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on product-specific guidances, news EUAs, hand sanitizer information and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tMedical Devices\n\t\t\tGuidance Documents\n04/12/2020\n\nCoronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Decontaminate Millions of N95 Respirators\nThe FDA issued an emergency use authorization (EUA) that has the potential to decontaminate approximately 4 million N95 or N95-equivalent respirators per day in the U.S. for reuse by health care workers in hospital settings.\n\nPress Release / Public Statement\nMedical Devices\n04/10/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on new EUAs for blood purification devices and PPE decontamination, warning letters and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n\t\t\tGuidance Documents\n\t\t\tWarning Letters\n\n04/10/2020\n\nA Perspective on the FDA\u2019s COVID-19 Response\nThe FDA is integral in the fight against the coronavirus, using science and innovative approaches to take a broad range of actions that advance our nation\u2019s response.\n\nFDA Voices: Leadership Perspectives\nAnimal & Veterinary\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n04/10/2020\n\nCoronavirus (COVID-19) Update: FDA Issues Second Emergency Use Authorization to Decontaminate N95 Respirators\nThe FDA issued the second emergency use authorization (EUA) to decontaminate compatible N95 or N95-equivalent respirators for reuse by health care workers in hospital settings. This EUA will support decontamination of approximately 750,000 N95 respirators per day in the U.S.\n\nPress Release / Public Statement\nMedical Devices\n04/10/2020\n\nCoronavirus (COVID-19) Update: FDA Authorizes Blood Purification Device to Treat COVID-19\nThe FDA issued an emergency use authorization for a blood purification system to treat patients 18 years of age or older with confirmed Coronavirus Disease 2019 (COVID-19) admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure.\n\nPress Release / Public Statement\nMedical Devices\n\t\t\tBiologics\n04/09/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on guidance for portable cryogenic containers during this public health emergency, warning letters, best practices for retail food stores, restaurants, and pickup and delivery services, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tBiologics\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n\t\t\tGuidance Documents\n\t\t\tWarning Letters\n04/08/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on recommendations on the administration and study of convalescent plasma, warning letters, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\nDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n04/08/2020\n\nCoronavirus (COVID-19) Update: FDA Warns Company Marketing Dangerous Chlorine Dioxide Products that Claim to Treat or Prevent COVID-19\nThe FDA has issued a warning letter to a company that markets fraudulent and dangerous chlorine dioxide products known as \u201cMiracle Mineral Solution\u201d for prevention and treatment of \u201cNovel Coronavirus Disease 2019\u201d (COVID-19).\n\nPress Release / Public Statement\nDrugs\n\t\t\tWarning Letters\n04/07/2020\n\nCoronavirus (COVID-19) Update: Serological Tests\nSerological tests measure the amount of antibodies or proteins present in the blood when the body is responding to a specific infection, like COVID-19.\n\nPress Release / Public Statement\nMedical Devices\n04/07/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues new guidance documents for remote ophthalmic assessment and monitoring devices, ECMO and cardiopulmonary bypass devices, temporary policy regarding enforcement of the Egg Safety Rule, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nMedical Devices\n\t\t\tFood & Beverages\n\t\t\tDrugs\n\t\t\tGuidance Documents\n\n04/06/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA issues new guidance on clinical electronic thermometers and infusion pumps and accessories and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nMedical Devices\n\t\t\tGuidance Documents\n\n04/06/2020\n\nWebinar: Enforcement Policy for Personal Protective Equipment (PPE) During COVID-19: Immediately in Effect Guidance\nOn April 6, 2020, the FDA will host a webinar for device manufacturers and industry to discuss and answer questions on the recently issued, immediately in effect guidances on enforcement policy for personal protective equipment (PPE) during COVID-19.\n\nEvent\nMedical Devices\n\t\t\tGuidance Documents\n04/03/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on convalescent plasma, a new EUA for non-NIOSH-approved respirators made in China, flexibility regarding the packaging and labeling of shell eggs, and more in its ongoing response to the COVID-19 pandemic\n\nDaily Roundup\n\nBiologics\n\t\t\tMedical Devices\n\t\t\tAnimal & Veterinary\n\t\t\tFood & Beverages\n\t\t\tGuidance Documents\n\n04/03/2020\n\nCoronavirus (COVID-19) Update: FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19\nThe FDA is taking the lead on a national effort to facilitate the development of, and access to, two investigational therapies derived from human blood. These are called convalescent plasma and hyperimmune globulin and are antibody-rich blood products made from blood donated by people who have recovered from the virus.\n\nPress Release / Public Statement\n\nBiologics\n\n04/02/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on blood donor eligibility, authorizing the first serology test to date, informing the public on food safety and the food supply, and more in its ongoing response to the COVID-19 pandemic\n\nDaily Roundup\n\nBiologics\n\t\t\tFood & Beverages\n\t\t\tDrugs\n\t\t\tMedical Devices\n\t\t\tGuidance Documents\n\t\t\tWarning Letters\n\n04/02/2020\n\nFDA Commissioned Corps Officers on the Front Line of COVID-19 Response\nAlmost 400 FDA Commissioned Corps officers have been deployed to aid in response to the coronavirus public health emergency.\n\nFDA Voices: Leadership Perspectives\n\u00a0\n04/02/2020\n\nCoronavirus (COVID-19) Update: FDA Provides Updated Guidance to Address the Urgent Need for Blood During the Pandemic\nThe FDA issued guidance for immediate implementation to address the urgent and immediate need for blood and blood components.\n\nPress Release / Public Statement\nBiologics\n\t\t\tGuidance Documents\n04/01/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on the FDA-ARGOS SARS-CoV-2 Reference Grade Sequence Data, temporary flexibility to chain restaurants and similar retail food establishments, warning letters, and more in its ongoing response to the COVID-19 pandemic\n\nDaily Roundup\n\nMedical Devices\n\t\t\tFood & Beverages\n\t\t\tDrugs\n\t\t\tGuidance Documents\n\n03/31/2020\n\nFDA: Food Access and COVID-19\nFood availability and food safety are vitally important to our well-being, and the FDA is working hard to help ensure the foods you, your family, and your pets eat are safe and available during the COVID-19 pandemic.\n\t\t\tVideo Length: 1:20\n\nSafety Information\nFood & Beverages\n03/31/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on the Coronavirus Treatment Acceleration Program, shortages of hydroxychloroquine and chloroquine, warning letters, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nDrugs\n\t\t\tMedical Devices\n\t\t\tWarning Letters\n\n03/31/2020\n\nCoronavirus (COVID-19) Update: FDA Continues to Accelerate Development of Novel Therapies for COVID-19\nThe FDA stood up a new program to expedite the development of potentially safe and effective life-saving treatments. The program, known as the Coronavirus Treatment Acceleration Program (CTAP), is using every tool at the agency\u2019s disposal to bring new therapies to sick patients as quickly as possible, while at the same time supporting research to further evaluate whether these medical countermeasures are safe and effective for treating patients infected with this novel virus.\n\nPress Release / Public Statement\nDrugs\n\t\t\tBiologics\n03/30/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nFDA actions on hydroxychloroquine sulfate and chloroquine phosphate products, N95 respirators, surgical apparel for health care professionals, and more in its ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nDrugs\n\t\t\tMedical Devices\n\t\t\tGuidance Documents\n\t\t\tWarning Letters\n\n03/30/2020\n\nVirtual Town Hall Series \u2013 Topic: Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nOn April 1, 2020, the FDA will host the first of a series of virtual Town Halls for clinical laboratories and commercial manufacturers that are developing or have developed diagnostic tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n\t\t\tGuidance Documents\n03/30/2020\n\nCoronavirus (COVID-19) Update: FDA expedites review of diagnostic tests to combat COVID-19\nThe FDA has been providing unprecedented flexibility to labs and manufacturers to develop and offer COVID-19 tests across the U.S. Every action the FDA has taken during this public health emergency to address the COVID-19 pandemic has balanced the urgent need to make diagnostic tests available with providing a level of oversight that ensures accurate tests are being deployed.\n\nPress Release / Public Statement\nMedical Devices\n03/30/2020\n\nFDA on Signing of the COVID-19 Emergency Relief Bill, Including Landmark Over-the-Counter Drug Reform and User Fee Legislation\nThe law grants the FDA transformative, new authorities that will meaningfully advance our efforts to modernize the OTC drug development and review process to help advance innovative, safe and effective options for consumers and secure a robust OTC marketplace.\n\nPress Release / Public Statement\nDrugs\n03/28/2020\n\nCoronavirus (COVID-19) Update: FDA takes further steps to help mitigate supply interruptions of food and medical products\nThe FDA is continuously examining the global supply chain to identify any concerns and assess the availability of the products Americans need most. We are also partnering with the Federal Emergency Management Agency (FEMA) on supply chain issues, including importation of needed medical products to support the U.S. response.\n\nPress Release / Public Statement\n\nMedical Devices\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tAnimal & Veterinary\n\t\t\tFood & Beverages\n\t\t\tImports\n\n03/27/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nActions by the FDA in our ongoing response to the COVID-19 pandemic\n\nDaily Roundup\n\nDrugs\n\t\t\tBiologics\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n\t\t\tGuidance Documents\n\n03/27/2020\n\nFood Safety and Availability During the Coronavirus Pandemic\nThere is no evidence of food or food packaging being associated with transmission of the coronavirus. Currently there are no food shortages nationwide, although certain foods may be temporarily out of stock.\n\nSafety Information\nFood & Beverages\n03/27/2020\n\nCoronavirus (COVID-19) Update: FDA takes action to help increase U.S. supply of ventilators and respirators for protection of health care workers, patients\nThe U.S. Food and Drug Administration took action to help increase the supply of ventilators, ventilator tubing connectors, and ventilator accessories, as well as filtering facepiece respirators (FFRs) due to shortages during COVID-19.\n\nPress Release / Public Statement\nMedical Devices\n03/27/2020\n\nSafely Using Hand Sanitizer\nYou can help stop the spread of COVID-19 by washing your hands with soap and water; if soap and water are not available, alcohol-based hand sanitizers can be used if they contain at least 60% alcohol and are used properly.\n\nConsumer Information\nDrugs\n03/26/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nActions by the FDA in our ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nFood & Beverages\n\t\t\tDrugs\n\t\t\tMedical Devices\n\t\t\tGuidance Documents\n\n03/25/2020\n\nFDA, Department of Veterans Affairs, National Institutes of Health, and America Makes Form a COVID-19 Response Public-Private Partnership\nThe FDA entered a Memorandum of Understanding (MOU) with the VA Innovation Ecosystem and the NIH 3D Print Exchange, to share data and coordinate on open-source medical products for the COVID-19 response. These agencies are also working closely with America Makes to provide resources that will connect health care providers and 3D printing organizations.\n\nSafety Information\nMedical Devices\n03/25/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nActions by the FDA in our ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nDrugs\n\t\t\tMedical Devices\n\t\t\tGuidance Documents\n\n03/24/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nActions by the FDA in our ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n\t\t\tAnimal & Veterinary\n\t\t\tFood & Beverages\n\n03/24/2020\n\nFDA Offers Assurance About Food Safety and Supply for People and Animals During COVID-19\nThe U.S. food supply remains safe for both people and animals during the COVID-19 pandemic.\n\nFDA Voices: Leadership Perspectives\nAnimal & Veterinary, Food & Beverages\n03/24/2020\n\nCoronavirus (COVID-19) Update: FDA takes action to increase U.S. supplies through instructions for PPE and device manufacturers\nThe FDA took action to increase U.S. supplies to support the U.S. response to COVID-19 by providing instructions to manufacturers importing personal protective equipment and other devices.\n\nPress Release / Public Statement\nMedical Devices\n\t\t\tImports\n03/24/2020\n\nInvestigational COVID-19 Convalescent Plasma - Emergency INDs\nInformation for healthcare providers about convalescent plasma\u2014plasma collected from the blood of fully recovered COVID-19 patients and given as treatment to very ill COVID-19 patients.\n\nSafety Information\nBiologics\n03/24/2020\n\nCoronavirus (COVID-19) Update: FDA Helps Facilitate Veterinary Telemedicine During Pandemic\nThe FDA announced today that it intends to temporarily not enforce certain requirements in order to allow veterinarians to better utilize telemedicine to address animal health needs during the pandemic.\n\nPress Release / Public Statement\nAnimal & Veterinary\n03/23/2020\n\nCoronavirus (COVID-19) Update: Daily Roundup\nActions by the FDA in our ongoing response to the COVID-19 pandemic.\n\nDaily Roundup\n\nDrugs\n\t\t\tMedical Devices\n\n03/23/2020\n\nFDA and EMA Collaborate to Facilitate SARS-CoV-2 Vaccine Development\nFDA and the European Medicines Agency jointly chaired the first global regulators meeting to discuss ways to streamline the development of SARS-CoV-2 vaccines.\n\nFDA Voices: Leadership Perspectives\nBiologics\n03/22/2020\n\nCoronavirus (COVID-19) Update: FDA provides update on patient access to certain REMS drugs during COVID-19 public health emergency\nThe FDA issued a new guidance to sponsors and healthcare providers regarding certain Risk Evaluation and Mitigation Strategy (REMS)-required testing during this time.\n\nPress Release / Public Statement\nDrugs\n03/22/2020\n\nCoronavirus (COVID-19) Update: FDA Continues to Facilitate Access to Crucial Medical Products, Including Ventilators\nThe FDA took significant action to help increase the availability of ventilators and accessories, as well as other respiratory devices, during the COVID-19 pandemic to support patients with respiratory failure or difficulty breathing.\n\nPress Release / Public Statement\nMedical Devices\n03/21/2020\n\nCoronavirus (COVID-19) Update: FDA Issues first Emergency Use Authorization for Point of Care Diagnostic\nThe FDA issued the first emergency use authorization for a point-of-care COVID-19 diagnostic for the Cepheid Xpert Xpress SARS-CoV-2 test.\n\nPress Release / Public Statement\nMedical Devices\n03/20/2020\n\nCoronavirus (COVID-19) Update: FDA Alerts Consumers About Unauthorized Fraudulent COVID-19 Test Kits\nThe FDA is actively and aggressively monitoring the market for any firms marketing products with fraudulent coronavirus (COVID-19) diagnostic, prevention and treatment claims as part of our ongoing efforts to protect public health during this pandemic. As a result of these activities, the agency is beginning to see unauthorized fraudulent test kits that are being marketed to test for COVID-19 in the home.\n\nPress Release / Public Statement\nMedical Devices\n\t\t\tWarning Letters\n03/20/2020\n\nPreguntas m\u00e1s frecuentes acerca de la Enfermedad del Coronavirus 2019 (COVID-19)\nCoronavirus Disease 2019 (COVID-19) Frequently Asked Questions are now available in Spanish.\n\nSafety Information\n\t\t\tConsumer Information\n\u00a0\n03/20/2020\n\nCoronavirus (COVID-19) Update: FDA allows expanded use of devices to monitor patients\u2019 vital signs remotely\nThe FDA issued a new policy that allows manufacturers of certain FDA-cleared non-invasive, vital sign-measuring devices to expand their use so that health care providers can use them to monitor patients remotely. The devices include those that measure body temperature, respiratory rate, heart rate and blood pressure.\n\nPress Release / Public Statement\nMedical Devices\n03/20/2020\n\nCoronavirus (COVID-19) Update: FDA provides guidance on production of alcohol-based hand sanitizer to help boost supply, protect public health\nAs part of the U.S. Food and Drug Administration\u2019s ongoing commitment to address the coronavirus (COVID-19) pandemic, the agency has issued two guidance documents to communicate its policy for the temporary manufacture of certain alcohol-based hand sanitizer products. These guidance documents will be in effect for the duration of the public health emergency declared by the Secretary of Health and Human Services (HHS) on January 31, 2020.\n\nPress Release / Public Statement\nDrugs\n\t\t\tGuidance Documents\n03/19/2020\n\nDHS Issues Guidance on the Essential Critical Infrastructure Workforce\nThe Department of Homeland Security (DHS)/Cybersecurity & Infrastructure Agency (CISA) issued new guidance to support state, local, and industry partners in identifying the critical infrastructure sectors and the essential workers needed to maintain the services and functions Americans depend on daily and need to be able to operate resiliently during the COVID-19 pandemic response. This includes essential workers in the food, health care, and public health sectors, including FDA-regulated industries.\n\nSafety Information\nFood & Beverages\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tMedical Devices\n03/19/2020\n\nFDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19\nAt this time, FDA is not aware of scientific evidence connecting the use of NSAIDs, like ibuprofen, with worsening COVID-19 symptoms. The agency is investigating this issue further and will communicate publicly when more information is available.\n\nSafety Information\nDrugs\n03/19/2020\n\nCoronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments\nThe U.S. Food and Drug Administration continues to play a critical role in the multifaceted all-of-government response to the COVID-19 pandemic, which includes, among other things, facilitating medical countermeasures to treat and prevent the disease, and surveilling the medical product and food supply chains for potential shortages or disruptions and helping to mitigate such impacts, as necessary.\n\nPress Release / Public Statement\nBiologics\n\t\t\tDrugs\n03/19/2020\n\nCoronavirus (COVID-19) Update: Blood Donations\nThe nation\u2019s blood supply requires a steady supply of donors who generously donate millions of units of potentially life-saving blood and blood components each year. At this time the number of blood donations has been dramatically reduced due to the implementation of social distancing and the cancellation of blood drives. In order to ensure that blood is available to those who need it most, it is important for healthy individuals who are able to donate to take the time to do so.\n\nPress Release / Public Statement\nBiologics\n03/18/2020\n\nCoronavirus (COVID-19) Update: FDA Focuses on Safety of Regulated Products While Scaling Back Domestic Inspections\nFor the health and well-being of our staff and those who conduct inspections for the agency under contract at the state level, and because of industry concerns about visitors, we have temporarily postponed all domestic routine surveillance facility inspections. These are facility inspections the FDA traditionally conducts every few years based on a risk analysis. Importantly, all domestic for-cause inspection assignments will be evaluated and will proceed if mission-critical.\n\nPress Release / Public Statement\nInspections\n03/18/2020\n\nCoronavirus (COVID-19) Update: FDA issues a guidance on conducting clinical trials\nThe FDA took steps to help industry and investigators navigate the COVID-19 pandemic and move forward with conducting clinical trials.\n\nPress Release / Public Statement\nGuidance Documents\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tMedical Devices\n03/18/2020\n\nFDA Briefing for Foods Stakeholders on Coronavirus Disease 2019 (COVID-19)\nThe FDA hosted a stakeholder call to discuss food safety and food supply questions, respond to concerns, and highlight key FDA resources for the response to the COVID-19 pandemic.\n\nEvent\nFood & Beverages\n03/17/2020\n\nCoronavirus (COVID-19) Update: FDA Issues Temporary Policy for FSMA Onsite Audit Requirements\nThe FDA took steps to help prevent disruptions in the food supply-chain by issuing a temporary policy for FDA Food Safety Modernization Act (FSMA) supplier verification onsite audit requirements during the coronavirus (COVID-19) public health emergency.\n\nPress Release / Public Statement\nFood & Beverages\n03/16/2020\n\nCoronavirus (COVID-19) Update: FDA Issues Diagnostic Emergency Use Authorization to Hologic and LabCorp\nThe FDA took two additional significant diagnostic actions during the coronavirus outbreak (COVID-19) by issuing Emergency Use Authorizations (EUAs) to: Hologic for its Panther Fusion SARS-COV-2 Assay, and Laboratory Corporation of America (LabCorp) for its COVID-19 RT-PCR test.\n\nPress Release / Public Statement\nMedical Devices\n03/16/2020\n\nCoronavirus (COVID-19) Update: FDA Provides More Regulatory Relief During Outbreak, Continues to Help Expedite Availability of Diagnostics\nThe FDA updated a policy originally issued on Feb. 29 on diagnostic testing for coronavirus (COVID-19) in order to achieve more rapid testing capacity in the U.S.\n\nPress Release / Public Statement\nMedical Devices\n\t\t\tGuidance Documents\n03/13/2020\n\nCoronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Thermo Fisher\nThe FDA took another significant diagnostic action during the coronavirus outbreak (COVID-19). The FDA issued the fourth COVID-19 diagnostic Emergency Use Authorization (EUA) to Thermo Fisher for its TaqPath COVID-19 Combo Kit.\n\nPress Release / Public Statement\nMedical Devices\n03/12/2020\n\nCoronavirus (COVID-19) Update: FDA gives flexibility to New York State Department of Health, FDA issues Emergency Use Authorization diagnostic\nThe two significant actions will expedite the availability of diagnostic tests.\n\nPress Release / Public Statement\nMedical Devices\n03/10/2020\n\nCoronavirus Disease 2019 (COVID-19) Update: Foreign Inspections\nAfter careful consideration, the FDA is postponing most foreign inspections through April, effective immediately. Inspections outside the U.S. deemed mission-critical will still be considered on a case-by-case basis.\n\nPress Release / Public Statement\nInspections\n03/09/2020\n\nCoronavirus Update: FDA and FTC Warn Seven Companies Selling Fraudulent Products that Claim to Treat or Prevent COVID-19\nThe FDA and the Federal Trade Commission issued warning letters to seven companies for selling fraudulent COVID-19 products. These products are unapproved drugs that pose significant risks to patient health and violate federal law. The FDA and FTC are taking this action as part of their response in protecting Americans during the global COVID-19 outbreak.\n\nPress Release / Public Statement\nDietary Supplements, Drugs, Food & Beverages\n\t\t\tWarning Letters\n03/07/2020\n\nCoronavirus (COVID-19) Update: White House Press Briefing by FDA Commissioner Stephen M. Hahn, M.D.\n\nEvent\nMedical Devices\n03/06/2020\n\nVirtual Town Hall - Policy for Diagnostics Testing in Laboratories Certified to Perform High Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency\nThe FDA hosted a town hall for laboratories certified to perform high-complexity testing under the Clinical Laboratory Improvement Amendments (CLIA) that are developing or have developed molecular diagnostic tests for SARS-CoV-2.\n\nEvent\nMedical Devices\n03/04/2020\n\nRemarks by FDA Commissioner Stephen Hahn to the American Clinical Laboratory Association\nThe Commissioner's remarks highlighted the role of diagnostic testing in the COVID-19 response.\n\nEvent\nMedical Devices\n03/03/2020\n\nHHS officials testified at a Senate HELP Hearing, An Emerging Disease Threat: How the U.S. Is Responding to COVID-19, the Novel Coronavirus.\nRemarks by Dr. Anne Schuchat, Principal Deputy Director, Centers for Disease Control and Prevention; Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Dr. Robert Kadlec, Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services; and Dr. Stephen Hahn, Commissioner, U.S. Food and Drug Administration\n\nEvent\nMedical Devices\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tInspections\n\t\t\tImports\n03/02/2020\n\nWebinar: Immediately in Effect Guidance on Coronavirus (COVID-19) Diagnostic Tests\nThe FDA hosted a webinar for laboratories certified to perform high-complexity testing under the Clinical Laboratory Improvement Amendments (CLIA), and others interested in learning more about this guidance.\n\nEvent\nMedical Devices\n\t\t\tGuidance Documents\n03/02/2020\n\nCoronavirus (COVID-19) Update: FDA and CDC take action to increase access to respirators, including N95s, for health care personnel\nIn a joint effort, the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention took action to make more respirators, including certain N95s, available to health care personnel. Currently, the majority of respirators on the market are indicated for use in industrial settings. Today\u2019s action allows certain National Institute for Occupational Safety and Health (NIOSH) approved respirators not currently regulated by the FDA to be used in a health care setting by health care personnel during the coronavirus (COVID-19) outbreak, thereby maximizing the number of respirators available to meet the needs of the U.S. health care system.\n\nPress Release / Public Statement\nMedical Devices\n02/29/2020\n\nCoronavirus (COVID-19) Update: FDA Issues New Policy to Help Expedite Availability of Diagnostics\nAs part of the U.S. Food and Drug Administration\u2019s ongoing and aggressive commitment to address the coronavirus outbreak, the agency issued a new policy for certain laboratories seeking to develop diagnostic tests for coronavirus in order to achieve more rapid testing capacity in the U.S.\n\nPress Release / Public Statement\nMedical Devices\n\t\t\tGuidance Documents\n02/27/2020\n\nCoronavirus (COVID-19) Supply Chain Update\nFDA has been closely monitoring the supply chain with the expectation that the COVID-19 outbreak would likely impact the medical product supply chain, including potential disruptions to supply or shortages of critical medical products in the U.S. A manufacturer has alerted us to a shortage of a human drug that was recently added to the drug shortages list. The manufacturer just notified us that this shortage is related to a site affected by coronavirus. The shortage is due to an issue with manufacturing an active pharmaceutical ingredient used in the drug. It is important to note that there are other alternatives that can be used by patients. We are working with the manufacturer as well as other manufacturers to mitigate the shortage. We will do everything possible to mitigate the shortage.\n\nPress Release / Public Statement\nAnimal & Veterinary\n\t\t\tBiologics\n\t\t\tDrugs\n\t\t\tFood & Beverages\n\t\t\tMedical Devices\n02/24/2020\n\nCoronavirus Update: FDA steps to ensure quality of foreign products\nFDA continues to take a multi-pronged approach to this public health emergency, including focusing on actively facilitating efforts to diagnose, treat and prevent the disease; surveilling the medical product supply chain for potential shortages or disruptions and helping to mitigate such impacts, as necessary; and leveraging the full breadth of our public health tools, including enforcement tools to stop fraudulent activity.\n\nPress Release / Public Statement\nImports\n02/14/2020\n\nFDA\u2019s Actions in Response to 2019 Novel Coronavirus at Home and Abroad\nFDA is an active partner in the Novel Coronavirus (COVID-19) response, working closely with our government and public health partners across the U.S. Department of Health and Human Services, as well as with our international counterparts. Our work is multifaceted, focusing on actively facilitating efforts to diagnose, treat and prevent the disease; surveilling the medical product supply chain for potential shortages or disruptions and helping to mitigate such impacts, as necessary; and leveraging the full breadth of our public health tools as we oversee the safety and quality of FDA-regulated products for American patients and consumers.\n\nPress Release / Public Statement\nMedical Devices\n\t\t\tDrugs\n\t\t\tBiologics\n\t\t\tInspections\n\t\t\tImports\n02/11/2020\n\nThe World Health Organization announced an official name for the disease that is causing the current outbreak of coronavirus disease, COVID-19. FDA's website has been updated to reflect the updated name.\n\nPress Release / Public Statement\n\u00a0\n02/05/2020\n\nCDC Media Telebriefing: Update on 2019 Novel Coronavirus (COVID-19), including updates from FDA Chief Scientist RADM Denise Hinton.\n\nPress Release / Public Statement\n\u00a0\n02/04/2020\n\nFDA Takes Significant Step in Coronavirus Response Efforts, Issues Emergency Use Authorization (EUA) for the First 2019 Novel Coronavirus Diagnostic\nFDA issued an EUA to enable broader emergency use of the Centers for Disease Control and Prevention\u2019s (CDC) 2019-nCoV Real-Time RT-PCR Diagnostic Panel. To date, this test has been limited to use at CDC laboratories; today\u2019s authorization allows the use of the test at any CDC-qualified lab across the country.\n\nPress Release / Public Statement\nMedical Devices\n01/30/2020\n\nThe HHS Assistant Secretary for Preparedness and Response (ASPR) hosted a stakeholder listening session (transcript PDF) to discuss medical countermeasure challenges associated with 2019-nCoV outbreak. FDA Acting Assistant Commissioner for Counterterrorism Policy Michael Mair provided FDA remarks.\n\nPress Release / Public Statement\nMedical Devices\n01/27/2020\n\nFDA Announces Key Actions to Advance Development of Novel Coronavirus Medical Countermeasures\n\u201cWe have a vital mission to protect and promote public health and the FDA is closely collaborating with our domestic and international public health partners to mitigate the impact of the novel coronavirus that emerged in Wuhan, China,\u201d said FDA Commissioner Stephen M. Hahn, M.D. \u201cWe are actively leveraging the vast breadth of the FDA\u2019s expertise and have begun employing the full range of our public health authorities to facilitate the development and availability of investigational medical products to help address this urgent public health situation.\u201d\n\nPress Release / Public Statement\nMedical Devices\n\n\n\n\nPersonal Protective Equipment\nMore information\u00a0about how to use personal protective equipment (PPE) and other resources.\n\n\nN95 respirators, surgical masks, and face masks\nMedical gloves\nMedical gowns\n\n\n\n\nEmergency Use Authorizations and Guidances\n\n\n\n\n\n\nEmergency Use Authorizations (EUAs)\nExpedited authorization of medical products to address public health emergencies.\n\n\nGuidance Documents and Policies\nPolicies and guidances to support rapid response to COVID-19.\n\n\n\n\n\n\n\n\nFrequently Asked Questions (FAQs)\n\nEnglish\nCoronavirus Disease 2019 (COVID-19) Frequently Asked Questions\n\n\nEspa\u00f1ol\nPreguntas frecuentes sobre la Enfermedad del Coronavirus 2019 (COVID-19)\n\n\n\n\nMore FAQs on specific topics\nHand sanitizer FAQs\nFAQs on testing for SARS-CoV-2\n3D printing of medical devices & parts FAQs\nMedical glove FAQs\nFace mask & surgical mask FAQs\nFood industry FAQs\nVentilator FAQs\nAnimal food safety & COVID-19 industry FAQs\nManufacturing, supply chain, & drug inspections FAQs\n\n\n\n\nPopular Coronavirus Topics\n\n\n\nCOVID-19 Testing\n\n\n\n\nCOVID-19 Treatments\n\n\n\n\n\n\nCOVID-19 Vaccines\n\n\n\n\nInformation for People with Health Conditions\n\n\n\n\n\n\nFraudulent Products\n\n\n\n\nFood Safety\n\n\n\n\n\n\nPaxlovid\n\n\n\n\nHand Sanitizer Safety\n\n\n\n\n\nFDA Response to COVID-19\n\n\n\nFDA 2021 Year in Review - Working for You (PDF)\n\n\n\n\nFDA's Work to Combat the COVID-19 Pandemic (PDF) - July 2022\n\n\n\n\n\n\nFDA COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) Initiative\n\n\n\n\nCoronavirus Treatment Acceleration Program (CTAP)\n\n\n\n\n\u00a0\n\nCOVID-19 Information About FDA Regulated Products\nLearn more about how FDA is facilitating the development and availability of medical countermeasures and protecting the public health.\n\n\n\nFood\n\n\n\n\nDrugs\n\n\n\n\n\n\nMedical Devices\n\n\n\n\nAnimal & Veterinary\n\n\n\n\n\n\nBiologics\n\n\n\u00a0\n\n\n\n\n\nContact FDA\n\n\n\nDiagnostic Test Developers\n\n\n\nSee FAQs on Diagnostic Testing for SARS-CoV-2. If you need additional information about completing the EUA template, would like to know how to submit your Pre-EUA/EUA submission to FDA, or wish to consider use of an alternative specimen type, please contact the Division of Microbiology Devices at (301) 348-1778 or email CDRH-EUA-Templates@fda.hhs.gov.\n\n\n\n\n\nVaccine & Biologic Developers\n\n\n\nContact Manufacturers Assistance and Technical Training Branch (MATTB). Email industry.biologics@fda.hhs.gov or call 1-800-835-4709 for further information.\n\n\n\n\n\nDrug Developers\n\n\n\nFor therapeutics sponsors interested in submitting drug development proposals for review, see Coronavirus Treatment Acceleration Program. Email covid19-productdevelopment@fda.hhs.gov\n\n\n\n\n\nPhysicians Seeking an Emergency IND\n\n\n\nPlease call 855-543-3784 if you are a physician who would like to request an Emergency Investigational New Drug (EIND) application for antiviral products\n\n\n\n\n\nPress / Media\n\n\n\nFDA\u2019s Office of Media Affairs\nEmail fdaoma@fda.hhs.gov\nCall 301-796-4540\n\n\n\n\n\nAll Other Inquiries\n\n\n\nFDA\u2019s main Contact Us page\n\n\n\n\n\n\nReport a Problem\n\nFraudulent Products (1-800-332-1088)\nShortages or Supply Issues\nImport Problem\n\n\n\n\n\nInformation From the Federal Government\n\n\n\nCenters for Disease Control and Prevention (CDC)\nHow to prepare and protect yourself, what to do if you\u2019re sick, vaccines \u2013 and more\u2026\n\n\n\n\nVaccines.gov\nFind a COVID-19 vaccine near you, get the latest COVID-19 vaccine information, and connect with the COVID-19 Vaccine Hotline\n\n\n\n\n\n\nCOVID-19 Treatment Guidelines\nEvidence-based recommendations on the management of COVID-19 for health care providers\n\n\n\n\nNo-Cost COVID-19 Testing\nLocations near you that offer no-cost COVID-19 testing\n\n\n\n\n\n\nOccupational Safety and Health Administration\nInformation for workers and employers about COVID-19 from the U.S. Department of Labor\n\n\n\n\nFederal Emergency Management Agency (FEMA)\nHow FEMA is supporting COVID-19 vaccine distribution, COVID-19 rumor control, and how you can help during the pandemic\n\n\n\n\n\u00a0\n\n\n\n\n\n\n\n\n\n\n\n\n\nContent current as of:\n04/28/2023\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCoronavirus Disease 2019 (COVID-19)\n\n\n\nCOVID-19-Related Guidance Documents for Industry, FDA Staff, and Other Stakeholders\nCOVID-19 Frequently Asked Questions\nCOVID-19 Vaccines\nCOVID-19 Bivalent Vaccines\nMultilingual COVID-19 Resources\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nFooter Links\n\n\n\nFDA Archive\nAbout FDA\nAccessibility\n\n\n\n\nVisitor Information \nWebsite Policies / Privacy\nNo FEAR Act\nVulnerability Disclosure Policy\n\n\n\n\nFOIA\nHHS.gov\nUSA.gov\n\n\n\n\n\n\nContact FDA\n\n\nFollow FDA on Facebook\n\n\n\n\nFollow FDA on Twitter\n\n\n\n\nFollow FDA on Instagram\n\n\n\n\n\nFollow FDA on LinkedIn\n\n\n\n\nView FDA videos on YouTube\n\n\n\n\nSubscribe to FDA RSS feeds\n\n\n\n\n\nFDA Homepage\n\n\n\n \nContact Number\n      1-888-INFO-FDA (1-888-463-6332)\n    \n\n\n\n\nBack to Top\n\n\n\n",
    "links": [
        "#main-content",
        "#search-form",
        "#section-nav",
        "#footer-heading",
        "/",
        "#primary-nav",
        "/about-fda/contact-fda",
        "/regulatory-information/search-fda-guidance-documents",
        "/safety/recalls-market-withdrawals-safety-alerts",
        "/news-events/newsroom/press-announcements",
        "/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters",
        "/advisory-committees",
        "/about-fda/en-espanol",
        "/food",
        "/drugs",
        "/medical-devices",
        "/radiation-emitting-products",
        "/vaccines-blood-biologics",
        "/animal-veterinary",
        "/cosmetics",
        "/tobacco-products",
        "/about-fda",
        "/combination-products",
        "/regulatory-information",
        "/safety",
        "/emergency-preparedness-and-response",
        "/international-programs",
        "/news-events",
        "/training-and-continuing-education",
        "/inspections-compliance-enforcement-and-criminal-investigations",
        "/science-research",
        "/consumers",
        "/patients",
        "/industry",
        "/health-professionals",
        "/federal-state-local-tribal-and-territorial-officials",
        "#section-nav",
        "/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-frequently-asked-questions",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-bivalent-vaccines",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/multilingual-covid-19-resources",
        "/",
        "/emergency-preparedness-and-response",
        "/emergency-preparedness-and-response/counterterrorism-and-emerging-threats",
        "/emergency-preparedness-and-response/counterterrorism-and-emerging-threats",
        "https://www.facebook.com/sharer/sharer.php?u=https://www.fda.gov%2Femergency-preparedness-and-response%2Fcounterterrorism-and-emerging-threats%2Fcoronavirus-disease-2019-covid-19",
        "https://twitter.com/intent/tweet/?text=Coronavirus%20Disease%202019%20%28COVID-19%29&url=https://www.fda.gov%2Femergency-preparedness-and-response%2Fcounterterrorism-and-emerging-threats%2Fcoronavirus-disease-2019-covid-19",
        "https://www.linkedin.com/shareArticle?mini=true&url=https://www.fda.gov%2Femergency-preparedness-and-response%2Fcounterterrorism-and-emerging-threats%2Fcoronavirus-disease-2019-covid-19&title=Coronavirus%20Disease%202019%20%28COVID-19%29&source=FDA",
        "mailto:?subject=Coronavirus%20Disease%202019%20%28COVID-19%29&body=https://www.fda.gov%2Femergency-preparedness-and-response%2Fcounterterrorism-and-emerging-threats%2Fcoronavirus-disease-2019-covid-19",
        "javascript:window.print();",
        "/about-fda/fda-en-espanol/enfermedad-del-coronavirus-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines",
        "https://youtu.be/bT5XM9Rti_A",
        "#new",
        "#ppe",
        "#eua",
        "#faq",
        "#popular",
        "#response",
        "#regulatedProds",
        "#contact",
        "#FedGov",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted",
        "/health-professionals/covid-19-health-care-professional-resources",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-frequently-asked-questions",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-frequently-asked-questions",
        "/about-fda/fda-en-espanol/preguntas-frecuentes-sobre-la-enfermedad-del-coronavirus-2019-covid-19",
        "/news-events/press-announcements/fda-roundup-april-28-2023",
        "/news-events/press-announcements/fda-roundup-april-21-2023",
        "/news-events/press-announcements/fda-roundup-april-18-2023",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines",
        "/news-events/press-announcements/fda-roundup-april-14-2023",
        "/news-events/press-announcements/fda-roundup-april-11-2023",
        "/news-events/press-announcements/fda-roundup-april-7-2023",
        "/news-events/press-announcements/fda-roundup-april-4-2023",
        "/news-events/press-announcements/fda-roundup-march-31-2023",
        "/news-events/press-announcements/fda-roundup-march-28-2023",
        "/news-events/press-announcements/fda-roundup-march-24-2023",
        "/news-events/press-announcements/fda-roundup-march-21-2023",
        "/news-events/press-announcements/fda-roundup-march-17-2023",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-bivalent-pfizer-biontech-covid-19-vaccine-booster-dose",
        "/news-events/press-announcements/fda-roundup-march-14-2023",
        "/news-events/press-announcements/fda-roundup-march-10-2023",
        "/news-events/press-announcements/fda-roundup-march-7-2023",
        "/news-events/press-announcements/fda-roundup-march-3-2023",
        "/news-events/press-announcements/fda-roundup-february-28-2023",
        "/news-events/press-announcements/fda-authorizes-first-over-counter-home-test-detect-both-influenza-and-covid-19-viruses",
        "/news-events/press-announcements/fda-roundup-february-24-2023",
        "/news-events/press-announcements/fda-roundup-february-21-2023",
        "https://www.fda.gov/news-events/fda-voices/highlighting-major-issues-critical-fda-across-our-diverse-agency-after-one-year-back",
        "/news-events/press-announcements/fda-roundup-february-17-2023",
        "/news-events/press-announcements/fda-roundup-february-10-2023",
        "/news-events/press-announcements/fda-roundup-february-7-2023",
        "/news-events/press-announcements/fda-roundup-february-3-2023",
        "/news-events/press-announcements/fda-roundup-january-31-2023",
        "/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us",
        "/news-events/press-announcements/fda-roundup-january-24-2023",
        "/news-events/press-announcements/fda-roundup-january-20-2023",
        "/news-events/press-announcements/fda-roundup-january-13-2023",
        "/news-events/press-announcements/fda-roundup-january-10-2023",
        "/news-events/press-announcements/fda-roundup-january-06-2023",
        "https://www.fda.gov/drugs/drug-safety-and-availability/fda-releases-important-information-about-risk-covid-19-due-certain-variants-not-neutralized-evusheld",
        "https://www.fda.gov/science-research/fda-grand-rounds/fda-grand-rounds-scientific-basis-proposed-tobacco-product-standards-prohibit-menthol-characterizing",
        "/news-events/press-announcements/fda-roundup-december-30-2022",
        "/news-events/press-announcements/fda-roundup-december-23-2022",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-december-20-2022",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-dec-16-2022",
        "https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/understanding-home-otc-covid-19-antigen-diagnostic-test-results",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-hold-advisory-committee-meeting-discuss-future-vaccination-regimens",
        "/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-january-26-2023-meeting-announcement",
        "/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-december-13-2022",
        "https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/medical-device-shortages-during-covid-19-public-health-emergency",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-december-9-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-updated-bivalent-covid-19-vaccines-children-down-6-months",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-december-6-2022",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-november-29-2022",
        "https://www.fda.gov/food/cfsan-constituent-updates/fda-issues-guidances-food-allergen-labeling-requirements",
        "/news-events/press-announcements/fda-roundup-november-22-2022",
        "/news-events/press-announcements/fda-roundup-november-18-2022",
        "https://www.fda.gov/news-events/fda-voices/fdas-cybersecurity-modernization-action-plan",
        "https://www.fda.gov/medical-devices/cardiovascular-devices/automated-external-defibrillators-aeds",
        "https://www.fda.gov/news-events/fda-voices/focusing-prevention-safeguard-infant-formula",
        "https://www.fda.gov/consumers/consumer-updates/how-buy-medicines-safely-online-pharmacy",
        "https://www.fda.gov/science-research/about-science-research-fda/modeling-simulation-fda/",
        "https://www.fda.gov/animal-veterinary/cvm-updates/fda-releases-draft-amended-environmental-assessment-aquadvantage-salmon-and-announces-virtual-public",
        "https://www.federalregister.gov/documents/2022/11/17/2022-25002/draft-amended-environmental-assessment-for-production-of-aquadvantage-salmon-at-the-bay-fortune-and",
        "https://www.mitre.org/news-insights/publication/medical-device-cybersecurity-regional-incident-preparedness-and-response",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-november-15-2022",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-november-8-2022",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-november-4-2022",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-november-1-2022",
        "/news-events/press-announcements/fda-roundup-october-28-2022",
        "https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-october-25-2022",
        "https://www.fda.gov/medical-devices/safety-communications/do-not-use-certain-mighty-bliss-electric-heating-pads-due-risk-injury-fda-safety-communication",
        "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/whele-llc-announces-national-voluntary-recall-mighty-bliss-electric-heating-pad-due-product-safety",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-october-21-2022",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-october-18-2022",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-october-14-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-bivalent-covid-19-vaccines",
        "http://wcms-internet.fda.gov/news-events/press-announcements/fda-roundup-october-11-2022",
        "/news-events/press-announcements/fda-roundup-october-7-2022",
        "https://www.fda.gov/medical-devices/emergency-use-authorizations-medical-devices/monkeypox-emergency-use-authorizations-medical-devices",
        "/news-events/press-announcements/fda-roundup-october-4-2022",
        "https://www.fda.gov/food/cfsan-constituent-updates/fda-and-cdc-partner-reduce-foodborne-illness-retail-and-foodservice-establishments%22 /h  HYPERLINK %22https:/www.fda.gov/food/cfsan-constituent-updates/fda-and-cdc-partner-reduce-foodborne-illness-retail-and-foodservice-establishments",
        "/news-events/press-announcements/fda-roundup-september-30-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-updates-covid-19-test-policy-encourages-developers-seek-traditional",
        "/news-events/press-announcements/fda-roundup-september-27-2022",
        "/news-events/press-announcements/fda-roundup-september-23-2022",
        "/news-events/press-announcements/fda-roundup-september-20-2022",
        "/news-events/press-announcements/fda-roundup-september-16-2022",
        "/news-events/press-announcements/fda-roundup-september-13-2022",
        "/news-events/press-announcements/fda-roundup-september-9-2022",
        "/news-events/press-announcements/fda-roundup-september-6-2022",
        "/news-events/press-announcements/fda-roundup-september-2-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use",
        "/news-events/press-announcements/fda-roundup-august-30-2022",
        "https://www.fda.gov/news-events/fda-voices/fdas-overdose-prevention-framework-aims-prevent-drug-overdoses-and-reduce-death",
        "/news-events/press-announcements/fda-removes-n95-respirators-medical-device-shortage-list-signaling-sufficient-supply",
        "/news-events/press-announcements/fda-roundup-august-26-2022",
        "/news-events/press-announcements/fda-roundup-august-23-2022",
        "https://www.fda.gov/drugs/news-events-human-drugs/challenges-and-opportunities-rems-integration-innovation-and-modernization-10112022",
        "/news-events/press-announcements/fda-roundup-august-19-2022",
        "https://www.fda.gov/media/160998/download",
        "/news-events/press-announcements/fda-roundup-august-16-2022",
        "/news-events/press-announcements/fda-roundup-august-12-2022",
        "https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/information-blood-establishments-regarding-monkeypox-virus-and-blood-donation",
        "/news-events/press-announcements/fda-roundup-august-9-2022",
        "https://www.fda.gov/international-programs/global-perspective/how-european-data-law-impacting-fda",
        "/news-events/press-announcements/fda-roundup-august-5-2022",
        "https://www.fda.gov/news-events/fda-voices/fda-recognizes-national-immunization-awareness-month",
        "/news-events/press-announcements/fda-roundup-august-2-2022",
        "/news-events/press-announcements/fda-roundup-july-29-2022",
        "/news-events/press-announcements/fda-roundup-july-26-2022",
        "/news-events/press-announcements/fda-roundup-july-22-2022",
        "/news-events/press-announcements/fda-roundup-july-19-2022",
        "/news-events/press-announcements/fda-roundup-july-15-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted",
        "/news-events/press-announcements/fda-roundup-july-8-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-paxlovid-certain-limitations",
        "/news-events/press-announcements/fda-roundup-july-5-2022",
        "/news-events/press-announcements/fda-roundup-july-1-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-recommends-inclusion-omicron-ba45-component-covid-19-vaccine-booster",
        "/news-events/press-announcements/fda-roundup-june-28-2022",
        "https://aspr.hhs.gov/COVID-19/Therapeutics/updates/Pages/important-update-28June2022.aspx",
        "/news-events/press-announcements/fda-roundup-june-24-2022",
        "/news-events/press-announcements/fda-roundup-june-17-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children",
        "https://www.help.senate.gov/hearings/an-update-on-the-ongoing-federal-response-to-covid-19-current-status-and-future-planning",
        "/news-events/congressional-testimony/update-ongoing-federal-response-covid-19-current-status-and-future-planning-06162022",
        "/news-events/press-announcements/fda-roundup-june-14-2022",
        "/news-events/press-announcements/fda-roundup-june-10-2022",
        "/news-events/press-announcements/fda-roundup-june-7-2022",
        "/news-events/press-announcements/fda-roundup-june-3-2022",
        "https://www.fda.gov/media/158909/download",
        "https://www.fda.gov/media/153713/download",
        "/news-events/press-announcements/fda-roundup-may-31-2022",
        "https://www.fda.gov/drugs/news-events-human-drugs/regulatory-education-industry-redi-annual-conference-2022-06062022",
        "/news-events/press-announcements/fda-roundup-may-27-2022",
        "https://aspr.hhs.gov/COVID-19/Therapeutics/updates/Pages/important-update-20May2022.aspx",
        "/news-events/press-announcements/fda-roundup-may-24-2022",
        "/news-events/press-announcements/fda-roundup-may-20-2022",
        "https://www.fda.gov/consumers/consumer-updates/know-your-treatment-options-covid-19",
        "/news-events/press-announcements/fda-roundup-may-17-2022",
        "https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-pfizer-biontech-covid-19-vaccine-booster-dose",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-available-without-prescription-also",
        "/news-events/press-announcements/fda-roundup-may-10-2022",
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207924s006lbl.pdf",
        "/news-events/press-announcements/fda-roundup-may-6-2022",
        "https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals",
        "/news-events/press-announcements/fda-roundup-may-3-2022",
        "/news-events/press-announcements/fda-roundup-april-29-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-tentative-advisory-committee-meeting-schedule-regarding",
        "/news-events/press-announcements/fda-roundup-april-26-2022",
        "/news-events/press-announcements/fda-roundup-april-22-2022",
        "/news-events/press-announcements/fda-roundup-april-19-2022",
        "/news-events/press-announcements/fda-roundup-april-15-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-diagnostic-test-using-breath-samples",
        "/news-events/press-announcements/fda-roundup-april-12-2022",
        "/news-events/press-announcements/fda-roundup-april-8-2022",
        "/news-events/press-announcements/fda-roundup-april-5-2022",
        "/news-events/press-announcements/fda-roundup-april-1-2022",
        "/news-events/press-announcements/fda-roundup-march-29-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-second-booster-dose-two-covid-19-vaccines-older-and",
        "/news-events/press-announcements/fda-roundup-march-25-2022",
        "/news-events/press-announcements/fda-roundup-march-22-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-hold-advisory-committee-meeting-covid-19-vaccines-discuss-future",
        "/news-events/press-announcements/fda-roundup-march-18-2022",
        "/news-events/press-announcements/fda-roundup-march-15-2022",
        "/news-events/press-announcements/fda-roundup-march-11-2022",
        "/news-events/press-announcements/fda-roundup-march-8-2022",
        "/news-events/press-announcements/fda-roundup-march-4-2022",
        "/news-events/press-announcements/fda-roundup-march-1-2022",
        "/news-events/press-announcements/fda-roundup-february-25-2022",
        "/news-events/press-announcements/fda-roundup-february-22-2022",
        "/news-events/press-announcements/fda-roundup-february-18-2022",
        "/news-events/press-announcements/fda-roundup-february-15-2022",
        "/news-events/press-announcements/fda-roundup-february-11-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-postpones-advisory-committee-meeting-discuss-request-authorization",
        "/news-events/press-announcements/fda-roundup-february-8-2022",
        "/news-events/press-announcements/fda-roundup-february-4-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-advisory-committee-meeting-discuss-request-authorization-pfizer",
        "/news-events/press-announcements/fda-roundup-february-1-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-key-action-approving-second-covid-19-vaccine",
        "/news-events/press-announcements/fda-roundup-january-28-2022",
        "/news-events/press-announcements/fda-roundup-january-25-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron",
        "/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19",
        "/news-events/press-announcements/fda-roundup-january-21-2022",
        "/news-events/press-announcements/fda-roundup-january-18-2022",
        "/news-events/press-announcements/fda-roundup-january-14-2022",
        "https://www.fda.gov/media/155422/download",
        "/news-events/press-announcements/fda-roundup-january-11-2022",
        "https://www.help.senate.gov/hearings/addressing-new-variants-a-federal-perspective-on-the-covid-19-response",
        "/news-events/congressional-testimony/addressing-new-variants-federal-perspective-covid-19-response-01112022",
        "/news-events/press-announcements/fda-roundup-january-7-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-shortens-interval-booster-dose-moderna-covid-19-vaccine-five-months",
        "/news-events/press-announcements/fda-roundup-january-4-2022",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-multiple-actions-expand-use-pfizer-biontech-covid-19-vaccine",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-28-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-23-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-21-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-17-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-14-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-10-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-pfizer-biontech-covid-19-booster-dose-16-and-17",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-7-2021",
        "/news-events/press-announcements/fda-expands-authorization-two-monoclonal-antibodies-treatment-and-post-exposure-prevention-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-30-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-actively-working-investigate-address-potential-impacts-omicron",
        "/advisory-committees/advisory-committee-calendar/november-30-2021-antimicrobial-drugs-advisory-committee-meeting-announcement-11302021",
        "https://youtu.be/fR9FNSJT64M",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-23-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-16-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-updates-test-policies-help-ensure-accuracy-and-reliability-tests-and",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-12-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-5-2021",
        "https://www.help.senate.gov/hearings/next-steps-the-road-ahead-for-the-covid-19-response",
        "/news-events/congressional-testimony/next-steps-road-ahead-covid-19-response-11042021",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-2-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-october-29-2021",
        "/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age",
        "/news-events/press-announcements/coronavirus-covid-19-update-october-26-2021",
        "/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-october-26-2021-meeting-announcement",
        "https://youtu.be/laaL0_xKmmA",
        "/news-events/press-announcements/coronavirus-covid-19-update-october-22-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines",
        "https://youtu.be/rou7tf4vaUU",
        "/news-events/press-announcements/coronavirus-covid-19-update-october-19-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-101521",
        "/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-october-14-15-2021-meeting-announcement",
        "https://youtu.be/BhlshZ7Lkr0",
        "https://youtu.be/c-H40GrvWz4",
        "/news-events/press-announcements/fda-hold-advisory-committee-meeting-discuss-merck-and-ridgebacks-eua-application-covid-19-oral",
        "/news-events/press-announcements/coronavirus-covid-19-update-october-12-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-october-8-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-october-5-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-otc-home-test-increase-access-rapid-testing",
        "/news-events/press-announcements/coronavirus-covid-19-update-october-1-2021",
        "/news-events/press-announcements/fda-hold-advisory-committee-meetings-discuss-emergency-use-authorization-booster-doses-and-covid-19",
        "https://www.youtube.com/watch?v=0rx8wsEPoAk",
        "/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations",
        "https://omny.fm/shows/in-the-bubble/the-fda-commissioner-on-boosters-vaccines-for-kids",
        "/news-events/press-announcements/coronavirus-covid-19-update-september-17-2021",
        "/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-september-17-2021-meeting-announcement",
        "https://youtu.be/WFph7-6t34M",
        "/drugs/drug-safety-and-availability/fda-authorizes-bamlanivimab-and-etesevimab-monoclonal-antibody-therapy-post-exposure-prophylaxis",
        "/news-events/press-announcements/coronavirus-covid-19-update-september-10-2021",
        "/news-events/press-announcements/fda-will-follow-science-covid-19-vaccines-young-children",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-september-7-2021",
        "/news-events/press-announcements/fda-brief-fda-hold-advisory-committee-meeting-discuss-pfizer-biontechs-application-covid-19-booster",
        "/news-events/press-announcements/coronavirus-covid-19-update-august-31-2021",
        "/animal-veterinary/animal-health-safety-and-coronavirus-disease-2019-covid-19/cvm-letter-veterinarians-and-retailers-help-stop-misuse-animal-ivermectin-prevent-or-treat-covid-19",
        "https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/resumption-in-distribution-bamlanivimabetesevimab.aspx",
        "/media/145801/download",
        "/media/151719/download",
        "/media/145802/download",
        "/media/145808/download",
        "/news-events/press-announcements/coronavirus-covid-19-update-august-27-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-august-24-2021",
        "/news-events/press-announcements/fda-approves-first-covid-19-vaccine",
        "/news-events/press-announcements/coronavirus-covid-19-update-august-20-2021",
        "/news-events/press-announcements/joint-statement-hhs-public-health-and-medical-experts-covid-19-booster-shots",
        "/news-events/press-announcements/coronavirus-covid-19-update-august-13-2021",
        "/about-fda/page-not-found",
        "https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines#videoFAQs",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised",
        "/news-events/press-announcements/coronavirus-covid-19-update-august-6-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-august-3-2021",
        "https://www.youtube.com/watch?v=dl57-UdPeT0",
        "/news-events/press-announcements/coronavirus-covid-19-update-july-30-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-july-23-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-july-20-2021",
        "https://www.help.senate.gov/hearings/the-path-forward-a-federal-perspective-on-the-covid-19-response",
        "/news-events/congressional-testimony/path-forward-federal-perspective-covid-19-response-07202021",
        "/news-events/press-announcements/coronavirus-covid-19-update-july-16-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021",
        "/medical-devices/workshops-conferences-medical-devices/webinar-series-respirators-and-other-personal-protective-equipment-ppe-health-care-personnel-use",
        "/medical-devices/letters-health-care-providers/update-fda-no-longer-authorizes-use-non-niosh-approved-or-decontaminated-disposable-respirators",
        "/news-events/press-announcements/coronavirus-covid-19-update-july-9-2021",
        "/news-events/press-announcements/joint-cdc-and-fda-statement-vaccine-boosters",
        "/news-events/press-announcements/coronavirus-covid-19-update-july-6-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-july-2-2021",
        "/medical-devices/letters-health-care-providers/update-fda-no-longer-authorizes-use-non-niosh-approved-or-decontaminated-disposable-respirators",
        "/news-events/press-announcements/fda-brief-fda-revokes-emergency-use-authorizations-certain-respirators-and-decontamination-systems",
        "/news-events/press-announcements/coronavirus-covid-19-update-june-29-2021",
        "/media/150409/download",
        "/drugs/drug-shortages/coronavirus-aid-relief-and-economic-security-act-cares-act-drug-shortage-mitigation-efforts",
        "/news-events/press-announcements/coronavirus-covid-19-update-june-25-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-june-22-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-june-15-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-june-11-2021",
        "/news-events/press-announcements/fda-takes-steps-increase-availability-covid-19-vaccine",
        "/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-10-2021-meeting-announcement",
        "https://youtu.be/70Xhn3K9SlQ",
        "/news-events/press-announcements/coronavirus-covid-19-update-june-8-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-june-4-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-june-1-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-may-28-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-may-25-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-may-21-2021",
        "/news-events/press-announcements/fda-brief-fda-authorizes-longer-time-refrigerator-storage-thawed-pfizer-biontech-covid-19-vaccine",
        "/news-events/press-announcements/fda-brief-fda-advises-against-use-sars-cov-2-antibody-test-results-evaluate-immunity-or-protection",
        "/news-events/press-announcements/coronavirus-covid-19-update-may-18-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-may-14-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-may-11-2021",
        "https://www.help.senate.gov/hearings/an-update-from-federal-officials-on-efforts-to-combat-covid-19",
        "/news-events/congressional-testimony/update-federal-officials-efforts-combat-covid-19-05112021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use",
        "https://youtu.be/npjhwpConSw",
        "/news-events/press-announcements/fda-brief-fda-hold-meeting-its-vaccines-and-related-biological-products-advisory-committee-discuss",
        "/news-events/press-announcements/coronavirus-covid-19-update-may-7-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-outlines-inspection-and-assessment-activities-during-pandemic",
        "/news-events/press-announcements/coronavirus-covid-19-update-may-4-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-april-30-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-april-27-2021",
        "/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough",
        "/news-events/press-announcements/coronavirus-covid-19-update-april-23-2021",
        "https://www.fda.gov/news-events/press-announcements/fda-continues-important-steps-ensure-quality-safety-and-effectiveness-authorized-covid-19-vaccines",
        "https://www.fda.gov/food/food-safety-during-emergencies/covid-19-vaccination-food-and-agriculture-sector",
        "https://www.fda.gov/food/food-safety-during-emergencies/covid-19-vaccination-food-and-agriculture-sector#HHStoolkit",
        "/news-events/press-announcements/fda-continues-important-steps-ensure-quality-safety-and-effectiveness-authorized-covid-19-vaccines",
        "/news-events/press-announcements/coronavirus-covid-19-update-april-20-2021",
        "https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#amendment",
        "/news-events/press-announcements/fda-announces-new-streamlined-approach-add-pooled-serial-screening-claims-certain-authorized-tests",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab",
        "/news-events/press-announcements/coronavirus-covid-19-update-april-16-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-april-13-2021",
        "/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine",
        "/news-events/fda-voices/vaccine-ready-addressing-covid-19-health-disparities-among-racial-and-ethnic-minority-communities",
        "/news-events/press-announcements/coronavirus-covid-19-update-april-9-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-april-6-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-symbiotica-covid-19-self",
        "/news-events/press-announcements/coronavirus-covid-19-update-april-2-2021",
        "/news-events/fda-brief/fda-brief-fda-provides-update-covid-19-pandemic-recovery-and-preparedness-plan-initiative",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-makes-two-revisions-moderna-covid-19-vaccine-emergency-use",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-advance-over-counter-and-other-screening-test-development",
        "/news-events/press-announcements/coronavirus-covid-19-update-march-30-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-march-26-2021",
        "/about-fda/page-not-found",
        "/news-events/press-announcements/coronavirus-covid-19-update-march-23-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-machine-learning-based-screening-device-identify",
        "/news-events/press-announcements/coronavirus-covid-19-update-march-19-2021",
        "/drugs/drug-safety-and-availability/fda-authorizes-revisions-fact-sheets-address-sars-cov-2-variants-monoclonal-antibody-products-under",
        "/news-events/fda-voices/fdas-ongoing-use-inspectional-tools-ensuring-access-safe-quality-food-and-medical-products-during",
        "https://www.help.senate.gov/hearings/examining-our-covid-19-response-an-update-from-federal-officials",
        "https://www.help.senate.gov/hearings/watch?hearingid=520CE6BF-5056-A066-60A9-5DCA7E089995",
        "/news-events/congressional-testimony/examining-our-covid-19-response-update-federal-officials-03182021",
        "https://www.ama-assn.org/delivering-care/public-health/covid-19-webinar-therapeutics-use",
        "/news-events/press-announcements/fda-permits-marketing-first-sars-cov-2-diagnostic-test-using-traditional-premarket-review-process",
        "https://energycommerce.house.gov/committee-activity/hearings/hearing-on-leading-the-way-forward-biden-administration-actions-to",
        "https://youtu.be/C94TH6Mqv3o",
        "/news-events/congressional-testimony/leading-way-forward-biden-administration-actions-increase-covid-19-vaccinations-03172021",
        "/news-events/press-announcements/coronavirus-covid-19-update-march-16-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-steps-streamline-path-covid-19-screening-tools-provides",
        "/news-events/press-announcements/coronavirus-covid-19-update-march-12-2021",
        "/consumers/consumer-updates/know-your-treatment-options-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-march-9-2021",
        "/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19",
        "/consumers/health-equity-forum-podcast/health-fraud-covid-19-what-you-need-know",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-adaptive-biotechnologies-t-detect-covid-test",
        "/news-events/press-announcements/coronavirus-covid-19-update-march-5-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-authorization-first-molecular-non-prescription-home-test",
        "/news-events/press-announcements/fda-alerts-public-about-improper-use-thermal-imaging-devices-warns-firms-illegally-offering-thermal",
        "/medical-devices/consumers-medical-devices/are-there-fda-registered-or-fda-certified-medical-devices-how-do-i-know-what-fda-approved",
        "/news-events/fda-voices/national-consumer-protection-week-fda-vigilant-protecting-consumers-against-covid-19-vaccine-scams",
        "/news-events/press-announcements/coronavirus-covid-19-update-march-2-2021",
        "https://youtu.be/lfymmiQpsv4",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-authorization-quidel-quickvue-home-covid-19-test",
        "/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine",
        "/news-events/press-announcements/fda-statement-vaccines-and-related-biological-products-advisory-committee-meeting-1",
        "/news-events/press-announcements/coronavirus-covid-19-update-february-26-2021",
        "/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-february-26-2021-meeting-announcement",
        "https://youtu.be/Qd7mlCD-rEA",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-allows-more-flexible-storage-transportation-conditions-pfizer",
        "/news-events/press-announcements/coronavirus-covid-19-update-february-23-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-policies-guide-medical-product-developers-addressing-virus",
        "/news-events/press-announcements/coronavirus-covid-19-update-february-19-2021",
        "/news-events/press-announcements/covid-19-update-usda-fda-underscore-current-epidemiologic-and-scientific-information-indicating-no",
        "/news-events/press-announcements/coronavirus-covid-19-update-february-16-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-february-12-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0",
        "/news-events/press-announcements/coronavirus-covid-19-update-february-9-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-february-5-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-janssen-biotech-incs",
        "/news-events/fda-brief/fda-brief-fda-updates-emergency-use-authorization-covid-19-convalescent-plasma-reflect-new-data",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address",
        "/news-events/press-announcements/coronavirus-covid-19-update-january-29-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-january-26-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-action-place-all-alcohol-based-hand-sanitizers-mexico-import",
        "/news-events/press-announcements/coronavirus-covid-19-update-january-22-2021",
        "/news-events/press-announcements/coronavirus-covid-19-update-january-19-2021",
        "/news-events/fda-insight/fda-insight-pandemic-recovery-and-preparedness-plan-prepp",
        "/news-events/press-announcements/coronavirus-covid-19-update-january-15-2021",
        "/news-events/fda-voices/pandemic-response-pandemic-preparation",
        "/news-events/press-announcements/coronavirus-covid-19-update-january-8-2021",
        "/news-events/press-announcements/fda-issues-alert-regarding-sars-cov-2-viral-mutation-health-care-providers-and-clinical-laboratory",
        "/news-events/press-announcements/coronavirus-covid-19-update-january-5-2021",
        "/news-events/fda-insight/fda-insight-compounded-drugs",
        "/news-events/press-announcements/fda-statement-following-authorized-dosing-schedules-covid-19-vaccines",
        "/medical-devices/safety-communications/risk-false-results-curative-sars-cov-2-test-covid-19-fda-safety-communication",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-30-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-28-2020",
        "https://www.webmd.com/coronavirus-in-context/video/whyte-topol-hahn-marks",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-22-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-21-2020",
        "https://youtu.be/NI3Tm0Tg5WY",
        "/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid",
        "https://youtu.be/V8ey3WYxQuQ",
        "/news-events/press-announcements/fda-statement-vaccines-and-related-biological-products-advisory-committee-meeting-0",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-17-2020",
        "/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-17-2020-meeting-announcement",
        "https://youtu.be/I4psAfbUtC0",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-16-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-authorization-binaxnow-covid-19-ag-card-home-test",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-antigen-test-first-over-counter-fully-home-diagnostic",
        "https://youtu.be/LDqzE3Zr8pk",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-14-2020",
        "https://youtu.be/L0K3RsIZIP0",
        "https://youtu.be/L0K3RsIZIP0",
        "https://www.facebook.com/FDA/live",
        "https://twitter.com/US_FDA",
        "/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19",
        "/news-events/press-announcements/fda-statement-vaccines-and-related-biological-products-advisory-committee-meeting",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-10-2020",
        "/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-10-2020-meeting-announcement",
        "/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-10-2020-meeting-announcement",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-holds-advisory-committee-meeting-discuss-authorization-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-direct-consumer-covid-19-test-system",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-8-2020",
        "/medical-devices/workshops-conferences-medical-devices/webinar-series-respirators-and-other-personal-protective-equipment-ppe-health-care-personnel-use",
        "/news-events/speeches-fda-officials/remarks-dr-hahn-fda-cms-summit-12072020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-and-flu-combination-test-use-home",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-4-2020",
        "/news-events/speeches-fda-officials/remarks-dr-hahn-national-academy-medicine-town-hall-covid-19-vaccine-12042020",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-3-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-december-1-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-second-covid-19-vaccine",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-policy-dry-heat-reuse-certain-respirators",
        "https://youtu.be/Yqcw1-oZG2Y",
        "https://youtu.be/nv3Sfh7zysM",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-24-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-23-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-20-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-covid-19-vaccine",
        "/vaccines-blood-biologics/development-approval-process-cber/vaccine-development-101",
        "/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained",
        "/media/143890/download",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19",
        "https://youtu.be/mIjWfYno3xc",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-self-testing-home",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-17-2020",
        "/news-events/fda-insight/fda-insight-personal-protective-equipment-and-covid-19",
        "/news-events/press-announcements/covid-19-update-fdas-ongoing-commitment-transparency-covid-19-euas",
        "/news-events/speeches-fda-officials/dr-hahns-remarks-meeting-regulatory-affairs-professionals-society-raps-11172020",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-16-2020",
        "/health-professionals/closer-look-covid-19-diagnostic-testing",
        "/media/143737/download",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-13-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-12-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-10-2020",
        "/news-events/fda-newsroom/fda-insight",
        "/news-events/fda-insight/fda-insight-hand-hygiene-during-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-9-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19",
        "/news-events/speeches-fda-officials/dr-hahns-remarks-grxbiosims-2020-virtual-conference-11092020",
        "/news-events/press-announcements/fda-offers-guidance-enhance-diversity-clinical-trials-encourage-inclusivity-medical-product",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-test-detects-neutralizing-antibodies-recent-or",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-november-3-2020",
        "/news-events/speeches-fda-officials/remarks-global-pharmaceutical-manufacturing-leadership-forum-11012020",
        "/news-events/press-announcements/coronavirus-covid-19-update-october-30-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-october-28-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "https://www.usatoday.com/story/opinion/2020/10/27/fda-covid-vaccine-ensuring-safety-and-efficacy-column/6047702002/",
        "/news-events/fda-insight/fda-insight-get-your-flu-vaccine",
        "/medical-devices/workshops-conferences-medical-devices/webinar-series-respirators-and-other-personal-protective-equipment-ppe-health-care-personnel-use",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-26-2020",
        "/news-events/speeches-fda-officials/fda-presentation-american-public-health-associations-2020-virtual-annual-meeting-10262020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-23-2020",
        "https://www.aarp.org/health/drugs-supplements/info-2020/coronavirus-vaccine-safety.html",
        "/news-events/press-announcements/fda-approves-first-treatment-covid-19",
        "/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-october-22-2020-meeting-announcement",
        "https://youtu.be/1XTiL9rUpkg",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-20-2020",
        "/news-events/fda-voices/fdas-vaccines-and-related-biological-products-advisory-committee-and-its-role-advising-agency-covid",
        "/news-events/fda-insight/fda-insight-advisory-committee-covid-19-vaccines",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-19-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-15-2020",
        "/news-events/press-announcements/fda-reissues-emergency-use-authorization-certain-non-niosh-approved-filtering-face-piece-respirators",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-13-2020",
        "/medical-devices/workshops-conferences-medical-devices/webinar-series-respirators-and-other-personal-protective-equipment-ppe-health-care-personnel-use",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-9-2020",
        "https://youtu.be/C75_eMnNvlc",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-8-2020",
        "https://www.webmd.com/coronavirus-in-context/video/stephen-hahn",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-7-2020",
        "/news-events/press-announcements/fda-issues-warning-letter-battelle-memorial-institute-manufacturer-authorized-decontamination-system",
        "/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/battelle-memorial-institute-610928-10072020",
        "https://youtu.be/Z06JQhyZLUI",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-6-2020",
        "/news-events/fda-brief/fda-brief-fda-issues-guidance-emergency-use-authorization-covid-19-vaccines",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-5-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-2-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-october-1-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-30-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/speeches-fda-officials/dr-hahns-remarks-national-consumers-league-vaccine-review-process-09292020",
        "/news-events/fda-voices/closer-look-fdas-center-devices-and-radiological-healths-unprecedented-efforts-covid-19-response",
        "/medical-devices/workshops-conferences-medical-devices/webinar-series-respirators-and-other-personal-protective-equipment-ppe-health-care-personnel-use",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-25-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-24-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-point-care-antibody-test-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-23-2020",
        "https://www.help.senate.gov/hearings/covid-19-an-update-on-the-federal-response",
        "/news-events/congressional-testimony/covid-19-update-federal-response-09232020",
        "/news-events/congressional-testimony/covid-19-update-federal-response-fda-opening-remarks-09232020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/consumers/consumer-updates/beware-fraudulent-coronavirus-tests-vaccines-and-treatments",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-21-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-18-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-17-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-16-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-publishes-comparative-performance-data-covid-19-molecular-diagnostic",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-15-2020",
        "/medical-devices/workshops-conferences-medical-devices/webinar-series-respirators-and-other-personal-protective-equipment-ppe-health-care-personnel-use",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-14-2020",
        "/emergency-preparedness-and-response/mcm-regulatory-science/fda-and-global-partners-analyze-coronavirus-samples",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-11-2020",
        "/news-events/fda-voices/fdas-scientific-and-regulatory-oversight-vaccines-vital-public-health",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-10-2020",
        "/science-research/fda-grand-rounds/advancing-science-real-world-data-address-covid-19-pandemic-09102020-09102020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-9-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-8-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-4-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-3-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-2-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/fda-insight/fda-insight-opioid-epidemic-and-covid-19-pandemic",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-september-1-2020",
        "/medical-devices/workshops-conferences-medical-devices/webinar-series-respirators-and-other-personal-protective-equipment-ppe-health-care-personnel-use",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-31-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-announces-advisory-committee-meeting-discuss-covid-19-vaccines",
        "/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-28-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-27-2020",
        "/news-events/press-announcements/covid-19-update-fda-warns-consumers-about-hand-sanitizer-packaged-food-and-drink-containers",
        "/news-events/press-announcements/covid-19-update-fda-authorizes-first-diagnostic-test-where-results-can-be-read-directly-testing-card",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-26-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-25-2020",
        "/news-events/fda-insight/fda-insight-drug-shortages-and-covid-19",
        "/consumers/consumer-updates/your-hand-sanitizer-fdas-list-products-you-should-not-use",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-24-2020",
        "/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-21-2020",
        "/news-events/speeches-fda-officials/remarks-fda-leadership-accelerate-recovery-covid-19-alliance-health-policy-08202020-08202020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-20-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-19-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-18-2020",
        "/news-events/fda-insight/fda-insight-health-fraud-and-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-17-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-yale-school-public-health",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-14-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-13-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-12-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-11-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-10-2020",
        "/news-events/speeches-fda-officials/critical-role-health-care-professionals-during-covid-19-pandemic-08102020",
        "/health-professionals/fda-health-professional-activities/live-video-conversation-fda-commissioner-stephen-hahn-critical-role-health-care-professionals-during",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-7-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-6-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-5-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-4-2020",
        "/medical-devices/workshops-conferences-medical-devices/webinar-series-respirators-and-other-personal-protective-equipment-ppe-health-care-personnel-use",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-august-3-2020",
        "/news-events/fda-voices/investing-advanced-manufacturing-support-public-health-preparedness",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-tests-estimate-patients-antibodies-past-sars-cov-2",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-31-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-30-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-29-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-posts-new-template-home-and-over-counter-diagnostic-tests-use-non",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-28-2020",
        "/news-events/fda-insight/fda-insight-vaccines-covid-19-part-2",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-27-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-reiterates-warning-about-dangerous-alcohol-based-hand-sanitizers",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-screening-people-without-known-or",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-24-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-23-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-22-2020",
        "/news-events/fda-brief/fda-brief-findings-real-world-data-study-reveal-higher-risk-hospitalization-and-death-among-cancer",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-21-2020",
        "/news-events/fda-voices/fdas-ongoing-work-support-and-advance-covid-19-diagnostic-test-accuracy-and-availability",
        "/news-events/fda-insight/fda-insight-vaccines-covid-19-part-1",
        "/medical-devices/workshops-conferences-medical-devices/webinar-series-respirators-and-other-personal-protective-equipment-ppe-health-care-personnel-use",
        "/news-events/congressional-testimony/protecting-americans-covid-19-scams-written-testimony-only-07212020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-20-2020",
        "/news-events/fda-voices/fda-protects-patients-and-consumers-fraud-during-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-first-emergency-authorization-sample-pooling-diagnostic",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-17-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-16-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-15-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-14-2020",
        "/news-events/fda-voices/update-and-behind-scenes-fdas-coronavirus-treatment-acceleration-program",
        "/news-events/fda-insight/fda-insight-clinical-trials-and-treatments-covid-19",
        "https://clinicaltrials.gov/",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-13-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-10-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-prepares-resumption-domestic-inspections-new-risk-assessment-system",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-9-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-8-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-7-2020",
        "https://www.fda.gov/news-events/fda-insight/fda-insight-food-safety-and-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-6-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issued-emergency-use-authorization-point-care-antigen-test",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-covid-19-combination-diagnostic-test-ahead-flu",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-2-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-action-warn-protect-consumers-dangerous-alcohol-based-hand",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-july-1-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-30-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-action-help-facilitate-timely-development-safe-effective-covid",
        "https://www.help.senate.gov/hearings/covid-19-update-on-progress-toward-safely-getting-back-to-work-and-back-to-school",
        "/news-events/congressional-testimony/covid-19-update-progress-toward-safely-getting-back-work-and-back-school-06302020",
        "/news-events/fda-insight/fda-insight-all-about-covid-19-testing",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-29-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-26-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-25-2020",
        "/news-events/fda-voices/partnering-european-union-and-global-regulators-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-24-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-joint-statement-usda-and-fda-food-export-restrictions-pertaining-covid",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/fda-newsroom/fda-insight",
        "/news-events/fda-insight/fda-insight-fighting-covid-19-fda",
        "/news-events/fda-newsroom/fda-insight",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-23-2020",
        "/news-events/fda-voices/fda-maintains-pace-meeting-its-goals-applications-medical-products-during-pandemic",
        "https://energycommerce.house.gov/committee-activity/hearings/full-committee-hearing-on-oversight-of-the-trump-administrations",
        "/news-events/congressional-testimony/oversight-trump-administrations-response-covid-19-pandemic-06232020",
        "/medical-devices/workshops-conferences-medical-devices/webinar-series-respirators-and-other-personal-protective-equipment-ppe-health-care-personnel-use",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-22-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-19-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-18-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-action-harness-real-world-data-inform-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-17-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-warning-letters-companies-inappropriately-marketing-antibody",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-16-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-facilitating-diagnostic-test-availability-asymptomatic-testing-and",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chembio-antibody-test",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-15-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-warns-newly-discovered-potential-drug-interaction-may-reduce",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-12-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-11-2020",
        "/news-events/fda-voices/rare-disease-therapy-development-and-access-remain-top-fda-priorities-during-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-10-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-next-generation-sequence-test-diagnosing-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-9-2020",
        "/about-fda/fda-pharmacy-student-experiential-program/fda-drug-topics-cure-id-capturing-clinicians-experiences-repurposing-drugs-inform-future-studies-era",
        "/medical-devices/workshops-conferences-medical-devices/webinar-series-respirators-and-other-personal-protective-equipment-ppe-health-care-personnel-use",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-8-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-reissues-emergency-use-authorizations-revising-which-types",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-5-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-4-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-publicly-shares-antibody-test-performance-data-kits-part-validation",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-3-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-2-2020",
        "/news-events/congressional-testimony/covid-19-and-beyond-oversight-fdas-foreign-drug-manufacturing-inspection-process-06022020",
        "/news-events/fda-voices/pandemic-challenges-highlight-importance-new-era-smarter-food-safety",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-action-protect-public-health-increase-supply-alcohol-based",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-june-1-2020",
        "/news-events/speeches-fda-officials/remarks-commissioner-stephen-hahn-md-covid-19-pandemic-finding-solutions-applying-lessons-learned",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-29-2020",
        "/news-events/fda-voices/bringing-cancer-doctors-perspective-fdas-response-covid-19-pandemic",
        "/consumers/consumer-updates/understanding-regulatory-terminology-potential-preventative-and-therapeutic-drugs-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-steps-streamline-development-tests-home-sample-collection",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-28-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-27-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-new-tool-aid-development-and-evaluation-diagnostic-tests",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-26-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-22-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-21-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-promised-transparency-antibody-tests",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-20-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/usda-fda-strengthen-us-food-supply-chain-protections",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-19-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-collaborations-promote-rigorous-analyses-real-world-data-inform",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-18-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-standalone-home-sample-collection-kit-can-be-used",
        "/consumers/consumer-updates/covid-19-test-basics",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-15-2020",
        "/medical-devices/medical-devices-news-and-events/virtual-town-hall-3d-printed-swabs-05152020-05152020",
        "/news-events/fda-voices/covid-19-supply-chain-update-importation-vital-food-and-medical-products",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-14-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-informs-public-about-possible-accuracy-concerns-abbott-id-now-point",
        "/news-events/press-announcements/coronavirus-covid-19-update-federal-judge-enters-temporary-injunction-against-xephyr-llc-doing",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-13-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-12-2020",
        "https://www.help.senate.gov/hearings/covid-19-safely-getting-back-to-work-and-back-to-school",
        "/news-events/congressional-testimony/covid-19-safely-getting-back-work-and-back-school-05122020",
        "/consumers/minority-health-and-health-equity/covid-19-social-media-toolkit",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-new-actions-accelerate-development-novel-prevention-treatment",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-updates-surveillance-inspections-during-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-11-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-antigen-test-help-rapid-detection-virus-causes",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-8-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-using-home-collection-saliva",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-7-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-combat-fraudulent-covid-19-medical-products",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-6-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-5-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-4-2020",
        "/news-events/fda-voices/insight-fdas-revised-policy-antibody-tests-prioritizing-access-and-accuracy",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-1-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-30-2020",
        "/about-fda/page-not-found",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-includes-ventilator-developed-nasa-ventilator-emergency-use",
        "/drugs/news-events-human-drugs/sbia-webinar-conducting-clinical-trials-during-covid-19-public-health-emergency-04302020-04302020",
        "/news-events/speeches-fda-officials/remarks-dr-hahn-2020-mdma-annual-meeting-04302020",
        "/consumers/consumer-updates/tips-good-nutrition-and-using-updated-nutrition-facts-label-during-coronavirus-pandemic",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-29-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-28-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-27-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-ensure-availability-alcohol-based-hand-sanitizer-during",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-24-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-reiterates-importance-close-patient-supervision-label-use",
        "https://www.ctti-clinicaltrials.org/briefing-room/webinars/designing-high-quality-covid-19-treatment-trials",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-23-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-court-grants-fdas-request-extension-premarket-review-submission-deadline",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-22-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-21-2020",
        "/news-events/fda-voices/fda-provides-flexibility-food-industry-support-food-supply-chain-and-meet-consumer-demand-during",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-test-patient-home-sample-collection",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-20-2020",
        "/news-events/fda-voices/path-forward-coronavirus-treatment-acceleration-program",
        "/news-events/press-announcements/coronavirus-covid-19-update-serological-test-validation-and-education-efforts",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-17-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-federal-judge-enters-temporary-injunction-against-genesis-ii-church",
        "https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-gates-foundation-unitedhealth-group-quantigen-and-us-cotton",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-16-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-user-fee-related-reviews-through-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-encourages-recovered-patients-donate-plasma-development-blood",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-15-2020",
        "/news-events/speeches-fda-officials/remarks-dr-hahn-2020-rx-drug-abuse-and-heroin-summit-04152020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-14-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-13-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-decontaminate-millions-n95",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-10-2020",
        "/news-events/fda-voices/perspective-fdas-covid-19-response",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-second-emergency-use-authorization-decontaminate-n95",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-blood-purification-device-treat-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-9-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-8-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-warns-seller-marketing-dangerous-chlorine-dioxide-products-claim",
        "/news-events/press-announcements/coronavirus-covid-19-update-serological-tests",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-7-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-6-2020",
        "/medical-devices/workshops-conferences-medical-devices/webinar-enforcement-policy-personal-protective-equipment-ppe-during-covid-19-immediately-effect",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-3-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-coordinates-national-effort-develop-blood-related-therapies-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-2-2020",
        "/news-events/fda-voices/fda-commissioned-corps-officers-front-line-covid-19-response",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-updated-guidance-address-urgent-need-blood-during-pandemic",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-1-2020",
        "https://youtu.be/8g3FIlRV2xU",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-31-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-accelerate-development-novel-therapies-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-30-2020",
        "/medical-devices/workshops-conferences-medical-devices/virtual-town-hall-test-development-and-validation-during-covid-19-public-health-emergency-04262023",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-expedites-review-diagnostic-tests-combat-covid-19",
        "/news-events/press-announcements/fda-signing-covid-19-emergency-relief-bill-including-landmark-over-counter-drug-reform-and-user-fee",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-further-steps-help-mitigate-supply-interruptions-food-and",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-27-2020",
        "/about-fda/page-not-found",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-action-help-increase-us-supply-ventilators-and-respirators",
        "/consumers/consumer-updates/safely-using-hand-sanitizer",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-26-2020",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/fda-efforts-connect-manufacturers-and-health-care-entities-fda-department-veterans-affairs-national",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-25-2020",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-24-2020",
        "/news-events/fda-voices/fda-offers-assurance-about-food-safety-and-supply-people-and-animals-during-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-action-increase-us-supplies-through-instructions-ppe-and",
        "/vaccines-blood-biologics/investigational-new-drug-applications-inds-cber-regulated-products/recommendations-investigational-covid-19-convalescent-plasma",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-helps-facilitate-veterinary-telemedicine-during-pandemic",
        "/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup",
        "/news-events/fda-voices/fda-and-ema-collaborate-facilitate-sars-cov-2-vaccine-development",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-update-patient-access-certain-rems-drugs-during-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-facilitate-access-crucial-medical-products-including",
        "/regulatory-information/search-fda-guidance-documents/enforcement-policy-ventilators-and-accessories-and-other-respiratory-devices-during-coronavirus",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-first-emergency-use-authorization-point-care-diagnostic",
        "/media/136316/download",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-alerts-consumers-about-unauthorized-fraudulent-covid-19-test-kits",
        "/about-fda/page-not-found",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-allows-expanded-use-devices-monitor-patients-vital-signs-remotely",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-guidance-production-alcohol-based-hand-sanitizer-help-boost",
        "https://www.cisa.gov/identifying-critical-infrastructure-during-covid-19",
        "https://www.cisa.gov/identifying-critical-infrastructure-during-covid-19",
        "/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-facilitate-development-treatments",
        "/news-events/press-announcements/coronavirus-covid-19-update-blood-donations",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-focuses-safety-regulated-products-while-scaling-back-domestic",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-guidance-conducting-clinical-trials",
        "/food/workshops-meetings-webinars-food-and-dietary-supplements/fda-briefing-foods-stakeholders-coronavirus-disease-2019-covid-19-03182020",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-temporary-policy-fsma-onsite-audit-requirements",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-diagnostic-emergency-use-authorization-hologic-and-labcorp",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-more-regulatory-relief-during-outbreak-continues-help",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-thermo-fisher",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-gives-flexibility-new-york-state-department-health-fda-issues",
        "/news-events/press-announcements/coronavirus-disease-2019-covid-19-update-foreign-inspections",
        "/news-events/press-announcements/coronavirus-update-fda-and-ftc-warn-seven-companies-selling-fraudulent-products-claim-treat-or",
        "/news-events/speeches-fda-officials/coronavirus-covid-19-update-white-house-press-briefing-fda-commissioner-stephen-m-hahn-md-03072020",
        "/about-fda/page-not-found",
        "/news-events/speeches-fda-officials/remarks-fda-commissioner-stephen-hahn-american-clinical-laboratory-association-03042020",
        "https://www.help.senate.gov/hearings/an-emerging-disease-threat-how-the-us-is-responding-to-covid-19-the-novel-coronavirus",
        "/news-events/congressional-testimony/hearing-emerging-disease-threat-how-us-responding-covid-19-novel-coronavirus-03032020",
        "/about-fda/page-not-found",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-and-cdc-take-action-increase-access-respirators-including-n95s",
        "/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-policy-help-expedite-availability-diagnostics",
        "/news-events/press-announcements/coronavirus-covid-19-supply-chain-update",
        "/news-events/press-announcements/coronavirus-update-fda-steps-ensure-quality-foreign-products",
        "/news-events/press-announcements/fdas-actions-response-2019-novel-coronavirus-home-and-abroad",
        "https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020",
        "https://www.cdc.gov/media/releases/2020/a0205-cdc-telebriefing-coronavirus-update.html",
        "/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first",
        "https://www.phe.gov/Preparedness/COVID19/Documents/2019nCoV-Listening-Session-Transcript.pdf",
        "/news-events/press-announcements/fda-announces-key-actions-advance-development-novel-coronavirus-medical-countermeasures",
        "/medical-devices/personal-protective-equipment-infection-control/n95-respirators-surgical-masks-face-masks-and-barrier-face-coverings",
        "/medical-devices/coronavirus-covid-19-and-medical-devices/medical-gloves-covid-19",
        "/medical-devices/personal-protective-equipment-infection-control/medical-gowns",
        "/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-frequently-asked-questions",
        "/about-fda/fda-en-espanol/preguntas-frecuentes-sobre-la-enfermedad-del-coronavirus-2019-covid-19",
        "/drugs/information-drug-class/qa-consumers-hand-sanitizers-and-covid-19",
        "/medical-devices/coronavirus-covid-19-and-medical-devices/faqs-testing-sars-cov-2",
        "/medical-devices/coronavirus-covid-19-and-medical-devices/3d-printing-medical-devices-accessories-components-and-parts-during-covid-19-pandemic",
        "/medical-devices/coronavirus-covid-19-and-medical-devices/medical-gloves-covid-19",
        "/medical-devices/coronavirus-covid-19-and-medical-devices/face-masks-barrier-face-coverings-surgical-masks-and-respirators-covid-19",
        "/food/food-safety-during-emergencies/food-safety-and-coronavirus-disease-2019-covid-19",
        "/medical-devices/coronavirus-covid-19-and-medical-devices/ventilators-and-ventilator-accessories-covid-19",
        "/animal-veterinary/animal-health-safety-and-coronavirus-disease-2019-covid-19/industry-faqs-animal-food-safety-and-coronavirus-disease-2019-covid-19",
        "/drugs/coronavirus-covid-19-drugs/manufacturing-supply-chain-and-drug-inspections-covid-19",
        "/consumers/consumer-updates/covid-19-test-basics",
        "/consumers/consumer-updates/know-your-treatment-options-covid-19",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines",
        "/patients/coronavirus-disease-2019-covid-19-resources-patients",
        "/consumers/health-fraud-scams/fraudulent-coronavirus-disease-2019-covid-19-products",
        "/food/food-safety-during-emergencies/food-safety-and-coronavirus-disease-2019-covid-19",
        "/media/158165/download",
        "/drugs/drug-safety-and-availability/fda-updates-hand-sanitizers-consumers-should-not-use",
        "https://www.fda.gov/media/155422/download",
        "https://www.fda.gov/media/160998/download",
        "/about-fda/reports/fda-covid-19-pandemic-recovery-and-preparedness-plan-prepp-initiative",
        "/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap",
        "/food/food-safety-during-emergencies/food-safety-and-coronavirus-disease-2019-covid-19",
        "/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs",
        "/medical-devices/emergency-situations-medical-devices/coronavirus-covid-19-and-medical-devices",
        "/animal-veterinary/outbreaks-and-advisories/animal-health-safety-and-coronavirus-disease-2019-covid-19",
        "/vaccines-blood-biologics/industry-biologics/coronavirus-covid-19-cber-regulated-biologics",
        "#6197acf4503bf",
        "/medical-devices/coronavirus-covid-19-and-medical-devices/faqs-testing-sars-cov-2",
        "#",
        "mailto:CDRH-EUA-Templates@fda.hhs.gov",
        "#6197acf4504e5",
        "/vaccines-blood-biologics/industry-biologics/manufacturers-assistance-and-technical-training-branch-mattb",
        "mailto:industry.biologics@fda.hhs.gov",
        "#",
        "#6197acf4505e2",
        "https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap#contact",
        "mailto:covid19-productdevelopment@fda.hhs.gov",
        "#6197acf4506d0",
        "#",
        "/drugs/investigational-new-drug-ind-application/emergency-investigational-new-drug-eind-applications-antiviral-products",
        "#6197acf45075f",
        "/news-events/fda-newsroom/contact-office-media-affairs",
        "mailto:fdaoma@fda.hhs.gov?subject=covid-19%20press%20inquiry",
        "#",
        "#6197acf4507d9",
        "/about-fda/contact-fda",
        "/safety/report-problem-fda/reporting-unlawful-sales-medical-products-internet",
        "/vaccines-blood-biologics/safety-availability-biologics/how-report-product-shortage-or-supply-issue-fda",
        "/industry/importing-fda-regulated-products/importing-covid-19-supplies",
        "https://www.cdc.gov/coronavirus/2019-ncov/index.html",
        "https://www.vaccines.gov/",
        "https://www.covid19treatmentguidelines.nih.gov/",
        "https://testinglocator.cdc.gov/",
        "https://www.osha.gov/SLTC/covid-19/",
        "https://www.fema.gov/disasters/coronavirus",
        "/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-frequently-asked-questions",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-bivalent-vaccines",
        "/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/multilingual-covid-19-resources",
        "/about-fda/about-website/fdagov-archive",
        "/about-fda",
        "/about-fda/about-website/internet-accessibility",
        "/about-fda/visitor-information",
        "/about-fda/about-website/website-policies",
        "/about-fda/jobs-and-training-fda/no-fear-act",
        "https://www.hhs.gov/vulnerability-disclosure-policy/index.html",
        "/regulatory-information/freedom-information",
        "https://www.hhs.gov/",
        "https://www.usa.gov/",
        "/about-fda/contact-fda",
        "https://www.facebook.com/FDA",
        "https://www.twitter.com/US_FDA",
        "https://instagram.com/FDA",
        "https://www.linkedin.com/company/fda/",
        "https://youtube.com/@US_FDA",
        "/about-fda/contact-fda/subscribe-podcasts-and-news-feeds",
        "/",
        ""
    ]
}